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Bacteriocins are ribosomally synthesised antimicrobial peptides, produced by many 
bacterial genera that display potent activity against closely (narrow spectrum) or 
distantly related (broad-spectrum) bacteria. Bacteriocins, produced by Lactic Acid 
Bacteria (LAB) that are natural constituents of fermented foods, are ideal natural 
preservatives to control food spoilage/pathogenic bacteria in minimally processed 
foods. In addition to their role as food preservatives, bacteriocins have potent activity 
against medically significant pathogens and are considered attractive alternatives or 
adjuncts to antibiotics, due to their inherent heat stability, potency at nanomolar scale, 
resistance to proteases and low levels of acquired resistance in commercial 
applications. Overall, bacteriocins are versatile antimicrobials with huge potential for 
use as biopreservatives, antibiotic alternatives, health promoting gut modulators and 
animal growth promotors. The aim of this thesis was to identify, purify and 
characterise novel bacteriocins from microorganisms isolated from a wide range of 
niches, with a view to expanding the number of bacteriocins currently available and 
exploring novel structures and activities. 
In this respect, Chapter 2.1 describes the discovery a novel nisin A variant, nisin H, 
produced by a porcine gut isolate Streptococcus hyointestinalis DPC6484. Nisin H 
differs from nisin A at five amino acid positions and is an intermediate between 
naturally occurring nisins of lactococcal and streptococcal origin. The operon 
encoding nisin H is noteworthy by virtue of the absence of an equivalent of nisI that 
encodes an immunity protein that protects the cell from its own bacteriocin. This is 
the first report of natural nisin variant production by an intestinal isolate of 
streptococcal origin and may confer an advantage to the strain by allowing it to 
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dominate its environment, fight infection or signal the immune system of the host. In 
a subsequent chapter another natural variant is characterised in the form of nisin J, 
produced by a human skin isolate Staphylococcus capitis APC2923. Nisin J is more 
dissimilar to nisin A than nisin H with nine amino acid changes, six of which are 
unique, and an extra amino acid making it the first nisin variant to contain 35 amino 
acids. Interestingly, the operon lacks both nisI (immunity) and nisRK (regulatory) 
equivalents. Nisin J, like nisin A and H, displays activity against a wide number of 
genera and represents the first natural nisin variant from staphylococci and the first 
nisin producer from human skin, suggesting a role in competitive colonization for 
producing organisms.  
The natural nisin variants described above (nisin H and J), in addition to nisin P 
produced by Streptococcus agalactiae DPC7040, are all produced by non GRAS 
strains and are therefore limited in their potential industrial applications. The recent 
increase in the prevalence of antibiotic resistant pathogens makes it important that all 
bacteriocins regardless of the producing organism are explored as antibiotic 
alternatives. As these lantibiotics are gene encoded, bioengineering (Chapter 3.1) was 
used to enable recombinant expression of peptides naturally expressed by non-GRAS 
organisms in a host derived from safe origins. Specifically, the Nisin A promotor and 
nisin A leader sequence were fused to nisin H, J or P structural genes and successfully 
expressed in the GRAS strain L. lactis NZ9700, demonstrating that the L. lactis 
production, transport and modification machinery can produce fully functional nisin 
variants from significantly different genetic backgrounds.  
In Chapter 4, Bactofencin A produced by Streptococcus salivarius DPC6502 was 
discovered following a porcine gut mining study. It is a 22 amino acid, class IId 
bacteriocin that displays activity against Staphylococcus aureus and Listeria 
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monocytogenes. Structurally, it consists of a positively charged N terminus that we 
propose could bind to the negatively charged cell surface. The small bacteriocin cluster 
also encodes a DltB homologue that may well be responsible for immunity through 
D-alanylation of teichoic acids. In order to probe structure/function relationships in 
bactofencin A, a library of synthetic bactofencin A peptide variants were synthesized. 
Substituting cysteine residues significantly reduced activity confirming the 
importance of the disulphide while sequential removal of the positively charged N 
terminal resulted in a decreasingly active peptide. Substituting each amino acid for 
alanine revealed that residues 9-17 within the loop were more affected by substitution, 
suggesting this region contributes significantly to the potency of the bacteriocin.  
In Chapter 5, bactofencin A was shown to enhance nisin bactericidal activity and 
reduce the overall frequency of resistance. Interestingly, these studies highlighted the 
relatively slow or delayed mode of action of bactofencin A.  
The last two chapters (Chapters 6.1 and 6.2) again focus on the discovery of two 
novel bacteriocins, namely formicin and actifensin. The first of these, formicin, is a 
novel bacteriocin that extends the class of two peptide lantibiotics. It was purified from 
Bacillus paralicheniformis APC1576, a mackerel intestine isolate. Compared with 
other two component lantibiotics, formicin is most similar to haloduracin and consists 
of a very hydrophilic Alpha peptide with a charge of +2 whereas the Beta peptide is 
negatively charged. Formicin displays activity against a broad range of Gram-positive 
bacteria including clinically relevant pathogens. The second bacteriocin is actifensin 
a 4091 Da, broad spectrum, Class IId bacteriocin containing three disulphide bridges 
with more than 50% similarity to eukaryotic defensins that we propose represents a 
new subclass of bacteriocins. It is produced by Actinomyces ruminicola, isolated from 
sheep feces. A pangenomic screen of available Actinomyces spp. revealed the presence 
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of very diverse actifensin homologues in 29% of genomes examined, suggesting that 
production of actifensin like bacteriocins is a common trait. This new class of 
bacteriocins may provide a template to design new broad-spectrum antimicrobials for 
treatment of human and animal infections.  
The developments described in this thesis can be used to contribute to increased 
commercialisation of bacteriocins in both food systems and human and animal 
medical treatments.   
xi 
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Figure 3 Inhibition of actifensin against a broad-spectrum of indicator 
species. Weak inhibition, 0.5- to 3-mm zone; strong inhibition, 3- 
to 5-mm zone; very strong inhibition, >5-mm zone. VRE, 
vancomycin-resistant Enterococcus; MRSA, methicillin-resistant 
Staphylococcus aureus. 
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Figure 4 Phylogram of Actinomyces genomes using 16S sequences 
overlaid with BAGEL4 predictions, strain source, and presence 
of actifensin or predicted homolog operon. 
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Figure 5 (a) Sixty-nine-residue propeptide identified following genome 
analysis using the 15-amino-acid sequence (underlined) 
determined by N-terminal amino acid sequencing. RBS, 
putative ribosome binding site highlighted 8 bp upstream of the 
start codon. (b) Genetic vicinity of structural gene containing 
nearby genes for transport, hypothetical and proteolytic 
proteins, and a transcription factor. 
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Figure 6 (a) Mature peptide sequence alignment of AfnA with 
characterized defensin family peptides from different phyla. (b) 
Available 3D structures of sequences in panel (a). 
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Figure 7 (a) Sequence alignment of actifensin propeptide sequence 
(boxed) with structural genes predicted for Actinomyces sp. 
peptides. 
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Figure 8 Conserved structures of the defensin peptide superfamily and 
defensin-like bacteriocins, laterosporulin and actifensin. 
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Figure S1 Minimum inhibitory concentration of actifensin peptide against 
Gram-positive pathogens determined by well diffusion assay. 
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Efforts are continuing to find novel bacteriocins with enhanced specificity and 
potency. Traditional plating techniques are still being used for bacteriocin screening 
studies; however, the availability of ever more bacterial genome sequences and the use 
of in silico gene mining tools have revealed novel bacteriocin gene clusters that would 
otherwise have been overlooked. Furthermore, synthetic biology and bioengineering-
based approaches are allowing scientists to harness existing and novel bacteriocin gene 
clusters through expression in different hosts and by enhancing functionalities. The 
same principles apply to bacteriocin-producing probiotic cultures and their application 
to control pathogens in the gut. We can expect that the recent developments on 
bacteriocins from Lactic Acid Bacteria (LAB) described here will contribute greatly 
to increased commercialisation of bacteriocins in food systems.  
 
1.1.2 Introduction 
Consumer awareness of the effect of diet on health has led to a demand for minimally 
processed foods in which chemical preservatives are replaced by more natural 
alternatives. Traditionally foods were preserved by LAB, natural constituents of 
fermented foods, which confer their preservative effects by the production of lactic 
acid, hydrogen peroxide and small peptides known as bacteriocins. Bacteriocins are 
active against a number of genera (broad spectrum) or particular species (narrow 
spectrum) (1-3) and are very diverse, varying in size, structure and specificity. The 
fact that many bacteriocins are produced by food-grade LAB and possess potent 
antimicrobial activity means that they are ideally suited to controlling food spoilage 
and pathogenic bacteria (4-6).  
Bacteriocins can be broadly divided into two classes: class I, of which the lantibiotics 
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(post-translationally modified peptides containing unusual amino acids) are the best-
known example and class II, containing unmodified peptides (7). Their mode of action 
is likely driven by the primary structure of the bacteriocin with membrane 
permeabilisation being a very common theme. The producing culture is protected by 
the production of specific immunity proteins and the low levels of resistance detected 
so far makes them desirable alternatives to antibiotics (6). Their main advantage over 
chemical preservatives is their ability to preserve without affecting the sensory 
qualities of the food while adhering to the demand for natural preservatives. The ideal 
bacteriocin should be potent at low concentrations, active against a range of spoilage 
and pathogenic organisms, innocuous to the host and economical to produce (8). These 
antimicrobials can be introduced into a food through incorporation of the bacteriocin-
producing strain into the food product (most commonly in fermented foods), the 
generation and use of a bacteriocin-containing fermentate or as a more concentrated 
bacteriocin-containing food preservative. Currently only two bacteriocins are being 
used commercially as food preservatives: nisin produced by Lactococcus lactis, 
(marketed as Nisaplin and under other brand names), has been used commercially for 
50 years (9) and carnocyclin A (marketed as Micocin) a circular bacteriocin produced 
by Carnobacterium maltaromaticum UAL307 is an approved biopreservative in the 
US and Canada developed to inhibit Listeria monocytogenes in ready-to-eat (RTE) 
meat products (10). This review focuses predominantly on bacteriocins as 
antimicrobial antagonists and efforts to develop them as viable food biopreservatives. 
(See Figure 1) 
 
1.1.3 The continuing search for novel bacteriocins  
A primary focus of bacteriocin research is identifying novel bacteriocins and 
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bacteriocin-producing strains for specific applications. The general consensus is that 
the bacteriocin/bacteriocin-producer that is best suited to controlling a problematic 
spoilage/pathogenic microorganism will often be one that is found in the same 
environmental niche. This is based on the expectation that bacteriocins provide an 
advantage to competitors fighting for scarce resources in a particular environment. A 
prime example relates to Weissella hellenica QU 13, isolated from a barrel in which 
Japanese pickles were fermented, which was found to produce two leaderless 
bacteriocins, weissellicin Y, homologous to the class IId Enterocin L50A and L50B, 
and weisselicin M. In the latter case, it is notable that this novel broad-spectrum class 
IId antimicrobial is effective against Bacillus coagulans, a known contaminant of 
pickle fermentations. Thus, strain QU 13 is a good example of a fermentation-
associated isolate which has the potential to be employed to control an undesirable 
microbial contaminant (11). Lactococcus garvieae is a pathogen affecting farmed and 
fresh fish from marine and freshwaters and is also considered an emerging zoonotic 
pathogen. Garvicin A, a novel class IIb bacteriocin produced by the human isolate L. 
garvieae 21881, inhibits other L. garvieae stains and has potential to treat or prevent 
L. garvieae infections. More specifically, it is suggested that the purified bacteriocin 
in combination with probiotic LAB would be useful in the fight against L. garvieae 
infections (12). Another L. garvieae strain, a fermented pork sausage isolate L. 
garvieae BCC 43578, produces garvieacin Q, a novel class IId bacteriocin active 
against other L. garvieae and L. monocytogenes (13). The ability to control L. 
monocytogenes is a particularly highly sought-after trait and it is thus notable that 
enterocin W, a two component lantibiotic produced by Enterococcus faecalis NKR-4-
1 isolated from pla-ra Thai fermented fish (14), exhibits activity against this pathogen. 
Given that Staphylococcus aureus is also a major concern for the food industry, it is 
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interesting that bactofencin A, a cationic disulphide bond-containing bacteriocin 
similar to eukaryotic defensins, is active against S. aureus. In addition to the unusual 
nature of this bacteriocin, it is notable that its producer, the porcine isolate 
Lactobacillus salivarius DPC6502, does not contain a classical immunity-like gene, 
but instead encodes a dltB homologue that confers resistance (15). While the examples 
provided above relate to strains that produce a single bacteriocin, it should be noted 
that the production of multiple bacteriocins by a single strain can be advantageous as 
the various bacteriocins are likely to have different modes of action, thereby extending 
the spectrum of inhibition and reducing the likelihood of development of resistance. 
The genome of Enterococcus faecium NKR-5-3, isolated from pla-ra Thai fermented 
fish, encodes 5 enterocins, NKR-5-3 –A, B, C, D and Z and produces at least four of 
them, that is NKR-5-3 –A, B, C and D. Enterocin NKR-5-3C was confirmed to be a 
class IIa bacteriocin which exhibits potent antilisterial activity. The other bacteriocins 
are proposed to represent different classes but further investigations are required to 
establish this definitively (16, 17).  
 
1.1.4 The particular expansion in numbers of circular bacteriocins 
Although previously regarded as being rare, the discovery of circular bacteriocins has 
become more common in recent years. This is notable as these bacteriocins are thought 
by some to have the potential to form the next generation of biopreservatives as a 
consequence of their stability and activity. Indeed, gassericin A, garvicin ML, 
lactocyclin Q and leucocyclin Q produced by LAB inhibit a range of Gram-positive 
bacteria including food spoilage bacteria and food pathogens (18). The remarkable 
stability and activity of these bacteriocins is attributed to their head to tail cyclisation 
which confers the bacteriocins with increased protease and heat resistance (19, 20). 
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Garvicin ML is a recently discovered circular bacteriocin produced by L. garvieae 
DCC43 isolated from a Mallard duck which inhibits L. garvieae (21). Leucocyclin Q, 
produced by a Japanese pickle isolate Leuconostoc mesenteroides TK41401, is 
particularly active against B. coagulans which, as noted above, is a major pickle food 
spoilage organism (22). Studies relating to the mode of action of these, and indeed 
other, bacteriocins continue to also attract attention. Notably, in this regard, Liu et al 
(23) recently noted that sublethal doses of carnocyclin A induced an adaptation 
response in L. monocytogenes 08-5923 by affecting genes responsible for cell wall 
biosynthesis and metabolic function maintenance. 
 
1.1.5 New studies relating to the use of bacteriocins as part of a hurdle approach 
to preservation  
Bacteriocins can become more effective biopreservatives when used in combination 
with other antimicrobial hurdles such as organic acids, chelating agents or essential 
oils. These additive or synergistic phenomena act by reducing the levels of bacteriocin 
required for target inhibition and, in some instances, can even extend the spectrum of 
inhibition of bacteriocins to include Gram-negative microorganisms (2). Cronobacter 
sakazakii DPC6445 is an opportunistic Gram-negative pathogen associated with 
powdered infant formula (PIF) milk which has been associated with meningitis, 
septicaemia and necrotizing enterocolitis in premature and immunocompromised 
babies. Producing PIF that could be reconstituted at 40-50°C without risk of C. 
sakazakii infection is of interest to the food industry. Significantly, it has recently been 
established that nisin or lacticin 3147 when combined with the lactoperoxidase system 
inhibited C. sakazakii outgrowth for 8 hours, thereby providing an excellent example 
of a combinatory approach to improving the safety of PIF (24).  
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It has also been frequently demonstrated that using bacteriocins in combination with 
chelators such as ethylenediaminetetraacetic acid (EDTA) can expand the 
antimicrobial spectrum of a bacteriocin. Indeed, although carnocyclin A is not 
effective against Escherichia coli, Pseudomonas aeroginosa or Salmonella 
Typhimurium when tested alone, it can inhibit E. coli and P. aeruginosa when 
combined with 40 mM EDTA. Anti-E. coli and S. Typhimurium activity could be 
improved even further when nisin, rather than carnocyclin A, was combined with 40 
mM EDTA (10).  
Bacteriocins can also be utilised by applying them to a food surface. Due to lower 
concentrations being sufficient for efficacy in these circumstances, production costs 
are reduced. The use of immobilised bacteriocins, such as nisin, as components of 
antimicrobial packaging has been the focus of increasing levels of research, though it 
is important to appreciate that understanding the mode of action of specific 
bacteriocins is important to ensuring further progress in the area. In one instance, nisin 
was absorbed on both hydrophobic and hydrophilic food films and the effectiveness 
of the active surface against L. monocytogenes, Bacillus cereus and S. aureus was 
compared. It was established that the hydrophilic surfaces were more bioactive and 
absorbed higher quantities of nisin than the hydrophobic surfaces and that S. aureus 
was most sensitive to the nisin functionalised films (25). Class IIb lactocin 705 and the 
pediocin-like class IIa lactocin CL705 also possess potential in this regard. These 
Lactobacillus curvatus CRL705-produced bacteriocins are active against spoilage 
LAB and Listeria and have been incorporated into wheat gluten films to assess their 
ability to inhibit L. monocytogenes in meat products. The bacteriocin-containing gluten 
film, made at pilot scale, retained antimicrobial activity for 50 days which, 
importantly, is the shelf life of RTE meat products such as cooked sausages (26). More 
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specifically, the film reduced L. monocytogenes levels in Wiener sausages at day 45 
by 2.5 log cycles relative to controls (27). In addition to food surfaces, the surfaces of 
equipment can also serve as a site for the contamination of food by food spoilers and 
pathogens such as L. monocytogenes. Many such bacteria can colonise surfaces such 
as stainless steel and form biofilms. Biocides are routinely used to clean processing 
equipment but biofilms can be particularly difficult to remove. It has recently been 
established that combining sub-inhibitory concentrations of the class IIc enterocin AS-
48 with concentrations of biocides 4-10 fold lower than their MICs inhibited the 
growth of planktonic (non-biofilm) L. monocytogenes. Unsurprisingly, higher 
concentrations of both bacteriocin and biocide were required to inhibit sessile cells 
though synergy was still observed (28). Proteomic analysis of the exposure of L. 
monocytogenes to enterocin AS-48 revealed that planktonic and sessile cells respond 
differently upon exposure to the bacteriocin. Planktonic cells may compensate for 
changes in cytoplasmic permeability by reinforcing carbohydrate transport and 
metabolism while sessile cells shift carbohydrate metabolism and reinforce protein 
synthesis. Both cells states also exhibit a differing response to stress (29).  
  
1.1.6 Bacteriocin engineering 
Bacteriocins are ribosomally synthesised and therefore are amenable to genetic 
manipulation through engineering, which is defined as modifying the amino acid 
sequence of a protein to change its structure and function (30). Bioengineering 
(engineering inside the cell) and the use of synthetic biology-based (in vitro 
engineering) approaches have contributed significantly to our understanding of the 
roles specific amino acids play in structure and activity and resulted in the production 
of bacteriocins which have extended bioactivity against selected pathogens (31). The 
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structure-activity relationship of nisin has been extensively studied through 
bioengineering and this has enabled researchers to design variants with enhanced 
activity against specific targets. Nisin S29G, with enhanced activity against S. aureus 
SA113, was found by screening a bank of nisin A variants following site-directed 
mutagenesis specifically targeted against this residue. This resulted in the generation 
of a number of variants with improved activity against both Gram-positive and Gram-
negative pathogens. Indeed, this is the first instance upon which bioengineering of a 
bacteriocin has led to enhanced activity of this kind (32). Saturation mutagenesis at 
another location in nisin, lysine 12, resulted in the finding that a K12A derivative 
displays increased specific activity against food pathogens such as B. cereus, S. aureus 
and S. agalactieae but not against L. monocytogenes (33). Another region of the nisin 
peptide, the three amino acid ‘hinge’ region, is particularly amenable to change and 
bioengineering of this region has had beneficial consequences (34). Indeed, Rouse et 
al. (35) created a bank of hinge mutants and found that nisin peptides containing hinges 
consisting of SVA or NAK (rather than the original NMK) displayed an enhanced 
ability to diffuse through complex polymers, a trait which enabled the variants to 
outcompete nisin A controlling L. monocytogenes in commercially produced chocolate 
milk containing the stabiliser carrageenan. Furthermore, Healy et al. (36) used site-
directed mutagenesis of the hinge region to create a novel bank of nisin derivatives 
and found that AAK, NAI and SLS had enhanced activity towards some 
microorganisms. On the basis of the observation that the incorporation of small, chiral 
amino acids at this location generally has positive consequences, AAA-containing and 
SAA-containing ‘hinge’ derivatives were designed, created and ultimately became the 
first example of enhanced nisin derivatives to be generated through rational design.  
In the case of another lantibiotic, actagardine A, saturation mutagenesis was employed 
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to engineer each amino acid, with the exception of those involved in bridge formation, 
in turn through using saturation mutagenesis. Through this approach it was established 
that the V15F variant demonstrates enhanced activity against Clostridium difficile, E. 
faecium and E. faecalis (37). The ribosomal nature of bacteriocins also allows for more 
dramatic changes. To highlight this point, the anti-Gram-negative microcin V was 
combined, through asymmetrical PCR, with the anti-Gram-positive enterocin 35 to 
generate the chimeric bacteriocin Ent35-MccV which is active against both Gram-
positive and Gram-negative pathogens and thus could be of value to the food or 
pharmaceutical industries (38). Finally, it is now possible to bioengineer circular 
peptides by introducing a covalent bond between the N and C termini using advances 
in molecular biology and protein engineering techniques (30). Theoretically these 
techniques could allow the generation of more stable bacteriocins with extended 
applications that could be employed by the food industry. Synthetic biology, 
considered complementary to bioengineering, is another promising area that provides 
insights into structure-stability relationships and the mechanism of action of 
bacteriocins (39, 40). In one instance, Solid Phase Peptide Synthesis (SPPS) has been 
used to synthesise and modify lantibiotics such as lacticin 481. Using this approach, 
the role of lanthionine and methyllanthionine residues was investigated by replacing 
them with diastereoisomers. In this case it was established that activity was lost, 
suggesting that the 3D structures were modified (41). Synthetic biology also inspired 
Kong et al (42) to clone the nisin biosynthesis pathway from Lactococcus lactis K9 
into a plasmid and express it in a nisin-deficient strain. They also overexpressed nisin 
A using constitutive promoters and further optimised yield by integrating the structural 
peptide determinant nisA, overexpression cassettes and the recombinant pathway into 
a single circuit enabling the strain to produce 6 fold higher levels of nisin. This could 
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potentially reduce the cost of nisin production for the food industry and also provides 
a means via which novel bacteriocin clusters identified through genome mining (see 
below) could be harnessed. Further efforts to increase bacteriocin yield have led to the 
use of synthetic genes encoding bacteriocins being cloned into and expressed in yeasts. 
A synthetic gene designed using adapted codon usage from the amino acid sequence 
of enterocin A from E. faecium T136 was cloned into Pichia pastoris X-33EAS and 
production levels increased 21.4 fold and antimicrobial activity against a number of 
listeria strains increased 4-603 fold when compared to the natural producer (43). 
 
1.1.7 Genome mining 
In the past, bacteriocin-producing strains have been identified primarily on the basis 
of culture-based approaches. However, traditional plating techniques will reveal 
bacteriocin-producing cultures only if the culture produces the bacteriocin under the 
conditions used for laboratory growth and only if it is effective against the target 
organism chosen for the overlay. Recently there has been a move to supplement 
traditional mining techniques with exploring the genomes of microorganisms from 
under-exploited environments which could be a reservoir of novel bacteriocins. The 
number of genome sequences being deposited in public databases is continually 
increasing as a consequence of significant developments in next generation sequencing 
technologies. This information is often freely available through online databases and 
provides an opportunity for screening a wide number of microorganisms to identify 
those which have the potential to produce bacteriocins (44, 45). This is seen as the 
dawn of a new era in which in silico and bioengineering based approaches can 
complement, and potentially supersede, culture based methods (45). Despite this 
potential, finding bacteriocin genomes can be a challenge due to the small size of the 
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structural peptides and diversity of their operons. BAGEL 3 is a fast genome mining 
tool that can identify putative bacteriocins based on conserved domains in structural, 
biosynthetic, transport and immunity genes (46). In addition the BACTIBASE 
database is a manually curated repository of bacteriocin sequences that can also be 
helpful. (47). Mass spectrometry is also being used more often in the quest for novel 
bacteriocins. Natural Product Peptidogenomics is a mass spectrometry based genome 
mining approach that connects chemotypes with biosynthetic gene clusters, the 
objective being to match a series of mass shifts from MSn spectrum of a putative 
bacteriocin to the genes responsible for production (48). Zendo and co-workers (49, 
50) developed a rapid screening method using electrospray ionisation liquid 
chromatography/mass spectrometry (ESI/LC/MS) coupled with statistical analysis of 
antimicrobial spectra to accelerate the discovery of novel bacteriocins isolated from 
various sources. An example of a novel lantibiotic that has recently been discovered 
using a genome mining and PCR approach is the broad-spectrum cerecidin A1 and 
cerecidin A7 from B. cereus strain As 1.1846 isolated from spoiled soya milk. The cer 
locus differs from other class II lantibiotics in that it contains seven tandem precursor 
cerA genes and the cerecidins are notably active against multidrug resistant S. aureus 
(MDRSA) and vancomycin resistant E. faecalis (VRE) (51).  
 
1.1.8 Probiotics 
Finally, over the last few years there has been growing evidence that bacteriocin 
production confers a number of advantages on probiotic strains. It is proposed that the 
ability to produce bacteriocins may help a strain to establish itself in a new niche, 
inhibit competitors and pathogens, alter the composition of the microbiota and even 
modulate the host immune system (52). A recent study of the gut microbiota of elderly 
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Irish subjects revealed Enterococcus strains with anti-listerial activity, which merit 
closer attention with a view to investigating their use as probiotic strains. In addition, 
a Lactobacillus gasseri strain producing gassericin T was isolated during the same 
screening programme (53). Notably, Lb. gasseri bacteriocins are very active against 
Gram-positive pathogens and have potential as food preservatives due to their heat 
stability and pH stability. Lb. gasseri have been evaluated as probiotics and these 
investigations have also highlighted its tolerance of low pH environments, resistance 
to bile salts, ability to adhere to the host epithelium and modulate the innate and 
adaptive immune system (54). There have also been a number of recent studies that 
have highlighted the impact of the Abp118 bacteriocin by Lactobacillus salivarius 
UCC118 on the overall composition of the gut microbiota and on the host epithelium 
(55-57). Finally, a study of LAB associated with fish for human consumption showed 
that bacteriocin activity against fish pathogens is a widespread probiotic property. 
Indeed LAB active against lactococcosis were common among LAB isolated from 
edible fish, further supporting the theory that the best place to find antimicrobials 
against a specific pathogen is in the niche the pathogen proliferates (58). 
 
1.1.9   Conclusion  
In conclusion, there is a continued drive to find novel bacteriocins that can control 
food pathogens more effectively. Novel LAB bacteriocins continue to be discovered 
and the use of LAB that produce multiple bacteriocins is receiving renewed attention. 
These screening programmes are being aided by the use of genome mining and mass 
spectrometry to find and characterise new bacteriocins while new engineering-based 
approaches are being used in parallel to improve previously identified bacteriocins for 
particular applications /targets. There is great potential to carry out investigations that 
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would assess the impact of bacteriocins on entire food microbial consortia as has been 
done previously to assess the impact of bacteriocins on gut microbial populations (56, 
59). 
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Bacteriocins are natural antimicrobials that have been consumed via fermented foods 
for millennia and have been the focus of renewed efforts to identify novel bacteriocins, 
and their producing microorganisms, for use as food biopreservatives and other 
applications. Bioengineering bacteriocins or combining bacteriocins with multiple 
modes of action (hurdle approach) can enhance their preservative effect and reduce the 
incidence of antimicrobial resistance. In addition to their role as food biopreservatives, 
bacteriocins are gaining credibility as health modulators, due to their ability to regulate 
the gut microbiota, which is strongly associated with human wellbeing. Indeed the 
strengthening link between the gut microbiota and obesity make bacteriocins ideal 
alternatives to Antibiotic Growth Promoters (AGP) in animal feed also. Here we 
review recent advances in bacteriocin research that will contribute to the development 
of functional foods and feeds as a consequence of their roles in food biopreservation 
and human/animal health.  
 
1.2.2 Introduction 
Fermented foods have been part of the human diet for thousands of years and evolved 
through the need to extend shelf life and improve food safety via the inhibition of food 
spoilage/pathogenic microorganisms (1, 2). Lactic acid bacteria (LAB) are natural 
constituents of many fermented foods and contribute greatly to food biopreservation. 
LAB exert their preservative effects through the production of antimicrobial 
metabolites including organic acids, diacetyl, ethanol, hydrogen peroxide and 
bacteriocins. Bacteriocins are a heterogeneous group of ribosomally-synthesised 
antimicrobial peptides with the ability to kill closely-related (narrow spectrum) or a 
diverse range of (broad spectrum) microorganisms (3). Bacteriocins are frequently 
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very potent, being active at nanomolar concentrations, and exert their killing effect 
predominantly through membrane permeabilisation. They are broadly divided into two 
classes with Class I containing Ribosomally synthesised and Post-translationally 
modified Peptides (RiPPs) and Class II containing predominantly unmodified peptides 
(4). Bacteriocins are produced by Generally Regarded as Safe (GRAS) or Qualitative 
Presumption of Safety (QPS) organisms and are often sensitive to human proteases. 
Bacteriocins are now the focus of increased attention i) due to consumer requirements 
for minimally processed foods free from chemical additives (5) ii) due to their potential 
as natural alternatives to antibiotics due to increasing concerns about the emerging 
problem of antimicrobial resistance (4, 6) iii) as modulators of the human microbiome 
and, therefore, potential to address complex metabolic conditions such as diabetes and 
inflammatory bowel disease (7), and iv) as bacteriocin-producing probiotic cultures 
for inclusion in animal feed to promote growth, improve animal health and/or reduce 
infection (8) (Figure 1). 
 
1.2.3 Bacteriocins as food biopreservatives 
Bacteriocins with optimal potential as biopreservatives are safe for human 
consumption, have minimal effects on the human microbiota and are effective against 
food pathogens/spoilage microorganisms. They are also stable in the food matrix in 
which they are employed, which may require resistance to heat, pH and food associated 
enzymes (9). Bacteriocins can be added to foods in three ways; i) as a pure bacteriocin 
preparation ii) as bacteriocin-containing fermentates or iii) as bacteriocin-producing 
cultures (4, 10).  
Nisin A is a broad-spectrum Class I lantibiotic, produced by Lactococcus lactis, 
characterized by five intermolecular lanthionine rings that confer inherent heat and 
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protease stability. It is the most studied bacteriocin and it is the only commercially 
produced bacteriocin approved as a food additive by regulatory agencies including the 
World Health Organization (WHO)/Food and Drug Administration (FDA) in the USA 
and the European Food Safety Authority (EFSA) in Europe (11). It was first produced 
in England in the 1950s (1) and is now available as, for example, Nisaplin (2.5% nisin) 
(www.dupontnutritionandsciences.com)(11). Nisin Z, a His27Asn variant of nisin A, 
with greater solubility at higher pH thereby extending its usefulness for food 
applications, is also commercially available as, for example, Nisin Z®P ultrapure nisin 
(>95% nisin) (www.handary.com). The ability to bioengineer nisin has led to a number 
of nisin variants with improved capabilities, perhaps the most notable of these being 
nisin V, a Met21Val variant, which has improved activity against a variety of 
foodborne pathogens, including Listeria monocytogenes and Bacillus cereus (12). 
Nisin variants can be bioengineered through food-grade techniques involving double 
crossover mutagenesis which do not introduce exogenous DNA or antibiotic resistance 
markers. When made in this way, the producing strains are not regarded as genetically 
modified microorganisms by the EFSA under contained use legislation. This opens the 
possibility to custom design nisin for specific applications by increasing yield, 
increasing potency against specific targets or expanding its spectrum of inhibition 
thereby increasing its commercial potential as food biopreservatives (13).  
Bacteriocin containing food-grade fermentates are also commercially available and 
widely used in the food industry. These include the FDA approved MicroGARDTM 
range from Danisco and ALTA 2431 from Quest International and both contain 
pediocin PA-1 produced by Pediococcus acidilactici (5).  
Bacteriocin-producing cultures used as starter cultures or as adjunct cultures serve a 
dual purpose as they can contribute to both flavour and food safety, providing 
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fermentation and preservation simultaneously. This is more cost effective than using 
pure peptide and is subject to less regulatory control (9). Examples include the 
BactofermTM range (www.chr-hansen.com), containing pediocin and sakacin 
producing strains, used to make fermented sausages and dry cured meat and 
HOLDBAC® protective cultures (www.dupontnutritionandsciences.com) containing a 
mix of bacteriocin-producing strains used to protect seafood, meat and dairy products 
from Listeria, yeasts and moulds (9). Micocin® is a specifically designed protective 
culture with potent activity against food spoilage and pathogenic microorganisms in 
ready to eat meat products and approved for use in the US and Canada (14). It contains 
Carnobacterium maltoaromaticum which produces piscicolin 126 and carnobacterium 
BM1 and the circular bacteriocin, carnocyclin A, that is particularly potent against L. 
monocytogenes (15). Including Micocin® as a feed additive in the diet of Grimaud 
rabbits resulted in reduced levels of L. monocytogenes in ground meat during storage 
indicating that including a protective culture in animal diets resulted in safer food 
products (16).  
Recently discovered novel bacteriocins with potential as food preservatives include 
plantaricyclin A, a circular bacteriocin produced by the olive isolate Lactobacillus 
plantarum NI326, with activity against the beverage spoilage bacterium 
Alicyclobacillus acidoterrestris, which causes significant economic losses to the food 
industry every year (17). Enterococcus mundtii CRL35, a non-virulent, non-antibiotic 
resistant strain, also shows promise as an adjunct culture. It reduces L. monocytogenes 
during meat fermentation, both in vitro and in a beaker sausage model in the presence 
of curing agents, due to production of enterocin CRL35, a class IIa bacteriocin. 
Bacteriocin-producing strains are adversely affected by the presence of curing salts so 
the ability of E. mundtii to grow and exert a higher protective effect in fermented meats 
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is particularly advantageous (18). Gómez-Sala et al (2016) found that the use of the 
multibacteriocinogenic strain Lactobacillus curvatus BCS35 as a protective culture, 
and of its cell free supernatant used as a food ingredient during refrigerated storage, 
significantly reduced bacterial counts on fresh fish, thereby increasing the both the 
quality and commercial value of the product (19). Another exciting development in 
recent years is the use of antimicrobial-containing edible films and coatings, composed 
of layers of biopolymers that protect the food from the environment, to improve food 
safety by inhibiting food pathogens during handling, transportation and storage of food 
products (5, 20). 
 
1.2.4 Antimicrobial resistance  
A recent WHO report highlights concerns about the lack of progress in the search for 
new antimicrobial classes and calls for increased investment in drug discovery to 
combat the threat of antimicrobial resistance (6, 21). Bacteriocins are considered 
promising alternatives due to their stability (especially in the case of modified peptides 
such as the lantibiotics), low toxicity, frequently excellent potency and potential for 
target specificity. Many bacteriocins interact electrostatically with the cell membrane 
and introduce permeabilisation through interaction with receptor or docking 
molecules. Resistance can occur due to innate mechanisms, including the ability to 
produce degradation enzymes or the presence of immunity proteins, while acquired 
resistance occurs due to horizontal gene transfer or gene mutations that alter the cell 
membrane, binding receptors or transport systems (22, 23). Previously described 
resistance mechanisms include specific adaptations such as the loss of a receptor, as 
seen in resistance to class IIa bacteriocins like pediocin, or non-specific adaptations 
that alter the cell envelope, as seen in the case of resistance to Class I lantibiotics such 
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as nisin (10, 22, 24, 25). Radical adaptations requiring high energy costs that reduce 
the fitness of the cell may limit the ability of resistant mutants to compete in established 
niches, possibly explaining why bacteriocin resistance is rarer than antibiotic 
resistance (24, 26, 27). Knowledge of a bacteriocin’s mode of action (4) and how it 
acquires resistance facilitates the development of methodologies to minimise 
resistance occurrence (27). Strategies successfully used to reduce resistance include 
combining bacteriocins with other bacteriocins with different modes of action (23, 28, 
29), other antimicrobials (21, 25), or phages or, generating peptides with increased 
antimicrobial resistance through bioengineering (30). These hurdle (combinatorial) 
approaches have the added advantages of broadening the antimicrobial spectra while 
reducing costs and toxicity (25). Indeed, Perales et al (2018) found that a combination 
of enterocin AS-48 and nisin A acted synergistically to kill antibiotic resistant 
staphylococci, a common contaminant in processed food, in fresh goat milk cheese 
potentially improving its shelf life and safety. Using multiple bacteriocins reduces the 
bacteriocin dose and prevents the regrowth of bacteriocin resistant/adapted cells (21). 
Mills et al (2017) also used a multibacteriocin approach to develop a cheese starter 
system producing both nisin A and lacticin 3147. The use of these, in combination 
with a Lactobacillus plantarum Class II plantaricin producer, reduced Listeria 
numbers in lab scale cheese more effectively than when individual bacteriocin 
producers were used singly. The concurrent production of nisin A and lacticin 3147 
reduces the likelihood of incidence of bacteriocin resistance and this approach shows 
great potential for food safety applications (31).  
A bioengineering approach was used to overcome the efficacy of nisin resistance 
protein (NSR), expressed by some microorganisms, that cleaves nisin between residue 
28, involved in ring E formation, and serine 29, resulting in a truncated nisin 1-28 with 
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significantly reduced activity (30). A screening study located a nisin Ser29Pro variant 
with 20 fold increased activity against a NSR+ strain and a similarly resistant nisin PV 
variant that was less affected by oxidation (30). Recently, a survey of 182 
Lactobacillus strains revealed a high level of intrinsic antimicrobial resistance genes, 
with resistance to kanamycin, vancomycin and trimethoprim being most prevalent 
(32). Eighty eight per cent of the strains surveyed would fail EFSA regulatory 
guidelines, despite them being species widely used in foods for human and animal 
consumption, as the presence of antimicrobial resistance genes impacts on their use in 
food applications. These findings led the authors to call for revision of EFSA 
regulatory guidelines for lactobacilli entering the food chain and highlight that a more 
thorough understanding of antimicrobial resistance and its spread within 
microorganisms is required (32). Overall, the general consensus is that bacteriocins, 
like antibiotics, should be used exiguously to avoid selection of resistant phenotypes 
that may compromise their potential role as biopreservatives (22,24,25).  
 
1.2.5 Bacteriocin-producing probiotic strains as gut microbiome modulators 
The role of the gut microbiota in human health is of increasing interest as the links 
between a balanced, healthy gut microbiota and disease prevention become more 
apparent (23, 33). Broad-spectrum antibiotics indiscriminately affect the entire 
microbiota, leading to imbalances that could potentially predispose to conditions such 
as obesity, diabetes, immune disorders and neurodegenerative disease (29, 34, 35). 
Bacteriocin-producing LAB are antibiotic alternatives that have the potential to 
enhance gut health through their ability to survive the gut environment, inhibit 
pathogens and competitors, modulate the immune system and prevent inflammation 
and oxidative stress (33, 34, 36, 37). Considerable efforts are being made to understand 
 
34  
the contribution of bacteriocins produced by LAB to gut modulation, pathogen 
inhibition and their role in the maintenance of host health. To this end, an in vitro 
faecal fermentation system that mimics the anaerobicity of the colon was used to assess 
the effect of bactofencin A, a class IId bacteriocin produced by the porcine gut isolate 
Lactobacillus salivarius, on the human faecal microbiota. The study found subtle but 
positive differences in taxonomic profiles between the bactofencin A+ producing 
culture and its bactofencin A- mutant, while more drastic effects in taxonomy were 
detected in the presence of pure peptide (38). Similarly, in vivo studies using mice fed 
with a L. salivarius UCC118 bacteriocin producer, Bac+, or its bacteriocin-negative, 
Bac-, derivative over 8 weeks resulted in slight changes in the gut microbiota at the 
Phylum level. Whereas at the genus level, the Bac+ treatment resulted in a significant 
increase in Bacteroides spp. and decrease in Bifidobacterium spp. in comparison with 
the Bac- group (39). Efforts to assess if bacteriocin production in vivo inhibits gut 
pathogens without negatively impacting beneficial populations require rigorous 
experimental methods to provide meaningful results (40). Bauer et al (2017) describe 
a generic method, using compositional 16S rDNA combined with bioinformatics, to 
compare the effect of bacteriocin producers to their isogenic non-producing 
equivalents on microbiota composition in a mouse model allowing impacts on the gut 
microbiota to be measured in a live animal model (36). This model was used in a mouse 
feeding trial, where five Class II bacteriocin-producing LAB were compared with 
isogenic non-producing equivalents. The trial showed that while the overall diversity 
was unchanged, advantageous changes relating to pathogen inhibition and increased 
LAB levels were seen briefly, suggesting that bacteriocin production facilitated 
favourable changes without collateral damage to the gut microbiota (41). These studies 
provide further evidence that bacteriocin production provides subtle positive changes 
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at lower taxonomic levels that maintain a desirable gut microbiota and are beneficial 
to the host (7).  
Bacteriocins, unlike antibiotics, are often very specific and can kill pathogens without 
causing detrimental imbalances to the host microbiota. Vancomycin resistant 
enterococci (VRE) are gut inhabitants that can cause fatal infections, particularly in a 
hospital environment. A recent report by Kim et al (2019) describes the ability of gut 
commensals to increase the resistance of the host to vancomycin resistant 
Enterococcus faecium (VREf). They found that one constituent of a four strain 
cocktail, Blautia producta BPSCSK, a nisin A variant producer, was responsible for 
reduced colonisation by VRE. A direct correlation was found between the amount of 
the lantibiotic gene and VRE reduction in germ free mice containing patient feces, thus 
demonstrating the potential of bacteriocins as antibiotic alternatives (42).  
The gut microbiota also enables the gastrointestinal tract and the brain to communicate 
through the gut brain axis, which is described as a neuroendocrine signalling system 
that transmits information through endocrine signals, neurons and the immune system 
(34). A recent microbiota-gut-brain–axis study demonstrated that nisin increased 
duodenal levels of the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) and 
dopamine (DA) in a bacterial diarrhoea mouse model induced by pathogenic E. coli 
O1. In addition, nisin increased the bacterial diversity in the mouse cecum samples by 
increasing beneficial Lactobacillus, Bacteroides and Bifidobacterium species while 
inhibiting pathogenic E. coli and Enterococcus spp. Taken together, the results show 
a positive correlation between nisin, the gut microbiota and stress reduction triggered 
by E. coli induced diarrhoea in mice, suggesting that probiotics can both regulate the 




1.2.6 Genome mining studies reveal that the gut microbiota is a rich source of 
bacteriocin genes 
In silico genome mining techniques are routinely used to identify bacteriocin gene 
clusters in bacteria from numerous sources including the commensal mammalian 
microbiota. An in-depth look at human commensal metagenomic sequences found that 
the number of putative bacteriocin genes varied according to body site, with a higher 
proportion found in the mouth, airway and vagina and lowest in the gut (44). However, 
analysis of genomes specifically from the human gut revealed that almost half, 
predominantly from LAB, encoded putative bacteriocins and are proposed to aid 
diversity through establishment of commensal relationships with the host and aid host 
defence by inhibiting pathogens (45). In silico analysis of genomes from rumen 
bacteria found numerous novel sactipeptide and lanthipeptide bacteriocin gene clusters 
suggesting that the rumen is a rich source of novel antimicrobial peptides with 
potential as food preservatives and use in animal production (46). A more recent 
metagenomic functional screening of the rumen metagenome identified 181 previously 
unidentified antimicrobial peptides, three of which (Lynronne-1, 2 and 3) were shown 
to have activity against methicillin resistant Staphylococcus aureus (MRSA) and other 
pathogens. Interestingly, MRSA did not produce resistant mutants when subcultured 
in sub MIC levels of these peptides over 25 days (47).  
Shotgun sequencing of the gut microbiome allows identification of microorganisms to 
species or strain level and even detects genes related to antibiotic resistance, vitamin 
production or short chain fatty acid production. However, advances in sequencing-
based microbiome profiling methods, such as metatranscriptomics, can go further to 
assess gene expression, thus providing an accurate method to determine which genes 
are expressed by the microbiome. This technique is capable of generating large-scale 
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profiles of complex microbiomes and is expected to improve our understanding of the 
role that bacteriocins play in gut ecology (48).  
 
1.2.7 Bacteriocin-producing probiotic cultures as antimicrobials in animal feed  
Since the 1930s, antibiotics have been used in animal husbandry to treat infections, 
prevent disease and improve feed efficiency (49). Antibiotic use in global food 
production is increasing worldwide to meet the growing demand for animal protein 
and now surpasses human consumption. Indeed, in some countries, it has been reported 
that 80% of antibiotics important for human medicine are consumed by healthy 
animals to promote growth (50, 51). Concerns about increases in drug resistance in 
animal pathogens and its potential transfer from livestock to humans, leading to 
untreatable infections, has led to the WHO introducing a Global Action Plan on 
Antimicrobial Resistance highlighting the need for a concerted international approach 
from consumers, environmentalists, agriculture, human and veterinary medicine to 
combat this growing crisis (51-53). In 2006, the European Union banned the use of 
animal growth promoters (AGP) in animal feed, creating a need for a new 
antimicrobial strategy. A pioneering study by Corr et al (2007) found that production 
of Abp118 by L. salivarius UCC118 protected mice in vivo from the food pathogen L. 
monocytogenes, thus confirming the antimicrobial potential of bacteriocin-producing 
probiotic cultures (54). Since then, there have been numerous studies, predominantly 
in vitro, providing evidence that bacteriocins are potential alternatives to antibiotics in 
animal production (53). Recently, Hu et al (2018) showed that a faecal microbiota 
transplantation (FMT) from diarrhoea resistant to diarrhoea susceptible pigs protected 
against early weaning diarrhoea induced by stress, a huge problem in the swine 
industry. Further investigation revealed that the protective effect was attributable to 
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the presence of Lactobacillus gasseri and Lactobacillus frumenti. More specifically, 
this effect was due to their ability to produce the circular bacteriocin, gassericin A, 
which binds to the pig’s intestinal epithelial membrane, thus preventing diarrhoea 
onset and providing further evidence that probiotic cultures have potential as antibiotic 
alternatives for diarrhoea prevention in mammals (55).  
The ability of AGP to improve growth and body weight gain of animals is tentatively 
attributed to modulation of the gut microbiota as it plays an important role in obesity 
(33). Direct Fed Microbials (DFM) such as probiotic LAB are associated with weight 
gain in animals (8) and tentative links are being established between feed efficiency in 
pigs and the intestinal microbiota (56). This makes it tempting to suggest that 
bacteriocin-producing LAB can be used to modulate the gut microbiota in a way that 
improves feed efficiency. Nisin has been proposed as a feed supplement for broiler 
chickens as preliminary experiments suggest that it improves body weight gain in a 
dose-related manner, an effect that may be due to gut microbiota modulation (57).  
One of the challenges for bacteriocins in feed applications is the ability to pass through 
the gastrointestinal tract without digestion by proteolytic enzymes. This can be 
achieved through encapsulation, a protective technique that ensures successful 
delivery to the target site without loss of bioactivity where they can be released in a 
controlled fashion (20). Both nisin A and bactofencin A were recently successfully 
encapsulated in mesoporous matrices, with nisin A being protected from degradation 
by pepsin and bactofencin A by trypsin (58, 59). Bioactive intact nisin and nisin 
fractions were detected in the feces of mice pellets following feeding with nisin 
encapsulated in starch-based matrices, therefore achieving the aim of delivering intact 
nisin to the gut by oral means (60). The amount of nisin detected in the feces varied 
with starch matrix, highlighting that optimum delivery requires examination of a range 
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of substrates and conditions. These preliminary studies show that bacteriocins are 
effective in a gut environment.  
 
1.2.8 Conclusions 
Current research is strengthening the view of bacteriocins as being versatile 
antimicrobials with considerable potential for use as biopreservatives, antibiotic 
alternatives, health-promoting gut modulators and animal growth promoters. 
Excessive use of antibiotics, and especially of broad-spectrum antibiotics, in medicine 
and food production has been recognised as a cause of microbiome disruption and 
select for accumulation and transfer of resistance genes within the microbial 
population of the human gut (35). Overall, though bacteriocins are likely expressed at 
low levels in the gut, it is considered that their production by gut commensals enables 
a healthy and stable microbiome by preventing invasion by undesirable species (44) 
and the establishment of desirable microbes.  
The use of DFM as alternatives to AGP is a relatively new area of research that shows 
promise for bacteriocin-producing LAB as initial studies show that bacteriocins are 
also effective in the animal gut. While obtaining approval from FDA and EFSA or 
other agencies to utilise bacteriocins within feed additives for animal nutrition is a 
lengthy process (61), their potential to play a role beyond that of biopreservative is 
notable, with a number of studies describing them as versatile health promoter 
molecules (11, 26).  
The incorporation of bacteriocin-producing probiotics into foods and feeds as well as 
assuring their activity during processing and subsequent passage through the host’s 
gastrointestinal tract are challenges that are being addressed through the discovery and 
development of new bacteriocin-producing strains and novel encapsulation techniques 
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(58-60, 62). Commercial scale bacteriocin production is still hampered by high costs 
and low peptide yield but cost efficiency is being improved through optimisation of 
fermentation processes and bioengineering strains for maximum bacteriocin 
production (63). It should also be noted that further studies are also required to 
establish dosage levels and to further improve effective delivery to target sites. 
Overall, the expanding potential role of bacteriocins in food preservation, gut 
modulation, antimicrobial resistance reduction and animal feed suggest that, if the 
hurdles described are overcome, there are considerable opportunities for widespread 
bacteriocin-based applications in the food and feed industries.   
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Figure 1 Potential applications of i) bacteriocin-producing cultures, ii) bacteriocin-
containing fermentates, iii) purified bacteriocins and iv) encapsulated bacteriocins as 
food preservatives, gut modulators, feed additives and therapeutics.  
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Accumulating evidence suggests that bacteriocin production represents a probiotic trait 
for intestinal strains to promote dominance, fight infection, and even signal the immune 
system. In this respect, in a previous study, we isolated from the porcine intestine a 
strain of Streptococcus hyointestinalis DPC6484 that displays antimicrobial activity 
against a wide range of Gram-positive bacteria and produces a bacteriocin with a mass 
of 3,453 Da. Interestingly, the strain was also found to be immune to a nisin-producing 
strain. Genome sequencing revealed the genetic determinants responsible for a novel 
version of nisin, designated nisin H, consisting of the nshABTCPRKGEF genes, with 
transposases encoded between nshP and nshR and between nshK and nshG. A similar 
gene cluster is also found in S. hyointestinalis LMG14581. Notably, the cluster lacks an 
equivalent of the nisin immunity gene, nisI. Nisin H is proposed to have the same 
structure as the prototypical nisin A but differs at 5 amino acid positions Ile1Phe (i.e., at 
position 1, nisin A has Ile while nisin H has Phe), Leu6Met, Gly18Dhb (threonine 
dehydrated to dehydrobutyrine), Met21Tyr, and His31Lys and appears to represent an 
intermediate between the lactococcal nisin A and the streptococcal nisin U variant of 
nisin. Purified nisin H inhibits a wide range of Gram-positive bacteria, including 
staphylococci, streptococci, Listeria spp., bacilli, and enterococci. It represents the first 
example of a natural nisin variant produced by an intestinal isolate of streptococcal 
origin. 
 
2.1.2  Introduction 
Bacteriocins of lactic acid bacteria have received extensive attention in recent years 
given their structural diversity and activity and their potential as biopreservatives and 
anti-infectives. Indeed, the production of bacteriocins by intestinal bacteria is 
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considered a probiotic trait and has been shown to be associated with strain 
dominance, infection control, and host cell signaling (1). One of the oldest and 
undoubtedly the most extensively characterized bacteriocins is nisin A, which was 
discovered by Rogers in 1928 (2). Nisin A is produced by many strains of Lactococcus 
lactis, a species widely used for cheese manufacture. It has a broad antimicrobial 
spectrum against a wide range of Gram-positive genera, including staphylococci, 
streptococci, Listeria spp., bacilli, and enterococci (3). Nisin A has been used in the 
food industry as a biopreservative for more than 50 years without inducing widespread 
microbial resistance (4, 5). The bacteriocin has multiple antimicrobial actions; it 
binds to the precursor of peptidoglycan, lipid II, to inhibit cell wall biosynthesis and 
then forms pores in the cell membrane, leading to the release of essential ions and, 
ultimately, cell death (6–8). 
The nisin gene cluster in L. lactis is associated with a conjugative transposon and 
consists of nisABTCIPRKFEG, where nisA encodes the nisin prepropeptide. Immunity 
to nisin is provided by a specific immunity protein, NisI, and a specialized ABC 
transporter, NisFEG (9). The lipoprotein, NisI, most probably orients to the outside of 
the cytoplasmic membrane and binds nisin, preventing it from binding to lipid II and 
forming pores in the cell membrane (10, 11). NisFEG are thought to transport nisin 
from the cytoplasmic membrane to the external environment, thus preventing the 
accumulation of the high number of nisin molecules necessary for pore formation (12, 
13). The extent to which nisin is produced is affected by the level of immunity of the 
producing microorganism. For maximal nisin immunity, both the lipoprotein and the 
nisin transporters are required (12, 14–16). 
To date, eight natural nisin variants have been discovered (Figure. 1). These include nisins 
Z, F, and Q, which have been isolated from lactococci, nisins U and U2, from 
 
55  
Streptococcus uberis, and nisin P, which is encoded on nisin operons present in both 
Streptococcus gallolyticus subsp. pasteurianus (17) and Streptococcus suis (18). Nisin 
Z producers are very common, and the amino acid sequence differs from that of nisin 
A at a single position (His27Asn) (19, 20), a change that improves the solubility of 
the peptide at a neutral pH (21). The operon encoding nisin F was found on a plasmid 
in L. lactis F10, isolated from the intestinal tract of a freshwater catfish in South Africa. 
Nisin F differs from nisin A at 2 amino acid positions: His27Asn, as seen in nisin Z, and 
Ile30Val (22). Nisin Q is produced by L. lactis 61-14, isolated from a river in Japan, 
and differs from nisin A at 4 amino acid positions, i.e., those observed in nisin F as well 
as Ala15Val and Met21Leu (23). The Streptococcus-associated variants differ more 
considerably from nisin A. The S. uberis producers of nisin U and U2 were isolated 
in cases of bovine mastitis in the United States. Nisin U differs from nisin A at 9 
positions—Ile4Lys, Ala15Ile, Gly18Thr, Asn20Pro, Met21Leu, His27Gly, Ser29His, 
Ile30Phe, and His31Gly—and also lacks the three C-terminal amino acids of nisin A. 
In addition to these changes, nisin U2 contains a further Ile1Val change (24). Finally, 
and most recently, a phylogenetic study of lanthipeptide synthetases by Zhang et al. 
(2012) (17) revealed an S. gallolyticus subsp. pasteurianus strain that encodes a 
structural gene with the potential to produce a new nisin analogue, nisin P. Nisin P is 
closely related to nisin U2, differing with respect to just 2 amino acids: Phe20 and 
Leu21 in nisin U2 are changed to Ala20 and Ile21 in nisin P. The more distantly related 
nisin-like lantibiotic salivaricin D, isolated from Streptococcus salivarius 5M6c, a 
human isolate, differs from nisin A at 17 positions, with most differences seen at the 
C-terminal end of the molecule (25). 
In this study, we have identified a new nisin variant, designated nisin H, produced by a 
strain of Streptococcus hyointestinalis isolated from the porcine intestine. The name S. 
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hyointestinalis was first employed in 1988 to reassign a number of strains that had 
previously been classified as Streptococcus salivarius (26) and was derived from the 
Greek noun hyos, meaning pig, and the Latin adjective intestinalis, which reflects the 
association of the strains with the porcine intestine. Previously an S. hyointestinalis 
isolate producing a broad-spectrum antimicrobial that inhibits bifidobacteria, 
lactobacilli, Leuconostoc spp., Listeria spp., Staphylococcus aureus, and Streptococcus 
agalactiae was isolated as part of a mammalian-gut-mining study by O’Shea et al. 
(2009) (27). Since this represented the first report of an S. hyointestinalis strain that 
produces an antimicrobial, we sequenced and analyzed the genome of this strain. 
Ultimately, this led to the isolation, characterization, and identification of a novel nisin 
variant, which we designate nisin H, produced by a gut-derived strain. 
 
2.1.3 Materials and Methods 
Bacterial strains and culture conditions 
The bacterial strains used in this study are listed in Table 1. Anaerobic conditions were 
generated through the use of anaerobic jars containing Anaerocult A gas packs (Merck, 
Darmstadt, Germany). Agar (Oxoid Ltd., Basingstoke, Hampshire, United Kingdom) was 
added (1%, wt/vol) to broth media when agar plates were required.  
 
Isolation of DNA for PCR analysis 
DNA was extracted from culture cell pellets for PCR analysis with a GenElute bacterial 
genomic DNA kit (Sigma-Aldrich, Co. Wicklow, Ireland) and molecular manipulation 
techniques from the work of Sambrook and Russell (2001) (28) were used when 
required. Oligonucleotide primers were synthesized by Sigma-Genosys (Poole, 
Dorset, United Kingdom), and purified PCR amplicons were sequenced by Beckman 
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Coulter Genomics (Essex, United Kingdom).  
DNA was amplified with MyTaq DNA polymerase (Bioline, London, United 
Kingdom) according to the manufacturer’s instructions. PCRs were carried out in a 
Techne TC-512 thermal cycler (Bibby Scientific, Staffordshire, United Kingdom). 
 
Genome sequencing and analysis of the nisin H gene cluster.  
The sequence of the genomic DNA extracted from S. hyointestinalis DPC6484 was 
determined by 454 pyrosequencing (Beckman Coulter Genomics, USA). The resulting 
sequence reads were assembled into contigs using the Newbler package. Coding 
regions in the draft genome assembly were predicted using GLIMMER, version 2.0 
(29), and annotation was subsequently determined using the GAMOLA software 
package (30). Sequence similarity analyses were performed using the gapped BLASTp 
algorithm and the nonredundant database provided by the NCBI (ftp://ftp.ncbi.nih 
.gov/blast/db) (31). By using the ARTEMIS genome viewer (32), components of the 
nisin H gene cluster were identified on two distinct contigs. PCR with the primer pair 
comprising 5’ GTTGACTTATTGAGCGAGG 3’ and 5’ GCCAACTTATTACGTT 
CTTCAC 3’, designed to be specific to the sequences flanking the 3 and 5 termini of 
the respective contigs, confirmed the contiguous nature of this gene cluster. The 
annotation of the gene cluster was then verified manually. The sequence data were 
aligned and analyzed by using LASERGENE software (DNAStar Inc., Madison, WI).  
The genome was searched for the presence of a nisI immunity gene equivalent with 
primers designed to be specific to the nisI immunity gene of L. lactis NZ9700 and the 
nsuI immunity gene of S. uberis 42 (Table 2).  
 
Purification of the antimicrobial produced by S. hyointestinalis DPC6484.  
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The antimicrobial was purified from the cell-free supernatant (CFS) of a 2-liter culture 
of S. hyointestinalis DPC6484 grown in tryptic soy broth (TSB) at 37°C overnight. The 
culture supernatant was applied to a 90-ml SP Sepharose column (GE Healthcare, 
Uppsala, Sweden) pre-equilibrated with 50 mM sodium acetate buffer, pH 4.4 (buffer 
A). The column was washed with 300 ml of buffer A, and the antimicrobial activity was 
eluted in 300 ml of buffer A containing 1 M NaCl. This eluent was then applied to a 
5-g, 20-ml Strata C18-E solid-phase extraction (SPE) column (Phenomenex, Cheshire, 
United Kingdom) preequilibrated with methanol and water. The column was washed 
with 20 ml of 25% ethanol, and the antimicrobial activity was eluted with 20 ml of 70% 
2-propanol 0.1% trifluoroacetic acid (TFA). The antimicrobial activities of cell-free 
supernatants and eluents from purification protocols were determined via the agar well 
diffusion assay described by Ryan et al. (1996) (33). Lactobacillus delbrueckii subsp. 
bulgaricus LMG6901 was used as the indicator strain, and bioactivity was assessed 
following aerobic incubation of plates overnight at 37°C. The 2-propanol was removed 
by rotary evaporation, and the sample was applied to a Jupiter Proteo reversed-phase 
high-performance liquid chromatography (RP-HPLC, Phenomenex, Cheshire, UK) 
column (length, 10 mm; inside diameter, 250 mm; particle size, 4 µm, pore size, 90 
Å) running a 25-to-45% acetonitrile– 0.1% TFA gradient over 35 min at 2.5 ml/min. 
The resultant eluent was monitored at 214 nm, and fractions were collected at 1-min 
intervals. Fractions were assayed for antimicrobial activity by a well diffusion assay with 
L. delbrueckii subsp. bulgaricus LMG6901 as the indicator strain, and those containing 
antimicrobial activity were analyzed via matrix-assisted laser desorption ionization–
time of flight mass spectrometry (MALDI-TOF MS) to determine the molecular mass 
of the antimicrobial peptide and to assess peptide purity. HPLC fractions deemed pure 
by MALDI-TOF MS were combined and were lyophilized in a Genevac (Suffolk, 
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United Kingdom) lyophilizer. MALDI-TOF mass spectrometry was performed with 
an Axima TOF2 MALDI-TOF mass spectrometer in positive-ion reflectron mode 
(Shimadzu Biotech, Manchester, United Kingdom). N-terminal sequencing (Edman 
degradation) of purified nisin H was performed by Abingdon Health Laboratory 
Services (Birmingham, United Kingdom). 
Pure nisin A peptide was prepared from L. lactis NZ9700 as described for nisin H. 
 
Cross immunity of S. hyointestinalis DPC6484 to other nisin-producing cultures  
The cross immunity of S. hyointestinalis DPC6484 to the bacteriocins produced by L. 
lactis NZ9700 (nisin A), S. uberis strain 42 (nisin U), L. lactis DPC3251 (lacticin 
3147) and to L. delbrueckii subsp. bulgaricus LMG6901, a non-bacteriocin producer 
used as a bacteriocin-sensitive strain, was determined by spotting 50-µl aliquots of cell 
free culture supernatants onto indicator plates seeded with 1% (vol/vol) of each of 
these strains. L. delbrueckii subsp. bulgaricus LMG6901, known to be sensitive to each 
of these nisin variants and to lacticin 3147, was used as an indicator strain to confirm 
the production of nisins A, H, and U and lacticin 3147 by the respective strains. 
 
Comparison of the inhibitory activities of pure nisin A and nisin H peptides 
Purified nisin A and H peptides were resuspended at 0.22 mg/ml in 35% 2-propanol for 
optimum solubility. Aliquots (50 µl) of each peptide were tested for antimicrobial 
activity by well diffusion using the indicator strains listed in Table 4. The culture 
media and incubation conditions are outlined in Table 1. A 50-µl aliquot of 35% 2-





Genomic profiles of S. hyointestinalis strains 
Molecular fingerprinting of S. hyointestinalis isolates was performed by pulsed-field gel 
electrophoresis (PFGE) as described by Simpson et al. (2002) (34) using SmaI 
restriction endonucleases and DNA molecular weight markers (9.42 to 242.50 kb; 
New England BioLabs, Beverly, MA). DNA fragments were resolved with a CHEF 
(contour-clamped homogeneous electric field) DRIII pulsed-field system (Bio-Rad 
Laboratories) at 6 V/cm for 18 h with a 1- to 30-s linear ramp time to resolve bands. 
 
Assessment of the distributions of nshA, nshF, nshR, and nshT in S. hyointestinalis 
strains 
The presence of the nshA, nshF, nshR, and nshT genes in S. hyointestinalis DPC6484 
and S. hyointestinalis strains obtained from the BCCM/LMG culture collection were 
checked using gene-specific primer pairs. The primer pairs and the sizes of the expected 
gene products are given in Table 2. 
 
Nucleotide sequence accession number 
The sequence of the nisin H gene cluster of Streptococcus hyointestinalis DPC6484 is 
available from GenBank/EMBL under accession number KP793707. 
 
2.1.4  Results 
Genome sequencing of S. hyointestinalis DPC6484 reveals a nisin-like gene cluster 
In a previous study, which involved the screening of mammalian samples from the 
gastrointestinal tracts of humans, pigs, and cows, we identified S. hyointestinalis 
DPC6484, a strain that inhibits bifidobacteria, lactobacilli, Leuconostoc spp., Listeria 
spp., S. aureus, and S. agalactiae (27). Given that antimicrobial production has not been 
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attributed to an S. hyointestinalis strain previously, the genome of DPC6484 was 
sequenced with a view to the identification of the gene cluster responsible for this 
phenotype. Analysis of the draft genome revealed the presence of a nisin homologue and 
of associated biosynthesis genes on two contiguous sequence regions. The assembled 
gene cluster, of ~15.8 kb (Figure. 2), was found to contain a putative nisin variant-
encoding structural gene designated nshA (nsh for nisin from S. hyointestinalis, or nisin 
H) followed by homologues of nisBTCP (designated nshBTCP), a region encoding a 
streptococcal transposase, the equivalents of nisRK (designated nshRK), another region 
encoding a streptococcal transposase, and nisFEG-like genes (designated nshFEG). A 
notable feature was the absence of an equivalent of the nisI immunity gene. Further 
investigation of the S. hyointestinalis strain via a BLAST analysis on the draft genome 
sequence and PCR-based approaches suggested the absence of an obvious NisI 
homologue (data not shown). 
The protein sequences ranged from 54% identity with the lactococcal equivalent for 
NshG to 82% identity for NshA. The predicted product of nshA is a 57-amino-acid 
peptide that, on the basis of comparison with other nisin peptides, is likely to consist of 
a 23-amino acid leader and a 34-amino acid propeptide. The putative propeptide differs 
from the corresponding nisin A peptide at five positions: Ile1Phe, Leu6Met, Gly18Thr, 
Met21Tyr, and His31Lys (Figure. 1). 
 
Purification and predicted structure of nisin H 
The nisin H peptide was purified using SP Sepharose cation-exchange SPE, C18 SPE, 
and reversed-phase HPLC. The HPLC chromatogram (Figure. 3) shows a dominant 
peak corresponding to a fraction that inhibited the indicator strain, L. delbrueckii 
subsp. bulgaricus LMG6901. This purification strategy typically yielded 0.15 mg/ 
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liter, which is lower than the 0.50 mg/liter of nisin A recovered from a corresponding 
starting volume by using the nisin A producer L. lactis NZ9700.  
The first 10 amino acids of the predicted NshA propeptide are FTSISMCTPG (Figure. 
2). Lantibiotics can be difficult to sequence using Edman degradation, because the 
dehydrated amino acids and ring structures are not compatible with this technique. 
Nonetheless, Edman sequencing of the newly purified antimicrobial revealed a 
sequence consisting of F-X-X-X-X-M-X-X-P-G. This sequence conforms to the gene 
predictions of the identifiable residues at positions 1, 6, 9, and 10 and is consistent with 
the predicted presence of modified residues at positions 2, 3, 5, 7, and 8. MALDI-TOF 
MS analysis revealed a molecular mass of 3,453 Da, which is consistent with a modified 
form of the NshA peptide. MALDI-TOF MS also showed a difference of 101 Da 
between the molecular mass of nisin A (3,352 Da) and that of the antimicrobial 
produced by DPC6484 (3,453 Da) (data not shown). This difference precisely matches 
the molecular mass differences expected from the predicted amino acid changes and 
the likely dehydration of the additional threonine residue. Converting Ile to Phe, Leu 
to Met, Gly to Thr, and Met to Tyr results in 34-, 18-, 44-, and 32-Da increases, 
respectively, and results in a total peptide mass of 3,480 Da. In addition, the alteration 
of His to Lys results in a 9-Da loss, giving a mass of 3,471 Da, 18 Da higher than the 
3,453-Da mass for nisin H. However, in nisin molecules, threonine is always 
dehydrated to dehydrobutyrine (Dhb), thus accounting for this 18 Da. It is thus 
apparent that the purified antimicrobial, referred to below as nisin H, represents a 
modified form of the NshA peptide with 5 substitutions. The proposed structure of 
nisin H, modeled on known structures of nisin variants, is shown in Figure. 4. 
Nisin A- and nisin H-producing strains are cross immune 
The nisin H producer was tested to assess its cross immunity to CFSs from producers 
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of nisins A and U. CFSs from nisin A-, H-, and U-producing cultures inhibited the 
growth of the indicator strain L. delbrueckii subsp. bulgaricus LMG6901, as expected 
(Table 3). Nisin A- and U-containing CFSs did not inhibit S. hyointestinalis DPC6484 
or L. lactis NZ9700. However, CFSs from the nisin A and H producers inhibited the 
nisin U-producing S. uberis strain 42, suggesting that S. uberis is not cross immune to 
nisin A or nisin H. Further analysis with purified nisins revealed that at the 
concentrations used (0.22 mg ml—1), the immunity mechanisms are overwhelmed, in 
that purified nisin A and nisin H generate zones of inhibition with areas of 0.32 cm2 
against the strains that produce these peptides and zones that are twice as large (0.69 
cm2) against the opposing producer. Notably, however, these peptides produce 
significantly larger zones, with areas of 3.39 and 2.38 cm2, respectively, against S. 
uberis strain 42 (Table 4). 
The activities of purified nisin A and nisin H peptides against Escherichia coli 
DPC6912, Bacillus cereus 9139, L. delbrueckii subsp. bulgaricus LMG6901, 
Lactococcus lactis subsp. cremoris HP, Enterococcus faecalis 6307, S. agalactiae ATCC 
13813, S. agalactiae DPC5338, Streptococcus bovis DPC6491, S. gallolyticus DPC6501, 
Listeria innocua DPC3572, Listeria monocytogenes 1042, S. aureus ATCC 25923, S. 
aureus DPC5245, S. hyointestinalis DPC6484, and S. uberis strain 42 were assessed 
(Table 4). In the majority of instances, nisin A was more inhibitory than nisin H. 
However, nisin H was more effective than nisin A against one of the S. aureus strains 
tested, DPC5245, and the two peptides were equally effective against L. innocua 
DPC3572. 
 
Not all S. hyointestinalis strains produce nisin H 
PFGE of S. hyointestinalis DPC6484 and seven S. hyointestinalis strains from the 
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BCCM/LMG culture collection confirm different banding patterns; thus, these strains 
are not clonal (Figure. 5A). Efforts to amplify each of the genes nshA, nshF, nshR, and 
nshT by PCR using specific primers (Table 2) resulted in the generation of amplicons 
of the appropriate sizes (Figure. 5Bi) for the nisin H producer S. hyointestinalis 
DPC6484 (positive control) and S. hyointestinalis LMG14581 but not for the other S. 
hyointestinalis strains. DNA sequencing of the S. hyointestinalis LMG14581 
amplicons confirmed the presence of nsh equivalents in this strain. Although S. 
hyointestinalis LMG14581 contains nsh gene equivalents, this strain did not produce 
a zone of inhibition against L. delbrueckii subsp. bulgaricus LMG6901 (Figure. 5Bii). 
 
2.1.5  Discussion 
 
Nisin H is of interest for several reasons. First, it is notable by virtue of being a nisin-
like bacteriocin that is produced by an intestinal strain. As such, production of the 
bacteriocin has the potential to give the strain a competitive advantage in the gut 
environment, either by directly inhibiting competitor bacteria or by facilitating 
communication with other strains or even the host. In addition, nisin H may also have 
a role in signaling to the host, since bacteriocin production has been associated with 
immunomodulatory effects often mediated through cytokine responses (35–37). 
Second, nisin H seems to represent an evolutionary link between lactococcal and 
streptococcal nisins in that, while it is quite different from nisin A by virtue of having 
five separate substitutions, it retains key features of the lactococcal peptides, including 
the three C-terminal amino acids, which are absent from the Streptococcus-associated 
nisin U. Third, the nisin H gene cluster is the only nisin gene cluster to lack an equivalent 
of the nisI immunity gene. 
The lactococcal nisin A gene cluster (Figure. 2) encodes nisin production genes in the 
order nisABTCIPRKFEG, and this gene order is conserved in the corresponding nisin 
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Z and nisin Q clusters (38). The gene order is different in streptococcal nisin gene 
clusters. In the nisin U gene cluster, nsuPRKFEG are at the start of the gene cluster, i.e., 
before the nsuABTCI genes, suggesting a rearrangement of nsuABTCI and 
nsuPRKFEG in S. uberis (24). Gene clusters containing structural genes for nisin 
analogues have also been identified in S. gallolyticus subsp. pasteurianus (17, 39), S. 
agalactiae (40), and, most recently, S. suis (18). The gene order in these gene clusters 
is identical to that for nisin U. It would seem most likely that nisin-like clusters have 
moved between streptococci by horizontal gene transfer, as proposed by Richards et 
al. (2011) (40). Interestingly, the nisin H gene cluster differs from the Lactococcus and 
Streptococcus nisin clusters identified previously. Although the order of nshABTCP is 
the same as that for lactococci, the absence of a nisI gene between nshC and nshP is 
notable. Attempts to amplify a nisI gene equivalent using primers designed to be 
specific to the nisI gene of L. lactis and the nsuI gene of S. uberis were unsuccessful. The 
absence of an obvious nisI gene in the remainder of the draft genome was confirmed 
by a comprehensive BLAST search; however, the presence of a novel immunity-like 
gene elsewhere in the genome cannot be ruled out. In addition, the nisin H gene cluster 
exhibits a number of other significant differences from previously described nisin 
clusters in gene order and orientation, most likely due to gene rearrangements brought 
about by the action of transposases. 
The lack of an equivalent to the immunity protein, NisI, can have negative implications 
for bacteriocin production by the producing cell (41, 42). The yield of nisin H from the 
culture supernatant is low relative to that of nisin A, a finding initially attributed to the 
lack of a nisI immunity gene. However, further investigations revealed that poor 
bacteriocin production is most likely due to low cell numbers following 16 h of growth 
in TSB, typically 6 × 107 cfu/ml for S. hyointestinalis DPC6484 compared to 4 × 108 
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cfu/ml for L. lactis NZ9700. S. hyointestinalis strain LMG14587, which does not contain 
the nisin H gene cluster, grew to levels similar to those of DPC6484, suggesting that 
the absence of nisI was not responsible for a growth defect in DPC6484. In addition, 
previous nisI knockout studies have shown that a specific immunity gene is not 
necessary to confer full immunity (10), and Stein et al. (2003) reported that either nisI 
or nisFEG were able to confer immunity on nisin-sensitive Bacillus subtilis host cells 
(12). In this study, it would appear that the ABC transporter genes nisFEG are sufficient 
for self-protection in S. hyointestinalis DPC6484. Of note, other lantibiotic gene 
clusters, such as those of mersacidin and lacticin 481, also lack a specific immunity 
protein but possess NisFEG equivalents (13, 43). 
The molecular mass difference of 101 Da between nisin A and nisin H can be accounted 
for by the amino acid differences. Given the highly conserved nature of nisin structures, 
we propose that nisin H has the same ring structure as nisins A, Z, F, and Q. It is more 
similar in structure to the lactococcal nisins in that it contains the three terminal amino 
acids that are missing from the streptococcal nisins U, U2, and P. 
Natural lantibiotic variants are likely to arise from point mutations in structural genes; 
by definition, they should have few amino acid differences and the same ring pattern, 
and the associated producers should exhibit cross immunity to other variants (44). 
Nisin H fits this definition in that it differs from nisin A with respect to five amino acids, 
is likely to have an identical ring pattern and is immune to nisin A. 
The lower antimicrobial activity of the CFS of DPC6484 than that of the control nisin 
A producer used in this study is not related exclusively to poor peptide production 
levels, since, at equal concentrations and purity, nisin A is more effective than nisin H 
against many of the target microorganisms investigated. Nisin has been extensively 
bioengineered in a quest to generate more active peptides and this strategy has provided 
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information on the effects of specific amino acid changes (45). It has been stated that 
an unusual feature of nisin is the absence of aromatic residues and that, to date, any 
bioengineered nisins containing aromatic residues display reduced activity (46–49). 
Indeed, Field et al. (2008) have shown that the bioactivity of a derivative of nisin A with 
Met21Tyr, a change that occurs naturally in nisin H, is reduced to 70% of that of the 
parental strain against S. aureus strains ST528 and DPC5245, and to 65% against S. 
agalactiae ATCC 13813. In addition, nisin H also contains a second aromatic residue, 
Phe1; thus, this is the first report of the presence of such aromatic amino acids in a 
natural nisin variant. Interestingly, salivaricin D also contains a phenylalanine at 
position 1. The presence of two aromatic residues may contribute to the potency of 
nisin H being lower than that of nisin A. It is also notable that the introduction of 
positively charged amino acids into nisin Z has had a beneficial impact on activity, in 
that the bioengineered Asn20Lys and Met21Lys variants were more active against the 
Gram-negative genera Shigella, Pseudomonas, and Salmonella (48). Although nisin H 
has a histidine-to-lysine change at position 32, this did not confer enhanced 
antimicrobial activity against Escherichia coli. However, since histidine is positively 
charged at low pHs, the addition of a lysine at this location does not constitute a 
significant change from a charge perspective. The Leu6Met amino acid change seen 
in nisin H is the first amino acid change at this position reported for a natural variant. 
However, the specific impact of this change on activity will require further 
investigation. 
Notably, nisin H appears as an intermediate between nisins of lactococcal and 
streptococcal origins, in that it retains the three terminal amino acids found in nisins A, 
F, Q, and Z while possessing other features, such as a Dhb at position 18, that are 
associated with nisins U, U2, and P. Alignment of the amino acid sequences of nisins 
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A, Z, F, Q, H, U, U2, and P in Figure 1 shows an increasing number of amino acid 
changes from the prototypical nisin A through to nisin P. Overall, nisin H aligns more 
closely with lactococcal than with streptococcal nisins, a fact that is reflected by amino 
acid identity.  
Very few S. hyointestinalis strains have been deposited in culture collections. Since S. 
hyointestinalis was designated a new species in 1988, it is possible that isolates were 
previously catalogued as S. salivarius. PFGE analysis revealed that the seven strains 
of S. hyointestinalis obtained from the BCCM/LMG culture collection differ in their 
PFGE patterns (Figure 5A). S. hyointestinalis LMG14581 conclusively contained the 
nshA, nshF, nshR, and nshT genes (Figure 5Bii), but this strain did not display a 
bacteriocin- producing phenotype (Figure 5Bi). A thorough analysis of the nisin H 
gene cluster in this strain would have to be carried out in order to determine the basis 
for this phenomenon. 
In conclusion, we describe nisin H, a novel natural nisin variant produced by an S. 
hyointestinalis strain of porcine origin. The production of nisin H by a gut strain lends 
further support to accumulating observations suggesting that bacteriocin production 
may represent a potential probiotic trait for intestinal strains. 
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Table 1 Bacterial strains and culture conditions. 
 




Streptococcus hyointestinalis DPC6484 GM17*/TSB** 37°C      Anaerobic 
Streptococcus hyointestinalis LMG14579 GM17/TSB 37°C      Anaerobic 
Streptococcus hyointestinalis LMG14581 GM17/TSB 37°C      Anaerobic 
Streptococcus hyointestinalis LMG14582 GM17/TSB 37°C      Anaerobic 
Streptococcus hyointestinalis LMG14583 GM17/TSB 37°C      Anaerobic 
Streptococcus hyointestinalis LMG14585 GM17/TSB 37°C      Anaerobic 
Streptococcus hyointestinalis LMG14586 GM17/TSB 37°C      Anaerobic 
Streptococcus hyointestinalis LMG14587 GM17/TSB 37°C      Anaerobic 
Lactococcus lactis NZ9700 GM17 30°C      Aerobic 
Streptococcus uberis strain 42 GM17 37°C      Anaerobic 
Lactococcus lactis DPC3251 GM17 30°C      Aerobic 
Escherichia coli DPC6912  LB~     37°C      Aerobic 
Bacillus cereus 9139                                                         BHI***                     37°C      Aerobic 
Lactococcus lactis subsp. cremoris HP                                                      GM17 30°C      Aerobic 
Enterococcus faecalis 6307                                           LB                    37°C      Aerobic 
Streptococcus agalactiae ATCC13813                    BHI       37°C      Anaerobic 
Streptococcus agalactiae DPC5338                            BHI       37°C      Anaerobic 
Streptococcus bovis DPC6491                                        BHI       37°C      Anaerobic 
Streptococcus gallolyticus DPC6501                             BHI       37°C      Anaerobic 
Listeria innocua DPC3572                                                 BHI 37°C      Aerobic 
Listeria monocytogenes 1042                                       BHI 37°C      Aerobic 
Staphylococcus aureus ATCC 25923                                BHI 37°C      Aerobic 
Staphylococcus aureus DPC5245                                    BHI 37°C      Aerobic 
Lactobacillus delbrueckii subsp. bulgaricus 
LMG6901 
MRS~~               37°C      Aerobic 
 
*M17 with 5 g/L Glucose added (Difco Laboratories, Detroit, MI), **Tryptic Soy 
Broth (Difco Laboratories, Detroit, MI), ***Brain Heart Infusion (Merck, Darmstadt, 
Germany), ~ Luria-Bertani or Lysogeny Broth (Merck, Darmstadt, Germany), ~~ 















Area of zone of inhibition (cm2) calculated as (πR1
2)-(π R2
2) where R1 is the radius of 




Table 4 Spectrum of inhibition of purified nisin A and nisin H peptides against a 
range of strains. 
 
 Target microorganisms Nisin A  Nisin H 
Escherichia coli DPC6912 0.00 ± 0.00 0.00 ± 0.00 
Bacillus cereus 9139 1.42 ± 0.14 1.03 ± 0.12 
Lactobacillus delbruckii subsp. bulgaricus LMG6901 23.83 ± 0.89 16.64 ± 0.38 
Lactococcus lactis subsp. cremoris HP 9.47 ± 0.51 6.52 ± 0.25 
Enterococcus faecalis 6307 6.24 ± 0.00 3.94 ± 0.00 
Streptococcus agalactiae ATCC13813 6.10 ± 0.25 2.66 ± 0.17 
Streptococcus agalactiae DPC5338 4.06 ± 0.21 2.56 ± 0.17 
Streptococcus bovis DPC6491 3.50 ± 0.38 1.75 ± 0.29 
Streptococcus gallolyticus DPC6501 5.82 ± 0.00 3.94 ± 0.00 
Listeria innocua DPC3572 1.50 ± 0.14 1.50 ± 0.14 
Listeria monocytogenes 1042 2.10 ± 0.00 1.58 ± 0.00 
Staphylococcus aureus ATCC25923 3.28 ± 0.00 2.76 ± 0.17 
Staphylococcus aureus DPC5245 3.39 ± 0.19 4.78 ± 0.21 
Lactococcus lactis NZ9700 0.32 ± 0.00 0.69 ± 0.00 
Streptococcus hyointestinalis DPC6484 0.69 ± 0.00 0.32 ± 0.00 
Streptococcus uberis strain 42 3.39 ± 0.19 2.38 ± 0.28 
 
Area of zone of inhibition (cm2) calculated as (πR1
2)-(π R2
2) where R1 = radius of zone 
and R2 = radius of well in centimetres. Purified nisin A and nisin H were assayed at a 




Figure 1 Alignment of natural nisin variants, with amino acid changes in bold face. 
Asterisks mark conserved amino acid residues. 
 
A  ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK  3352 Da 
Z  ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK  3331 Da 
F  ITSISLCTPGCKTGALMGCNMKTATCNCSVHVSK  3315 Da 
Q  ITSISLCTPGCKTGVLMGCNLKTATCNCSVHVSK  3327 Da 
H  FTSISMCTPGCKTGALMTCNYKTATCHCSIKVSK  3453 Da 
U  ITSKSLCTPGCKTGILMTCPLKTATCGCHFG  3029 Da 
U2  VTSKSLCTPGCKTGILMTCPLKTATCGCHFG  3015 Da 
P  VTSKSLCTPGCKTGILMTCAIKTATCGCHFG  2989 Da  
SalD  FTSHSLCTPGCITGVLMGCHIQSIGCNVHIHISK  3468 Da 






Figure 2 Representation of the bacteriocin-encoding nshA gene cluster as revealed 
by genome sequencing (center), compared with the nisA (top) and nsuA (bottom) gene 
clusters. The nshA gene cluster contains the nisin production genes nshABTCP, a gap 
region encoding a transposase, nshRK, a region encoding a second transposase, and 
nshFEG. For each gene, the percentage of amino acid identity to the protein encoded 
by the corresponding nisin A-associated gene is presented. The amino acid sequence 
of the unmodified NshA peptide is shown below the gene cluster. Residues predicted 
to be within the leader peptide are shown in gray, and those thought to correspond to 








Figure 3 Purification of nisin H from Streptococcus hyointestinalis DPC6484 grown in 
TSB broth. (A) RP-HPLC chromatogram; (B) MALDI-TOF MS of the active fraction; 
(C) zone of inhibition of an aliquot of the HPLC fraction on a Lactobacillus delbrueckii 















Figure 5 (A) PFGE macrorestriction patterns of Streptococcus hyointestinalis strains 
restricted with SmaI. Lane 1, S. hyointestinalis DPC6484; lane 2, S. hyointestinalis 
LMG14579; lane 3, S. hyointestinalis LMG14581; lane 4, S. hyointestinalis 
LMG14582; lane 5, S. hyointestinalis LMG14583; lane 6, S. hyointestinalis 
LMG14585; lane 7, S. hyointestinalis LMG14586; lane 8, S. hyointestinalis LMG14587. 
(B) (i) PCR amplification of strains of S. hyointestinalis template DNA with nshT-, nshH-
, nshF-, and nshR-specific primers. Lanes correspond to those in panel A. (ii) 
Comparison of antimicrobial activities of S. hyointesinalis strains DPC6484 (H), 
LMG14579, LMG14581, LMG14582, LMG14583, LMG14585, LMG14586, and 
LMG14587 against the indicator strain, L. delbrueckii subsp. bulgaricus LMG6901. 
Wells are labeled with H (for nisin H) and with the last two digits of the strain 
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The skin microbiota is thought to play a key role in host protection from infection. Nisin 
J is a novel nisin variant produced by Staphylococcus capitis APC 2923, a strain isolated 
from the toe web space area in a screening study performed on the human skin microbiota. 
Whole-genome sequencing and MALDI TOF mass spectrometry of the purified peptide 
confirmed that S. capitis APC 2923 produces a 3,458-Da bacteriocin, designated nisin J, 
which exhibited antimicrobial activity against a range of Gram-positive pathogens, 
including methicillin-resistant Staphylococcus aureus (MRSA) and Cutibacterium 
acnes. The gene order in the nisin J gene cluster (nsjFEGBTCJP) differs from that of 
other nisin variants in that it is lacking the nisin regulatory genes, nisRK, as well as the 
nisin immunity gene nisI. Nisin J has nine amino acid changes compared to 
prototypical nisin A, with eight amino acid substitutions, six of which are not present 
in other nisin variants (Ile4Lys, Met17Gln, Gly18Thr, Asn20Phe, Met21Ala, 
Ile30Gly, Val33His, and Lys34Thr), and an extra amino acid close to the C terminus, 
rendering nisin J the only nisin variant to contain thrity five amino acids. This is the 
first report of a nisin variant produced by a Staphylococcus species and the first nisin 
producer isolated from human skin. 
 
2.2.2 Importance  
This study describes the characterization of nisin J, the first example of a natural nisin 
variant, produced by a human skin isolate of staphylococcal origin. Nisin J displays 
inhibitory activity against a wide range of bacterial targets, including MRSA. This 
work demonstrates the potential of human commensals as a source for novel 
antimicrobials that could form part of the solution to antibiotic resistance across a 




2.2.3 Introduction  
The human skin microbiome is home to ~1012 bacteria (1), and interest in the 
potential of skin bacteria to produce antimicrobials is growing, given the spread of 
antibiotic resistance (AR). Staphylococcus capitis is a member of the resident skin 
microbiota. First isolated from human skin in 1975, it has since been regarded as an 
opportunistic pathogen and has been associated with sepsis in neonates, meningitis, 
and endocarditis (2). Little is known about the inhibitory nature or antimicrobial 
activity of S. capitis, with only one report of S. capitis EPK-1 producing the 
glycylglycine endopeptidase ALE-1, an enzyme that targets the cell wall of 
Staphylococcus aureus (3). More recently, genomic analysis of an S. capitis strain 
isolated from the skin of a human toe revealed the presence of gene clusters capable of 
encoding gallidermin, epidermin, and phenol soluble modulins, highlighting its 
potential to produce antimicrobial peptides (AMPs) (4). 
In a recent study, our group detected antimicrobial activity by a number of S. capitis 
strains isolated from different areas of the human skin (5) and highlighted the potential 
for S. capitis species to produce bacteriocins (small ribosomally synthesized peptides 
produced by a range of bacteria which kill other bacteria). Interestingly, bacteriocin 
production is considered to be a probiotic trait in that bacteriocins function in helping 
the producer strain to become established in a niche, by killing off competitors and 
interacting with the immune system. Although the impact of nisin on immune systems 
has not yet been completely elucidated, this peptide stimulates a wide array of effects, 
and it influences various populations of cells involved in immunity (6–12). 
One of the oldest known and most intensively studied bacteriocins is nisin, which was 
first described in this journal by Rogers and Whittier in 1928 (13). Nisin has been used 
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in food preservation since 1953 (14) and was granted Generally Regarded As Safe 
(GRAS) status in 1988 by the Food and Drug Administration (FDA). It is also 
approved by the World Health Organization (WHO) as a food additive and has been 
assigned the E number E234. Since the discovery of nisin, interest in bacteriocins has 
grown rapidly. Nisin A, composed of 34 amino acids, is produced by several strains of 
Lactococcus lactis (15). Nisin is a lantibiotic and thus a member of the class I 
bacteriocins (16). Lantibiotics are small peptides (<5 kDa) and are produced by many 
Gram-positive bacteria to inhibit or kill other Gram-positive bacteria (17). Production 
of other lantibiotics is common among commensal coagulase-negative staphylococci. 
For example, Staphylococcus gallinarum, Staphylococcus epidermidis, and 
Staphylococcus hominis produce the lantibiotics gallidermin, epidermin, and 
hominicin, respectively (18–20). Class I bacteriocins consist of post-translationally 
modified bacteriocins which are subdivided into 4 classes, as follows: class Ia, 
lanthipeptides (of which nisin is the most prominent member); class Ib, head-to-tail 
cyclized peptides; class Ic, sactibiotics; and class Id, linearazol(in)e-containing 
peptides (8, 21). Lantibiotics are characterized by the presence of lanthionine/þ-
methyllanthionine residues and are produced through the dehydration of serine and 
threonine residues to form dehydroalanines and dehydrobutyrines respectively. These 
dehydrated residues in turn react with cysteine thiols, forming lanthionine bridges (22, 
23). The lantibiotics are subdivided based on the enzymes catalyzing the formation of 
lanthionines. Subclass I requires two distinct enzymes, LanB and LanC, whereas 
subclass II is modified by a single enzyme, LanM. Subclass III has no associated 
antimicrobial activity and is modified by a single enzyme, LanKC, while subclass IV 
is modified by LanL (24). Studies have revealed that nisin and other structurally 
related lantibiotics use the membrane-bound peptidoglycan precursor lipid II as a 
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docking molecule, which consequently promotes two bactericidal activities, pore 
formation and inhibition of peptidoglycan biosynthesis (25). Significantly, lantibiotics 
have been shown to possess activity against antibiotic-resistant targets such as 
vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus 
aureus (MRSA) and may have the potential to mitigate the looming global AR crisis 
(26). 
A number of nisin variants have been discovered since the original nisin A was 
characterized (Figure 1A). Nisin variants of lactococcal origin are more similar to 
each other than to variants from other genera such as Streptococcus (Figure 1B). 
Nisin Z is the most closely related nisin variant to nisin A, with only a single amino 
acid substitution, His27Asn. Nisin U, U2 and P each contain 31 amino acids, nisins 
O1–3 contain 33 amino acids, and nisin O4 contains 32 amino acids, making them 
shorter than other previously described nisin variants. Here, we describe nisin J, 
produced by the S. capitis strain APC 2923, isolated in a screening study of the 
human skin microbiota. At 35 amino acids, nisin J is the longest nisin variant 
identified to date and has antimicrobial activity against significant human 
pathogens, including staphylococci, streptococci, and Cutibacterium acnes. 
 
2.2.4 Materials and Methods 
The antimicrobial-producing strain S. capitis APC 2923 was isolated in a previous 
screening study of the human skin microbiota by our group (5). 
 
Bacterial strains and culture conditions  
The growth conditions of the bacterial strains used in this study are listed in Table 4. 
Anaerobic conditions, where appropriate, were attained using anaerobic jars and 
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Anaerocult A gas packs (Merck, Darmstadt, Germany). 
 
Draft genome sequence of S. capitis APC 2923 and in silico analysis of the nisin 
J gene cluster 
Bacterial DNA was extracted using the GenElute kit, as described by the 
manufacturer (Sigma-Aldrich Ireland Limited, Co. Wicklow, Ireland), and was 
prepared for sequencing following the Nextera XT DNA library prep reference 
guide (Illumina, Inc.). A Qubit 3.0 fluorometer (Thermo Fisher Scientific, MA) 
was used for DNA quantification. Sequencing was performed at the Teagasc/APC 
Microbiome Ireland Sequencing facility, Teagasc Food Research Centre, 
Moorepark, Fermoy, Co. Cork, Ireland. In total, 94 contigs, including 16 large 
contigs, were revealed by de novo assembly using SPAdes (version 3.10.0). A total 
of 2,453 open reading frames (ORFs) and 60 tRNAs were detected and 
subsequently annotated using Prokka (version 1.11). The online tools BActeriocin 
GEnome mining tooL (BAGEL4) and antiSMASH 3.0 were employed to identify 
bacteriocin operons/gene clusters in the genomes of interest, and by combining 
these software programs with the ARTEMIS genome viewer, the presence of the 
nisin J gene cluster was confirmed. 
 
Evolutionary links between natural nisin variants  
The European Bioinformatics Institute toolkit (https://www.ebi.ac.uk/services) was 
used to investigate the evolutionary relationships between the nisin structural variants. 
A multiple-sequence alignment was generated using MUSCLE (version 3.8) and 
visualized on a neighbor-joining tree without distance corrections. This tree was 




Purification of the antimicrobial produced by S. capitis APC 2923  
To purify the antimicrobial produced by S. capitis APC 2923, the culture was 
grown in a shaking 37°C incubator overnight in 1,800 ml of brain heart infusion 
(BHI) which had been passed through a column containing Amberlite XAD 16N 
to remove hydrophobic peptides before autoclaving (XAD-BHI). The culture 
supernatant was applied to an Econo-Column containing 60 g Amberlite XAD-16N 
beads (Sigma Aldrich, Co. Wicklow, Ireland). The column was then washed with 
350 ml of 30% ethanol, and the antimicrobial activity was eluted with 70% propan-
2-ol (IPA) containing 0.1% trifluoroacetic acid (TFA) (Sigma Aldrich). The IPA 
was removed from the active column eluent and the pH adjusted to 4.4 with 7.5 N 
NaOH. The sample was then applied to an Econo-Column containing 90 ml SP 
Sepharose beads preequilibrated with 20 mM sodium acetate buffer (pH 4.4) 
(buffer A). The column was washed with 50 ml of buffer A and the antimicrobial 
activity eluted in 250 ml buffer A containing 1 M NaCl. The salt-containing eluent 
was applied to a 60 ml, 10-g C18 solid-phase extraction (SPE) column 
(Phenomenex, Cheshire, United Kingdom) preequilibrated with methanol and 
water. The column was washed with 60 ml of 25% ethanol, and nisin was eluted 
in 60 ml IPA (0.1% TFA), which was subjected to reversed-phase high-
performance liquid chromatography (RP-HPLC). The sample was applied to a 
semi-preparative Jupiter Proteo (250 mm [length] by 10 mm [inside diameter], 90 
Å [pore size], 4 µm [particle size]) RP-HPLC column (Phenomenex, Cheshire, 
UK) running a gradient of 25 to 40% acetonitrile and 0.1% TFA, where buffer A 
was 0.1% TFA and buffer B was 90% acetonitrile and 0.1% TFA. The resulting 
eluent was monitored at 214 nm, and fractions were collected at 1-min intervals. 
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Column eluents and HPLC fractions were assayed for antimicrobial activity by 
well diffusion assays (WDAs), according to the method of Parente and Hill (41), 
using L. delbrueckii subsp. bulgaricus LMG 6901 as the target organism. Column 
eluents and HPLC fractions displaying antimicrobial activity were assayed for the 
nisin J molecular mass by matrix-assisted laser desorption ionization–time of flight 
mass spectrometry (MALDI-TOF MS) on an Axima TOF2 MALDI-TOF MS in 
positive-ion reflectron mode (Shimadzu Biotech, Manchester, United Kingdom). 
Fractions containing pure nisin J were pooled and lyophilized in a Genevac 
lyophilizer (Suffolk, United Kingdom). Pure nisin A peptide was prepared from L. 
lactis NZ9700 as described for nisin J but excluding the SP Sepharose step. Nisin 
Z pure peptide was sourced from Handary (Fleurus, Belgium). 
 
Comparison of the inhibitory spectra of nisins A, Z, and J 
Pure nisins A, Z, and J were resuspended in RNase-free water to a final concentration 
of 1 mg/ml and subsequently assayed by WDA against a range of target indicator 
strains (Table 2). Zone diameters were measured in millimeters using Vernier 
calipers (DML-Digital Micrometers Ltd., Sheffield, United Kingdom) and recorded in 
Table 2 as area of the zone (Πr2) minus the area of the well (Πr2) in millimeters. 
 
MIC determinations  
MICs were determined in triplicate from pure nisins A, Z, and J against approximately 
1 × 105 cfu/ml of the target indicator strain Lactococcus lactis subsp. cremoris HP 
using 96-well microtiter plates (Sarstedt, Co. Wexford, Ireland) and using a Libra S2 
colorimeter (Biochrom Ltd., Cambridge, United Kingdom) to measure the optical 
density at 600 nm (OD600) of the indicator strains. Peptide concentrations of 4x the 
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test concentration (2,048 nM) were prepared in 400 µl RNase-free and DNase-free 
water. One hundred microliters of growth medium was added to all wells of the 96-
well plate. One hundred microliters of 4x concentration was added to the first well, and 
subsequently, 2-fold serial dilutions were carried out. MIC readings were taken after 
16 h at 30°C. The MIC was recorded as the lowest concentration of lantipeptide where 
no growth of the indicator was observed (42). 
 
Cross-immunity of nisin J-producing S. capitis APC 2923 to other nisin-
producing strains 
To investigate if the nisin J-producing S. capitis APC 2923 strain was immune to 
other nisin-producing cultures (L. lactis NZ9700 producing nisin A, Streptococcus 
hyointestinalis DPC 6484 producing nisin H, and S. uberis strain 42 producing 
nisin U), cross-immunity assays were performed based on the WDA method, 
whereby each strain was tested as an indicator and a producer (43). 
 
Determining if the nisin J structural gene is unique to S. capitis APC 2923  
To determine if the nisin J structural gene was present in other S. capitis strains 
isolated from the study by O’Sullivan et al. (5), oligonucleotide primers designed 
to specifically amplify the nisin J structural gene (nisJ F, 5’-ACTT 
TATAACTAAGATTAGC-3’, and nisJ R, 5’-TCGCTTTATTATTTAGTAT 
GCACG-3’) were used in a PCR under the following conditions: initial 
denaturation, 94°C for 5 min; 35 cycles of 94°C for 40 s, 52°C for 30 s, and 72°C 
for 1 min; and a final extension 72°C for 10 min. Sequencing was conducted by 
Genewiz (Essex, United Kingdom). Sequencing data were analyzed employing the 
Lasergene 8 software (DNAStar, Inc., Madison, WI) and subsequently input into 
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the ExPASy online translate tool (https://web.expasy.org/translate/) to translate the 
nucleotides into amino acid sequences. 
 
Sequence analysis of the nisin J plasmid pJOS01  
To confirm that the nisin J  gene cluster was plasmid associated, the plasmid DNA of 
S. capitis APC 2923 was extracted using the Plasmid maxi kit (Qiagen, Hilden, 
Germany), according to the manufacturer’s instructions following an adapted user-
developed protocol specific to staphylococcal species (https://www.qiagen.com 
/ie/resources/resourcedetail ?id=82ddd661-fbab-4d35819c-defd6269fc64&lang=en), 
using lysostaphin (Sigma-Aldrich Ireland Limited, Co. Wicklow, Ireland). The 
resulting DNA extract was sequenced by Illumina MiSeq technology (2 x 250-bp 
paired-end reads; GenProbio, Parma, Italy). De novo sequence assemblies and 
automated gene calling were performed using the MEGAnnotator pipeline (44) and 
assessed for predicted tRNA genes via transcend-SE version 1.2.1 (45). Predicted open 
reading frames (ORFs) were determined via Prodigal version 2.6 and Genemark.hmm 
(46). A BLASTP (47) analysis was performed to assign functional annotations to the 
predicted ORFs (https://blast.ncbi.nlm.nih.gov/Blast.cgi) (Table 1). PlasmidFinder 
(version 2.0) was employed to confirm that the generated assembled contigs were 
plasmid sequences based on the identification of Rep proteins. SnapGene version 
2.3.2 was employed to generate a map of the plasmid harboring the nisJ gene 
cluster (designated pJOS01 here). In addition to the sequence data analysis to 
confirm the plasmid association of the nisin J cluster, PCR-based analysis was 
undertaken using the plasmid DNA extract as the template. Oligonucleotide 
primers designed to specifically amplify the nisin J structural gene (nisJ F, 5’-
ACTTTATAACTAAGATTAGC-3’, and nisJ R, 5’-TCGCTTTATTATT 
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TAGTATGCACG-3’) were used in a PCR using Phusion Green Hot Start II high-
fidelity PCR master mix with the following conditions: initial denaturation, 98°C 
for 5 min; 30 cycles of 98°C for 10 s, 52°C for 30 s, and 72°C for 15 s; and a final 
extension of 72°C for 10 min. Validation of the amplicon was performed by Sanger 
sequencing of the generated product (Source BioScience, Waterford, Ireland). 
Furthermore, restriction digestion of the plasmid DNA was carried out using EcoRI 
in 10x CutSmart buffer (New England BioLabs, Herts, United Kingdom). 
 
Investigation for the presence of nisin-resistant determinants in S. capitis 
APC 2923  
To determine if the gene encoding the nisin resistance protein (NSR) was present in 
S. capitis APC 2923 and the 7 other S. capitis isolates previously identified from the 
O’Sullivan et al. study (5), PCR was employed using the primers and reaction 
conditions described by Simões et al. (38). To determine if the nisin J-producing S. 
capitis strain APC 2923 was cross-immune or sensitive to NSR-producing strains, 
bioassays were carried out by spotting 10 µl of the nisin J overnight culture onto 1.5% 
BHI agar (Merck, Darmstadt, Germany). Following overnight incubation at 37°C, the 
plates were then overlaid with soft (0.75%) GM17 agar (BD Difco Trafalgar Scientific 
Ltd., Leicester, United Kingdom) seeded with 0.25% of an overnight culture of the 
NSR-positive strain L. lactis subsp. diacetylactis DRC3. To directly compare the 
resistance levels of nisin A and nisin J to NSR, WDAs were carried out as previously 
described (43), employing L. lactis MG1614/pNP40 (NSR-positive strain) and L. lactis 
MG1614 (NSR-negative strain) as target indicators. All lactococcal NSR indicator 
strains were grown aerobically overnight at 30°C. Agarose assays were subsequently 
performed as outlined in reference 42. Data obtained from the agarose assays were 
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subjected to normality tests prior to statistical analysis using the GraphPad Prism 
software (version 8.2.1).  P values were calculated using an unpaired t test. 
 
Data availability  
The plasmid map of pJOS01 has been deposited in GenBank under accession 
number MN602039. This whole-genome shotgun project has been deposited at 
DDBJ/ENA/GenBank under the accession number WHVU00000000. The version 
described in this paper is version WHVU01000000.1. 
 
2.2.5 Results 
A nisin-like gene cluster exists within the S. capitis APC 2923 genome  
S. capitis APC 2923 was previously isolated from the toe web space area in a 
screening study of the human skin microbiota that sought to identify novel 
antimicrobial-producing strains (5). This strain was of particular interest due to 
its potent activity against the indicator strain Lactobacillus delbrueckii subsp. 
bulgaricus LMG 6901 and its broad inhibitory spectrum against a panel of 
Staphylococcus, Streptococcus, and Corynebacterium species and against 
Cutibacterium acnes. Whole-genome sequencing of this strain revealed a nisin 
gene cluster of ~9.78 kb compared to ~13.3 kb for nisin A. The structural gene 
nisJ encodes a peptide with the following eight amino acid variations compared 
to nisin A: Ile4Lys, Met17Gln, Gly18Thr, Asn20Phe, Met21Ala, Ile30Gly, 
Val33His, and Lys34Thr. Nisin J also contains an extra amino acid at the C 
terminus, making nisin J the longest nisin variant identified to date (Figure 1A). A 
dendrogram of the natural nisin variants (Figure 1B) demonstrates that peptides 
which have a closer common ancestor are more similar than are peptides that have 
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more distant branching points. Lactococcal nisin variants are structurally distinct 
from all other nisin variants. Staphylococcal nisin J groups in the middle of the 
tree and appears to be more similar to streptococcal nisin than to lactococcal 
nisins. Nisins of Blautia origin appear to be more phylogenetically distinct due to 
longer branching. Streptococcal nisins H and J are more closely related to 
lactococcal nisins than to other streptococcal nisins, U, U2 and P. The gene order 
of the nisin J cluster (FEGBTCJP) also differs from that of the nisin A in that it 
contains eight as opposed to the 11 genes within the cluster (Figure 2). The BAGEL4 
bacteriocin genome mining tool predicted that the nisin J prepeptide is composed of 
61 amino acids with a leader sequence consisting of 26 amino acids. Overall, the nisin 
J mature peptide has 62.5% identity to the nisin H structural peptide produced by 
Streptococcus hyointestinalis (27). The identity and function of features of the nisin 
J operon are listed in Table 1. 
 
Other genes contained in the S. capitis APC 2923 draft genome  
In addition to the nisin J cluster, BAGEL4 and antiSMASH3.0 also highlighted a 
small gene cluster containing the lanB and lanC genes and a gene encoding a peptide 
with 93% identity to the gallidermin family in S. capitis APC 2923. These were 
located on a different contig from that of the nisin J gene cluster, and this mass was 
not detected from either the colony or purified cell free supernatants. 
 
Purification and predicted structure of nisin J  
Nisin J was purified in four steps using Amberlite XAD-16N solid-phase 
extraction (SPE), SP Sepharose cation exchange, C18 SPE, and reversed-phase 
high-performance liquid chromatography (HPLC). Antimicrobial activity 
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correlated with the most dominant peak eluting at 24.5 min in the HPLC 
chromatogram, and matrix-assisted laser desorption ionization–time of flight 
mass spectrometry (MALDI-TOF MS) revealed that the corresponding fractions 
had a mass of 3,458 Da (Figure 3). This correlates with the predicted mass of the 
putative nisin J bacteriocin (following subsequent dehydration and ring formation 
reactions) as calculated from the draft genome sequence. Fractions deemed pure 
by MALDI-TOF MS were combined and lyophilized to give a yield of 3.00 mg 
liter-1. Given that nisin J is a natural nisin variant with demonstrable conservation 
between key structural amino acids common to all natural nisin variants, it is 
predicted that the structure will be in line with those of other lactococcal nisins, 
as shown in Figure 4. 
 
Comparing the activities of purified nisins A, Z, and J  
The spectrum of activity of pure nisin A, nisin Z, and nisin J, by means of a well 
diffusion assay (WDA), was performed on several target indicator strains. Nisin J was 
more active than nisin A against 12 of the 13 strains tested, while nisin J was more 
active than nisin Z for 7 of the target strains tested, including Corynebacterium 
xerosis, MRSA, Streptococcus uberis, and S. aureus (Table 2). However, in an MIC 
assay using L. lactis HP as the indicator, no difference was observed between nisins 
A, Z, and J, with all exhibiting MICs of 32 nM.  
 
The nisin J-producing strain is cross-immune to nisin A and H but not to nisin U 
producers  
Cross-immunity assays were performed to investigate whether the nisin J-, A-, H- 
and U-producing strains were cross-immune to one another (Table 3). No zones were 
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observed between nisins A, H and J, indicating that these producing strains are all 
cross-immune. However, a zone was observed from the nisin J-producing strain against 
the nisin U producer (S. uberis strain 42), demonstrating that the strain is sensitive to 
nisin J. 
 
Not all S. capitis strains contain a nisin-like gene cluster  
The nisJ structural gene was amplified from nine antimicrobial-producing S. capitis 
strains isolated from human skin in a previous study by our group (5). Two of the 
nine S. capitis strains (APC 2918 and APC 2934) did not contain the nisJ structural 
gene. The other seven S. capitis strains tested positive for the nisJ structural gene, 
correlating with findings from our earlier study which found these strains to be 
cross-immune and to possess the same pulsotype, indicating that they were the 
same strain or very closely related strains and were therefore most likely producing 
the same bacteriocin (5). These 7 strains were isolated from 4 different subjects, 
indicating that the same pulsotype is shared across a number of individuals, 
implying that the ability to produce nisin J may be a dominant feature and thus an 
ecological advantage for this S. capitis strain. 
 
The nisin J gene cluster resides on a plasmid  
Analysis of the S. capitis APC 2923 contig harboring the nisin J gene cluster 
identified the presence of a plasmid replication protein A (RepA) and other plasmid 
replication-associated proteins, suggesting that it was of plasmid origin. Plasmid 
DNA was readily obtained from S. capitis APC 2923 using a commercially 
available plasmid maxi kit (data not shown). Short-read sequencing was performed 
on the plasmid DNA using the Illumina MiSeq platform to approximately 200-fold 
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coverage. De novo assembly resulted in four contigs (Figure 5), with a combined 
size of 49,951 bp. A plasmid map of pJOS01 (GenBank accession number 
MN602039) shows all of the genes encoding immunity and the biosynthetic 
machinery for nisin J (nsjFEG, nsjB, nsjT, nsjC, nisJ, and nsjP) reside on one of the 
contigs, supporting the plasmid association of the nisin J gene cluster (Figure 5). 
Furthermore, three genes encoding plasmid replication functions (RepA and RepB) 
as well as genes encoding other nonessential plasmid-associated roles were present 
on the other contigs (Figure 5 and Table 1). Restriction digestion with EcoRI 
yielded a profile comparable to the virtual digestion of the generated plasmid 
sequence, supporting the predicted size of ~50 kb (data not shown). Subsequent 
analysis revealed a GC content of ~28%, which is considerably lower than that of 
S. capitis chromosomal DNA (32 to 33%), a characteristic that has been observed 
for plasmids of many Gram-positive species (28). 
 
Nisin J exhibits resistance to NSR  
Deferred antagonism assays using L. lactis subsp. diacetylactis DRC3 (nisin resistance 
protein positive [NSR+]) as a target indicator strain revealed that nisin J is partially 
resistant to NSR (result not shown). To establish if nisin J had increased inhibitory 
activity against NSR compared to that of nisin A, further WDAs were conducted using 
the NSR
+ and NSR
- strains L. lactis MG1614/pNP40 and L. lactis MG1614, 
respectively. While the inhibition zone of the nisin J producer is slightly decreased 
against the NSR-positive strain compared to the NSR- negative strain, it appears that 
nisin J is more active than nisin A and may be less susceptible to the proteolytic effects 
of NSR (Figure 6A), which was also demonstrated in agarose assays (Figure 6B). The 
analysis revealed a significant difference in the zones of inhibition between nisin A 
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and nisin J against an NSR+ strain (MG1614/pNP40), with a P value of 0.0001 
compared to zone sizes against an NSR
- strain (MG1614), where no statistical 
difference (P = 0.1701) was observed (these data support Figure 6). 
 
2.2.6 Discussion 
As the burden of antibiotic resistance increases globally, there is an urgent need for 
novel therapeutic options. In addition to the well-established use of nisin as a food 
preservative, many studies have focused on using nisin against drug–resistant 
pathogens in clinical or veterinary settings due to its high potency and multiple 
mechanisms of action (10 –12). Nisin J is a novel nisin variant and the first such 
variant reported from a Staphylococcus species. A combination of whole-genome 
sequencing of S. capitis APC 2923 and peptide purification resulted in the 
identification of this broad-spectrum lantibiotic. The nisin J-producing S. capitis 
strain was isolated from the toe web space, an area associated with high microbial 
load. This suggests that the production of a broad-spectrum bacteriocin confers an 
advantage on this strain over competing commensal skin flora, as was also 
observed by O’Sullivan and colleagues (5) when four of the twenty subjects 
screened in the study exhibited the same pulsotype. The residence of the nisin J 
gene cluster on a plasmid is significant in that it may facilitate its dissemination to 
other skin microbes.  
As mentioned previously, nisin J has eight amino acid changes and one extra amino 
acid near the C-terminal end compared to nisin A. Interestingly, six of the eight 
changes are unique compared to natural nisin variants. Natural nisin variants are 
tolerant to some amino acid changes at the N terminus, with Ile4 being the most 
commonly substituted amino acid. Nisin J contains an Ile4Lys substitution which 
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is also seen in nisins P, U, U2, and O1–3 but remains unchanged in lactococcal nisins 
(A, Z, F, and Q) and nisin H. Nisin J differs most from other natural nisin variants 
in the center and at the C terminus of the peptide, which could be key to nisin J’s 
enhanced activity. At the center of nisin J, amino acid positions 17 to 21, there are 
4 amino acids that differ compared to nisin A. It contains a Met17Gln substitution 
which is unique, as all other natural nisin variants that demonstrate antimicrobial 
activity have Met at this position. The Gly18Thr change is also interesting, as it is 
observed in nisins H, U, U2, P, and O1–3 and is proposed to be modified to 
dehydrobutyrine (Dhb), in light of the dehydration observed in a M17Q-G18T 
derivative of nisin Z (29). At position 20, nisin J has a highly hydrophobic residue, 
phenylalanine, compared to the polar asparagine in nisin A. Li et al. (30) found that 
extending the C terminus of nisin improves both its ability to permeate membranes 
and its inhibitory potential against Gram-negative bacteria. Therefore, nisin J’s 
longer C terminus (compared to other nisin variants) could be more attracted to 
negatively charged cell membranes resulting in enhanced membrane insertion, 
which may be responsible for its broader host range. The skin origin of this nisin J 
producer suggests that its exposure to many competitors from the external 
environment may be responsible for the greater variation in the structure of nisin 
J. 
Analysis of the nisin J gene cluster identified several key features associated with 
bacteriocin operons. These include a structural gene (nisJ), 2 genes associated with 
enzymatic modification (nsjB and nsjC), a gene involved in transport (nsjT), and 
immunity genes (nsjFEG) (Table 1 lists the identity and functions of features of 
the nisin J gene cluster). The arrangement of genes in the nisin J gene cluster differs 
from that of other nisin operons. Interestingly, the only conservation of gene order 
 
103  
throughout all operons of natural nisin variants is lanBTC. Similarities in the 
structural peptides of different nisin variants from different origins indicate the 
possibility that an evolutionary link exists between lactococcal, streptococcal, 
Blautia, and now, staphylococcal species, a link previously mentioned by 
O’Connor et al. (27) with reference to streptococcal and lactococcal species. A 
dendrogram based on the primary structures of all known natural variants 
highlights the genetic relatedness between the nisin-producing species and further 
suggests the likelihood of this evolutionary link. The FEG locus is present in 
lantibiotic systems other than nisin, including subtilin (31) and epidermin (32), and 
has been linked to transport, immunity, and defense (33). Inactivation of these genes 
in the nisin A gene cluster decreased nisin production and immunity, confirming their 
role in immunity (34). Although the nsjFEG genes are present in the nisin J gene 
cluster, the absence of a specific immunity gene, nsjI, as well as the absence of an 
expression regulatory system, nsjRK, could explain why nisin J immunity mechanisms 
appear to be less able to protect the cell. It also further supports the finding that the 
producing strain was more sensitive to its own purified nisin J peptide than was a nisin 
A producer with a specific nisin immunity determinant. 
The production of lantibiotics such as gallidermin and epidermin is associated with 
increased release of lipids and ATP and protein excretion, which are indicators of 
cell membrane damage (35). Thus, the production of these lantibiotics has been 
deemed a “burden” to staphylococci that produce them; therefore, the incomplete 
lantibiotic gene cluster, having only the lanB and lanC genes present, may be either 
an evolutionary feature of S. capitis genomes or may be an incomplete cluster of 
lantibiotic biosynthetic genes previously shown to occur in many microbes (35). 
As previously discussed, the nisin J gene cluster resides on a plasmid, inviting the 
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speculation that S. capitis acquired its antimicrobial ability through horizontal gene 
transfer. Indeed, residence on mobile genetic elements is a feature of natural nisin 
variants, as observed with nisins A and H, and may explain their presence in many 
different species. 
Purification of nisin J resulted in a peptide with a mass of 3,458 Da. The mass of 
nisin J was predicted to be 3,622 Da, where the difference between predicted and 
observed masses can be accounted for by 9 dehydration reactions (-18 Da per loss 
of water residue) involved in the formation of lanthionine and β-methyl-lanthionine 
bridges (36). The predicted peptide structure was based on the nisin A template, 
with a lanthionine bridge likely to occur between Ser3 and Cys7 and four β-methyl-
lanthionine bridges between Thr8 and Cys11, Thr13 and Cys19, Thr23 and Cys26, 
and Thr25 and Cys28. 
True to all nisin variants, nisin J is a broad-spectrum lantibiotic with inhibitory 
activity similar to that of nisins A and Z, as can be seen in Table 2, inhibiting a 
wide range of bacterial genera with greater inhibition of staphylococcal targets 
than with nisins A and Z. This suggests that the nisin J-producing S. capitis strain 
may have naturally evolved to produce a nisin peptide with enhanced activity 
against other staphylococci in the skin microbiota (Table 2). Nisin J-, A- and H-
producing strains are immune to nisin peptides J, A, H, and U; however, the nisin 
U-producing strain is not immune to nisin J (Table 3). This may be due to the lack 
of the nsjI immunity gene in the nisin J cluster. 
The nisin resistance protein (NSR) is a protease which cleaves nisin A at Ser29, 
significantly reducing the activity of the peptide. Employing a bioengineering strategy, 
Field et al. (37) demonstrated that the substitution of residues 29 and 30 with proline 
and valine respectively (derivative designated S29PV), rendered the peptide resistant 
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to proteolytic digestion by NSR. In this study, we found that the nisin J producer 
displays a higher resistance to NSR proteolytic enzymes than does nisin A, which is 
possibly due to a glycine residue at position 30 instead of the isoleucine as found in 
nisin A. Interestingly, a study carried out by Simões et al. (38) involving a multidrug- 
resistant S. capitis clone, NRCS-A, a major pathogen involved in sepsis in preterm 
neonates, demonstrated the presence of an NSR-encoding gene. PCR analysis failed to 
detect the presence of any nsr gene in any nisin J-producing S. capitis strain from our 
previous study (5). 
Nisin J may have evolved to be more potent against specific competing organisms 
in a particular niche environment such as the skin. Employing a bioengineering 
strategy, Rink et al. (39) demonstrated that the replacement of residues I, S, and L 
at positions 4, 5, and 6 in nisin A with the residues K, S, and I, respectively resulted 
in enhanced bioactivity. Notably, the residues K-S-L are naturally present in nisin 
J at the same positions. In a separate bioengineering study, Kuipers et al. (29) 
generated a novel nisin variant (M17Q/G18T) exhibiting enhanced bioactivity. It is 
interesting that both of these mutations are naturally present in nisin J. Furthermore, 
Field et al. (40) reported that a nisin A derivative, M21A, demonstrated enhanced 
bioactivity. Remarkably, alanine is naturally present at position 21 in nisin J. 
In conclusion, we have identified a new natural nisin variant, nisin J, produced by S. 
capitis APC 2923, which was isolated from the human skin microbiota. Nisin J 
represents the first nisin variant isolated from Staphylococcus species and the first to 
demonstrate partial recalcitrance to NSR. Indeed, the enhanced activity of nisin J 
compared to that of nisin A and Z as observed against all staphylococcal strains utilized 
in this study is notable. The production of bacteriocins such as nisin J from skin bacteria 
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Table 1 Identity and function of features of the draft pJOS01 plasmid sequencea. 
 









E value Putative function (conserved 
domain) 
% identity to best match 
J1 3 518 172 3E—124 DDE_Tnp_IS240 superfamily; Rve 
transposase 
100 to IS6 family transposase of S. 
epidermidis 
J2 562 1221 220 6E—149 ABC2_membrane superfamily; 
NosY ABC-type transport system 
involved in multicopper enzyme 
maturation, permease component 
100 to ABC transporter permease 
subunit of S. capitis 
J3 1749 1874 125 3E—17 DUF2648 superfamily; unknown 
function 
100 to multiple species; DUF2648 
domain- containing protein 
J4 1886 3385 500 0 NADB_Rossmann superfamily; MqO 
malate: quinone oxidoreductase 
100 to multiple species; malate 
dehydrogenase (quinone) 
(Staphylococcus) 
J5 3446 5050 535 0 L-Lactate permease superfamily 
(energy production and 
conversion) 
100 to L. lactate permease 
(Staphylococcus) 
J6 5085 5789 235 6E—171 Alpha-acetolactate decarboxylase 
superfamily (secondary metabolite 
biosynthesis, transport, and 
catabolism) 
100 to alpha-acetolactate 
decarboxylase 
J7 5823 7487 555 0 Acetolactate synthase superfamily 
(P RK08617) (amino acid transport 
and metabolism, coenzyme 
transport, and metabolism) 
100 to acetolactate synthase 
J8 8213 8413 67 8E—39 CspA family (transcription) DNA 
binding domain 
100 to cold shock protein 
(Staphylococcus) 
CdR 8807 9424 206 1E—139 Cadmium resistance transporter 
superfamily; CadD protein, 
predicted permease (inorganic ion 
transport and metabolism) 
100 to cadmium resistance 
transporter (Mycobacteroides 
abscessus subsp. massiliense) 
J10 9442 9789 116 4E—74 Arsenical resistance operon 
repressor family; DNA-binding 
transcriptional regulator 
(transcription) 
100 to HTH transcriptional 
regulator (Staphylococcus) 
J11 10002 10610 203 2E—144 Serine recombinase family 100 to recombinase family protein 
(Staphylococcus) 
J12 10716 11276 187 1E—124 None detected 100 to hypothetical protein 
(Staphylococcus) 
J13 11884 12369 162 2E—112 None detected 100 to hypothetical protein 
(Staphylococcus) 
J14 12632 13309 226 5E—166 NlpC/P60 family; the function of this 
domain is unknown; it is found in 
several lipoproteins 
100 to hypothetical protein 
(Staphylococcus) 
PSM 13578 13712 45 1E—22 Staphylococcus hemolytic protein 100 to beta class phenol-soluble 
modulin 
J16 13944 14054 37 4E—17 DUF2648 superfamily; protein of 
unknown function 
100 to multiple species; DUF2648 














E value Putative function (conserved 
domain) 
% identity to best match 
J17 14064 15560 499 0 NADB_Rossmann superfamily; MqO 
malate: quinone oxidoreductase 
100 to malate dehydrogenase: 
quinone (S. capitis) 
J18 15780 16118 113 6E—75 DNA binding transcription 
regulator 
100 to transcriptional regulator 
HXIR family (Staphylococcus 
caprae) 
RepA 17825 18760 312 0 Replication initiator protein A 
(RepA) N terminus family; DNA 
replication initiator in plasmids 
100 to replication initiator 
protein A (Staphylococcus) 
J20 19190 19957 256 1E—178 Polar chromosomal segregation 
protein 
100 to DUF536 binding domain 
(Staphylococcus) 
J21 20132 20734 201 2E—140 NADB Rossmann superfamily; 
PRK07578 short-chain 
dehydrogenase 
100 to short-chain dehydrogenase 
(bacteria) 
J22 21220 21894 225 7E—165 DDE_Tnp_IS240 superfamily; Rve 
transposase 
100 to IS6-like element IS257 
family transposase 
nsjF 22148 22855 236 6.0E—119 ABC-type multidrug transport 
system, ATPase component 
(defense mechanisms) 
75 to Lan protection ABC 
transporter ATP binding subunit 
in Staphylococcus succinus 
nsjE 22857 23603 249 4E—85 Lantibiotic protection ABC 
transporter permease subunit, 
MutE/EpiE family; ABC-2 membrane 
superfamily 
61.29 to hypothetical protein 
BU069_09230 in S. succinus 
nsjG 23600 24337 246 1E—73 Lantibiotic protection ABC 
transporter permease subunit, 
MutG family; ABC-2 membrane 
superfamily 
52.92 to hypothetical protein in S. 
succinus 
nsjB 24362 27277 972 8E—90 Lantibiotic dehydratase C-
terminal, thiopeptide-type 
bacteriocin biosynthesis domain 
30.11 to lantibiotic dehydratase 
Lactobacillus bombicola 
nsjT 27450 29000 517 2E—120 MdIB: ABC-type multidrug transport 
system, ATPase and permease 
component (defense mechanisms) 
40.95 to ABC transporter ATP-
binding protein L. bombicola 
nsjC 28993 30222 410 2E—40 LanC is the cyclase enzyme of 
lanthionine synthetase; LanC-like 
superfamily 
29.31 to lanthionine synthetase 
family protein (Bacillus 
nakamurai) 
nisJ 30263 30445 61 1E—09 Structural gene; lantibiotic 
precursor in gallidermin/nisin 
family 
62.5 to nisin H structural protein 
(Streptococcus hyointestinalis) 
nsjP 30565 31905 447 2E—58 Peptidase S8 family domain in 
lantibiotic-specific proteases 
32.58 to peptidase S8 (Bacillus 
endophyticus) 
J31 31962 32357 132 7E—88 None detected 99.24 to hypothetical protein (S. 
epidermidis) 
J32 32449 33057 203 4E—144 Serine recombinase revolvase 
invertase superfamily; PinE 
100 to multiple species; 
recombinase family protein 
(Staphylococcus) 
J33 33277 33477 67 1E—39 Predicted transcriptional regulator; 
COG3905 superfamily 
100 to plasmid replication-
associated protein (S. 
epidermidis) 
ParA 33483 34277 265 0 ParA family chromosomal 
segregation and plasmid partition: 
cellulose biosynthesis protein BcsQ 
99.62 to ParA family protein (S. 
epidermidis)   


















E value Putative function (conserved 
domain) 
% identity to best match 
RepA 35097 36089 331 0 DNA replication initiator of 
plasmids; HTH superfamily 
99.7 to replication initiator protein 
A (S. capitis) 
J37 36119 36820 234 1E—173 Putative transposase (InsQ) DNA-
binding domain; OrfB_Zn_ribbon 
superfamily 
100 to transposase (S. capitis) 
J38 36827 37102 92 8E—60 None detected 100 to hypothetical protein 
EQ811_12225 (S. capitis) 




38932 286 0 COG5527 superfamily 99.65 to RepB family plasmid 
initiator protein (Staphylococcus) 
J41 39215 39664 150 2E—99 None detected 100 to hypothetical protein 
(Staphylococcus) 
J42 39867 40565 233 3E—169 None detected 98.28 to hypothetical protein 
(Staphylococcus) 
J43 40667 41023 119 5E—80 None detected 100 to hypothetical protein 
(Staphylococcus 
J44 41124 41618 165 1E—107 Asp_carb_tr superfamily; pyrimidine 
biosynthesis 
99.38 to aspartate 
carbamoyltransferase (S. 
epidermidis) 
J45 41674 41847 58 2E—22 None detected 93.48 to molybdopterin 
biosynthesis protein MoaB 
HTH 41985 42665 227 3E—161 HTH superfamily 99.12 to “winged” HTH 
transcription regulator (S. 
epidermidis) 
J47 42777 44150 458 0 Multidrug resistance MFS family 
permease; transport and 
metabolism 
99.78 to MFS transporter (S. 
epidermidis) 
J48 44846 45340 165 3E—109 None detected 98.78 to hypothetical protein (S. 
epidermidis) 
J49 45337 46101 255 6E—176 None detected 100 to hypothetical protein (S. 
epidermidis) 
HTH 46186 46455 90 2E—58 HTH XRE superfamily 100 to HTH transcription regulator 
(Auricoccus indicus) 
J51 47042 47155 38 1E—15 None detected 100 to hypothetical protein 
UF66_0802 (Staphylococcus cohnii 
subsp. cohnii) 
J52 48210 48476 89 8E—57 None detected 98.86 to multispecies hypothetical 
protein (Staphylococcus) 
J53 48623 49843 407 0 None detected 100 to hypothetical protein (S. 
capitis) 
 
aa, amino acid. HTH, helix-turn-helix; XRE, xenobiotic response element; MFS, 








Table 2 Inhibition spectra of purified peptides of nisins A, Z, and J against 
indicator strains using well diffusion assays and expressed as the area of the zone 
of inhibition 
 
*Calculated as the area of zone of inhibition (Πr2) — area of well (Πr2) in  
millimeters. Assays were carried out in duplicate; mean zone areas shown. 
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Table 3 Cross-immunity of nisin A-, U-, H and J-producing strains using well 











Area of zone of inhibitiona 
(mm2) against nisin: 
A U H J 
Lactococcus lactis NZ9700 A 0 0 0 0 
Streptococcus uberis 42 U 0 0 0 85 
Streptococcus hyointestinalis DPC 6484 H 0 0 0 0 
Staphylococcus capitis APC 2923 J 0 0 0 0 
 
aCalculated as the area of zone of inhibition (Πr2) area of well (Πr2) in millimeters. 























Table 4 Growth conditions of the bacterial strains used in this study. 
 
 
aATCC, American Type Culture Collection; APC, APC Microbiome Ireland 
Culture Collection; DPC, Teagasc Culture Collection; WSLC, Weihenstephan 
Listeria Collection; LMG, Laboratorium voor Microbiologie. 
bAnaerobic conditions, where appropriate, were achieved through the use of anaerobic 
jars and Anaerocult A gas packs (Merck, Darmstadt, Germany). 
cMRS, de Man-Rogosa-Sharpe; mRCM, modified reinforced Clostridium medium 
(made following the ATCC medium: 2107 modified reinforced clostridial agar/broth 
[prereduced] protocol); RCA, reinforced Clostridium agar; BHI, brain heart 
infusion; GM17, 0.5% glucose added to M17 agar. 
dMRSA, methicillin-resistant S. aureus.  
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Figure 1 (A) Visualization of the multiple-sequence alignment from MUSCLE 
(plotted using http://msa.biojs.net/app/) of all natural nisin (nis) variants aligned with 
strain origin. The total height of the sequence logo at each position reflects the degree 
of conservation at that position in the alignment, while the height of each letter in that 
position is proportional to the observed frequency of the corresponding amino acid at 
that position. Nisin A (13), nisin Z (48), nisin F (49), nisin Q (50), nisin H (27), nisin 
J (5), nisins U and U2 (51), nisin P (52, 53), and nisins O1 to O4 (54) are shown. L., 
Lactococcus; S., Staphylococcus; B., Blautia; St., Streptococcus. (B) Dendrogram 
showing phylogenetic relatedness in primary structures of all known natural nisin 
variants, suggesting the possible existence of an evolutionary link between the nisin-
producing species. The order in which they branch shows the relatedness between them 



















Figure 3 Purification of nisin J from S. capitis APC 2923 grown in XAD-BHI. (A) 
Original overlay plate where antimicrobial activity of the S. capitis APC 2923 strain 
was detected. (B) The RP-HPLC profile shows a peak at HPLC-active fraction of 
24.5 minutes, which correlates with where pure nisin J elutes. (C) MALDI-TOF MS 








Figure 4 Proposed structure of the novel nisin variant nisin J. Residues are 
represented by the single-letter code. Post-translational modifications are 
indicated as follows: Dha, dehydroalanine; Dhb, dehydrobutyrine; Abu, 2-








Figure 5 Plasmid map of pJOS01 draft sequence created on SnapGene version 








Figure 6 Activity of cell-free supernatant of nisin J- and A-producing strains as 
observed in WDA against MG1614 (NSR
-
) (A) and MG1614/pNP40 (NSR+) (B). The 
assay results are representative of triplicate experiments. The results reveal no 
significant differences in zones of inhibition against NSR
- (P value of 0.1701) (bar 
graph in panel A) but show a significant difference (***) against NSR+ (P value of 
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Nisin A and its natural variants, like other lantibiotics, are Class I bacteriocins encoded 
by gene clusters which typically include a structural peptide, modification enzymes, a 
protease, regulatory, immunity and transporter proteins. Many of the more recently 
discovered nisin variants, such as nisin H, nisin J and nisin P, are produced by non-
GRAS strains. Growing concerns regarding the increases in antimicrobial resistance 
(AMR) has meant that the antimicrobial potential of lantibiotics is now being 
investigated irrespective of the nature of the producing organism. Bioengineering and 
synthetic biology approaches may offer a solution by permitting the recombinant 
expression of peptides naturally expressed by non-GRAS organisms in well 
characterized hosts derived from safe strain lineages.  
This study involved cloning the nisin promoter and nisin A leader sequence fused to 
either nisin H, nisin J or nisin P structural gene sequences originally produced by 
Streptococcus hyointestinalis DPC 6484, Staphylococcus capitis APC 2923, and 
Streptococcus agalactiae DPC 7040 respectively. This resulted in their expression in 
Lactococcus lactis NZ9800, a genetically modified strain that does not produce nisin 
A. Antimicrobial activity of nisin H, nisin J and nisin P was observed following 
induction of the nisin-controlled gene expression system demonstrating that these 3 
nisin variants could be acted on by Nisin A machinery provided by the host strain. This 
study describes the first successful heterologous production of natural nisin variants 
by a GRAS strain, and demonstrates how such systems could be harnessed not only 
for lantibiotic production, but also in the expansion of their structural diversity and 





Resistance to antibiotics has increased the risks associated with many infectious 
bacterial strains, resulting in higher mortality and increased costs on health care 
services (1). A combination of overuse and/or misuse of antibiotics has played a 
detrimental role in the spread of antimicrobial resistance (2). Proliferation in the 
number of multidrug resistant (MDR) bacteria combined with an alarming paucity of 
new antibiotics means the discovery and development of novel antimicrobial therapies 
is vital (3, 4). Antimicrobial peptides (AMPs) are produced by a wide array of 
organisms, forming part of the innate response in plants, animals, bacteria and fungi 
(5). Due to an enhanced understanding of their properties and functions, many AMPs, 
and especially bacteriocins, are now under consideration as suitable alternatives to 
antibiotics with potential applications in both animal and human health (6, 7). 
Bacteriocins are small ribosomally-synthesised heat stable peptides produced by 
bacteria and can have either a broad or narrow antimicrobial inhibition spectrum. As 
such, they are increasingly attractive alternatives to antibiotics for some applications 
(8-11). Lantibiotics (lanthionine containing antibiotics) make up the largest class (class 
I) of  bacteriocins and are generally associated with low levels of resistance (9,12). 
The presence of lanthionine (Lan) and/or B-methyllanthionine (MeLan) residues are 
characteristic features of lantibiotics and are the result of the dehydration of serine and 
threonine to form 2,3 dehydroalanine (Dha) and 2,3 dehydrobutyrine (Dhb), 
respectively. These dehydrated residues subsequently react with the thiols of cysteine 
molecules forming Lan/MeLan bridges (13-16). 
Discovered by Rogers in 1928 (17), nisin A, a 34 amino acid peptide produced by 
Lactococcus lactis (L. lactis), is the oldest and most extensively characterised 
lantibiotic. It is synthesised by a typical nisin gene cluster that encodes the 
modification enzymes NisB and NisC responsible for catalysing dehydration and 
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cyclisation reactions respectively, a transporter (NisT), a regulatory system (NisRK), 
a protease involved in cleaving the pre-peptide (NisP)  and immunity proteins NisI and 
NisFEG (18, 19). Structurally, nisin A consists of one Lan and four MeLan rings and 
three dehydrated residues, two Dha and one Dhb (20). Nisin A binds to Lipid II, a 
bactoprenol-bound peptidoglycan precursor, essential for peptidoglycan synthesis. 
The N-terminal of nisin A sequesters the pyrophosphate moiety of Lipid II resulting 
in the formation of a pyrophosphate cage complex. This complex induces a 
conformational change at the C-terminal of nisin enabling it to translocate into the cell 
membrane thus interfering with membrane integrity causing pore formation and cell 
death (21). While nisin has been widely used as a safe food preservative for decades 
(22), the increased incidence of  multidrug-resistant bacterial infections has resulted in 
a revival in interest surrounding its potential use in life-threatening infections. Many 
studies have highlighted the in vitro potency of nisin against human pathogens (the 
reader is directed to comprehensive reviews (23, 24)). 
While nisin A is Food and Drug Administration (FDA) approved as a food ingredient 
due to its production by Generally Recognised as Safe (GRAS) strains of L. lactis, 
several recently characterised nisin variants have been identified in rare and/or 
emerging pathogenic bacteria. It is becoming apparent that nisin production has a 
broader distribution than first thought and variants have been found in a number of 
genera including lactococci, streptococci, staphylococci and Blautia species. In 
addition, the nisin variants, such as the three used here, have many amino acid 
substitutions compared to nisin A. For example, Nisin H is produced by St. 
hyointestinalis, a member of the viridans streptococci group (VGS) that have the 
pathogenic potential to cause a variety of infections. The nisin H peptide has 5 amino 
acid substitutions in comparison to nisin A specifically, Ile1Phe (i.e., at position 1, 
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nisin A has Ile while nisin H has Phe), Leu6Met, Gly18Dhb, Met21Tyr, and His31Lys 
(25). Nisin J, produced by Staphylococcus capitis (S. capitis) (also an emerging 
opportunistic pathogen), has 9 alterations with respect to nisin A, comprising 8 amino 
acid changes (Ile4Lys, Met17Gln, Gly18Thr, Asn20Phe, Met21Ala, Ile30Gly, 
Val33His and Lys34Thr) and an extra amino acid (Lys35) at the C- terminus, making 
it the longest natural nisin variant (26). Nisin P, produced by Streptococcus agalactiae 
(St. agalactiae) (group B Streptococcus) (27) is the shortest natural nisin variant, 
consisting of just 31 amino acids, and has 10 amino acid differences with respect to 
prototypical nisin A (Ile1Val, Ile4Lys, Ala15Ile, Gly18Thr, Asn20Ala, Met21Ile, 
His27Gly, Ser29His, Ile30Phe, His31Gly) (28,29) (Figure 1). All nisin variants are 
predicted to have a similar structure and mode of action to nisin A. 
Nisin has been the subject of extensive bioengineering strategies in a bid to improve 
and enhance its antimicrobial activity, heat stability, solubility, diffusion, and protease 
sensitivity (30–34). To that end, the development of novel expression systems has been 
necessary. As multiple genes are required for nisin synthesis and immunity, it is often 
effective to produce bioengineered nisin variants against the background of the 
original producer (31, 35–37). Moreover, it has been demonstrated that a L. lactis 
strain expressing nisABTC is sufficient for the production and export of not only fully 
modified nisin but also a non-lantibiotic fusion of leader peptide with dehydrated 
angiotensin (38). This broad substrate specificity of the nisin dehydrating and transport 
machinery suggests that lantibiotic enzymes could be utilized for the synthesis of a 
wide range of novel dehydro residue-containing peptides or novel lantibiotic structures 
(39–41). 
The development or utilization of heterologous bacteriocin expression systems offers 
advantages over natural producers including: i) the potential to improve yield as 
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production levels in their original hosts can be very low (42) ii) improved efficiency 
of purification protocols as many producing cultures require complex broth for growth, 
making purification time consuming and expensive and iii) production in a GRAS 
organism in instances where the original producer may be pathogenic with limited 
industrial application (43). The looming antimicrobial resistance crisis makes it 
inevitable that the creation of such heterologous systems will become more important 
to produce novel alternative antimicrobials at industrial scale for both food safety and 
healthcare applications.  
The aim of this study was to develop a heterologous expression system for the 
production of the natural nisin variants nisin H, nisin J and nisin P, in a GRAS host, 
namely L. lactis NZ9800, by adopting a synthetic biology approach. 
 
3.1.3 Materials and Methods  
Bacterial strains, culture conditions and plasmids  
Bacterial strains, their growth conditions and plasmids used in this study are listed in 
Table 1. Anaerobic conditions for bacterial strains, where applicable, were achieved 
using anaerobic jars and Anaerocult A gas packs (Merck, Darmstadt, Germany). L. 
lactis strains were grown in M17 broth or agar (Sigma-Aldrich, (Merck, Darmstadt, 
Germany), supplemented with 0.5% glucose (GM17) at 30°C. E. coli was grown in 
Luria-Bertani (LB) agar or broth with vigorous shaking at 37°C. Antibiotics were used, 
where indicated, at the following concentrations: Chloramphenicol (Cm) at 5 and 10 
μg mL–1 respectively for L. lactis and E. coli (31). 
 
Synthetic gene hybrid design  
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To express nisin H, nisin J and nisin P into a lactococcal background, synthetic gene 
hybrids containing the full NisA leader sequence (nisAL), followed by each of the nisin 
H, nisin J and nisin P structural gene sequences were designed (Table 2). Hybrid genes 
containing the NisA promoter, the full NisA leader sequence (nisAL), followed by each 
of the structural sequences, nisin H, nisin J and nisin P, were synthesised by IDT (1710 
Commercial Park, Coralville, Iowa, 52241, USA). 
 
Molecular cloning procedures  
The E. coli/L. lactis shuttle vector pCI372 (64) was extracted from E. coli HB101 cells 
using a NucleoSpin plasmid kit (Macherey-Nagel, Duren, Germany). The nisAL–
nisH/nisJ/nisP gene strands (100 ng) were amplified by polymerase chain reaction 
(PCR) set up as follows: templates (100 ng) pUCIDT-KAN-nisJ,  pUCIDT-KAN-nisH 
and pUCIDT-KAN-nisP; Forward and Reverse oligos (0.3 µM) (including EcoRI and 
XbaI (NEB) restriction sites), (see Table 3, (Sigma-Aldrich, Merck, Darmstadt, 
Germany); 0.2 mM dNTPs; 1.5 mM Mg2+ and 2 units of KOD polymerase (Novagen) 
in a final volume of 50 µL. PCR reactions were carried out in a MJ Research PTC-200 
thermocycler using the following conditions: initial denaturation at 98°C x 2 minutes, 
cycling conditions: 30 cycles of 95°C x 20 seconds, 50°C x 10 seconds, 72°C x 10 
seconds each, followed by a final extension at 72°C x 10 minutes. PCR products were 
purified using NucleoSpin Gel and PCR clean-up (Macherey-Nagel, Duren, Germany) 
and (~3000 ng) digested with EcoRI and XbaI restriction enzymes (20 U) in CutSmart 
10X buffer (New England Biolabs, Ipswich, UK) in a 40 µL reaction. The plasmid 
pCI372 (14.76 µg) was also digested in a 70 µL reaction, with EcoRI and XbaI (40 U).  
The digested plasmid and insert were purified using the Thermo Scientific GeneJET 
PCR purification kit and the products ligated in a reaction set up as follows: T4 ligase 
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(800 U) (New England Biolabs, Ipswich, UK); final volume of nisJ and nisP ligation 
reactions = 20 µL, final volume of nisH ligation reaction = 30 µL; insert concentration 
= 1 µg; plasmid concentration = 60 ng/µL. The ligation reactions were transformed 
into E. coli Top10 competent cells (Invitrogen, Dublin, Ireland) as per manufacturer’s 
instructions. Plasmid DNA was extracted and the nisH/nisJ/nisP genes were amplified, 
and products sequenced (Source BioScience, Waterford, Ireland) to ensure integrity 
and subsequently introduced by electroporation into L. lactis NZ9800, a non-
producing derivative of the nisin A producer L. lactis NZ9700, as previously described 
(65). 
 
Nisin induction experiments  
Production of nisin H, nisin J and nisin P was achieved through induction via the 
addition of 1 µL of nisin A cell-free supernatant (CFS) per mL to each culture broth, 
corresponding to approximately 10 ng/mL nisin A. Single colonies from each nisin 
producer were inoculated into 5 mL GM17 broth (Difco laboratories Inc, Omagh, UK) 
with and without 5 µL of nisin A CFS. Cultures were incubated at 30°C overnight and 
the presence of antimicrobial activity in CFS assessed by deferred antagonism assays, 
as outlined by Parente and Hill (1992), using L. delbrueckii subspecies (ssp) bulgaricus 
LMG 6901 as the target organism (66). 
 
Purification of nisin A, nisin H, nisin J and nisin P  
NZ9800 transformants containing pCI-nisH, pCI-nisJ and pCI-nisP plasmids were 
streaked on GM17 agar plates (Difco Laboratories Inc., Omagh, UK) containing 10 
µg/ mL chloramphenicol (Cm10). Colonies of each culture were subsequently grown 
in liquid media supplemented with Cm10 and 1 µL of nisin A per ml of broth. 
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Specifically, a single colony was inoculated into 5 ml GM17 (0.5% glucose) broth and 
grown aerobically overnight at 30°C. This was then used to inoculate 25 mL GM17 
which, in turn, was used to inoculate 2 Litres of TY broth. The nisin A producer was 
grown as described above but without the addition of Cm10 or nisin A supernatant. 
Cultures were centrifuged (8000 rpm, 20 mins, 10°C), and cell free supernatant (CFS) 
retained for purification of nisin variants.  
The Activity Units per ml (AU/mL) of each CFS was determined as follows: 100 µL 
aliquots of nisin A, nisin H, nisin J and nisin P CFS were 2 fold serially diluted in Milli 
Q water and 50 µL aliquots of each dilution assayed by well diffusion assays (WDA) 
against L. delbrueckii ssp. bulgaricus LMG 6901. AU/mL is taken as the reciprocal of 
the highest dilution showing activity against the indicator strain corrected per mL of 
culture.  
Two Litres of culture supernatant were passed through an Econo column containing 
60 g Amberlite XAD16N beads (Sigma Aldrich, Co. Wicklow, Ireland), prewashed 
with Milli Q water. The column was washed with 400 mL of 35% ethanol (30% 
ethanol for nisin J as it is more hydrophilic) and antimicrobial peptide eluted in 400 
mL of 70% 2 propanol 0.1% TFA (IPA). To allow interaction with a C18 SPE column, 
the IPA was removed from the XAD IPA eluent by rotary evaporation (Buchi, Flawil, 
Switzerland) and sample concentrated to approximately 80 mL. The concentrated 
sample was then applied to a 5 g, 20 mL Strata-E C18 SPE column (Phenomenex, 
Cheshire, UK) pre-equilibrated with methanol and water. The column was washed 
with 30 mL 25% ethanol (20% ethanol for nisin J) and antimicrobial activity eluted 
with 30 mL IPA. 
IPA was removed from the previously eluted C18 SPE IPA eluent and the resulting 
sample (2 ml) applied to a semi-preparative Jupiter Proteo (10 x 250 mm, 90Å, 4 µm) 
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RP-HPLC column (Phenomenex, Cheshire, UK) running a 25-50% acetonitrile 
gradient 0.1% TFA where buffer A is 0.1% TFA and B is 90% acetonitrile 0.1% TFA. 
Eluent was monitored at 214 nm and fractions were collected at 1-minute intervals 
(27). Fifty μl aliquots of HPLC fractions were assayed for antimicrobial activity 
against the indicator organism, L. delbrueckii ssp. bulgaricus LMG 6901, and active 
fractions checked by MALDI TOF mass spectrometry to assess fraction purity.  
 
MALDI TOF Mass Spectrometry  
MALDI TOF Mass Spectrometry was performed with an Axima TOF2 MALDI TOF 
mass spectrometer (Shimadzu Biotech, Manchester, UK) as described by Field et al., 
2015 (67).The instrument was operated in positive ion linear mode and masses 
reported as average values. 
 
In silico comparison of nisin H/J/P biosynthetic machinery to nisin A 
Each gene sequence of each segment of the nisin H/J/P bacteriocin gene cluster was 
inputted into NCBI BLASTP suite and aligned to the corresponding section of nisin A 
gene cluster so as to obtain the percentage identity. 
 
3.1.4 Results  
Cloning nisAL- nisin H nisin J, and nisin P pre-peptides into L. lactis NZ9800 
Gene constructs containing the nisin A leader (nisAL) fused to the nisin H, nisin J and 
nisin P structural genes were amplified and subcloned from pUCIDT-KAN into the 
Escherichia coli-(E. coli)- L. lactis shuttle vector pCI372 (31, 44), to generate pcI-
nisH, pcI-nisJ and pcI-nisP plasmids. DNA sequence analysis confirmed the integrity 
of each synthetic hybrid gene. These plasmids were purified and subsequently 
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introduced into L. lactis NZ9800 following the cloning strategy outlined in Figure 2. 
L. lactis NZ9800 was chosen as it is derived from the wild type nisin A producing 
strain NZ9700. A 4bp deletion from the structural gene nisA means this strain does 
not produce nisin, and the transcription of the nisin operon is blocked. This was one of 
the early host strains of the nisin-controlled gene expression (NICE) system since it 
provides the necessary regulatory (nisK and nisR) and immunity (nisI, nisFEG) genes. 
Importantly, it contains genes for the nisin biosynthetic machinery (nisBCTP) thus 
making it a potentially suitable strain in which to express nisin H, nisin J and nisin P 
genes cloned under the control of the nisin promoter (36), see Table 1.  
 
Production of nisin H, nisin J and nisin P by L. lactis NZ9800  
Initially, transformants of pCI-nisH, pCI-nisJ and pCI-nisP failed to produce zones of 
inhibition against the indicator strain, Lactobacillus delbreuckii ssp. bulgaricus LMG 
6901, when assayed by deferred antagonism assays on solid agar (data not shown). 
Similarly, when cell free supernatant (CFS) from overnight cultures was assessed 
using well diffusion assays (WDA), no antimicrobial activity was observed when 
compared to the nisin A control (Figure 3A). However, the addition of nisin A CFS at 
1 µL/mL (approx 10 ng nisin A) resulted in bioactivity against the indicator strain L. 
delbreuckii ssp. bulgaricus LMG 6901 (Figure 3B). Addition of exogenous nisin A 
CFS to growing transformant cultures was essential for antimicrobial production, 
presumably because it was necessary to induce the system. 
 
Purification of nisin A, nisin H, nisin J and nisin P from L. lactis NZ9800 grown 
in TY broth  
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The ability of the transformants to produce fully modified and active nisin H, nisin J 
and nisin P, in comparison to the nisin A producer, was assessed by growing the 
producing strains in equal volumes of TY broth and, purifying the peptides from CFS 
using Amberlite XAD16N, C18 SPE and Reversed Phase HPLC. The cell pellet is not 
typically a good source of nisin A and so is routinely discarded. The cell pellets of the 
nisin H, J and P producers were assayed for antimicrobial activity by WDA and 
potential masses of interest by MALDI TOF MS. Both assays suggested that activity 
was low from cells as evidenced by low AU/mL in WDA of cell extract and failure to 
detect nisin H, nisin J and nisin P masses by MALDI TOF MS (data not shown). 
Determination of the AU/mL of each of the culture supernatants revealed that the nisin 
A producer, L. lactis NZ9700, produces the most activity (10,240 AU/mL) when 
compared to nisin H (80 AU/mL), J (80 AU/mL) and P (160 AU/mL). The HPLC 
chromatogram for nisin A shows that it elutes at 47 minutes, the corresponding fraction 
is active against L. delbrueckii ssp. bulgaricus LMG 6901 and a 3354 Da mass was 
detected in this fraction which agrees with the 3352 Da theoretical mass (Figure 4a). 
Nisin H and P are similarly hydrophobic and elute at 47 and 48 minutes, respectively. 
The corresponding fractions are active and masses of 3453 Da (expected mass 3453 
Da) and 2989 Da (expected mass 2989 Da) were detected for nisin H and P 
respectively. Nisin J is a more hydrophilic peptide and elutes earlier in the gradient in 
fraction 31.  
The HPLC chromatograms also show that the mV response is low for nisin H (Figure 
4b), J (Figure 4c) and P (Figure 4d) compared to nisin A (Figure 4a). This is expected 
as the initial WDA assay of TY supernatants show that the AU/mL was much lower 
for nisin H, J and P than nisin A.  
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The purification of nisin H, J and P from transformants confirms the successful 
expression of nisin H, J and P in L. lactis NZ9800, albeit with a low purification yield 
for the three nisin variants (< 0.01 mg/L for H, J and P compared to 2.5 mg/L for nisin 
A). HPLC and MALDI TOF MS confirm the functioning of the NICE system as 
peptides of the correct mass for each of the nisin variants are being produced. Low 
production levels could be the result of impaired processing, given the low percentage 
identities between the nisin A biosynthetic genes and the nisin H, J and P counterparts, 
or may result from the inability of the cell to export the unprocessed peptide due to 
incompatibility with the transporter peptide or codon usage. Production could 
potentially be improved by substituting cognate modification genes and optimising 
codon usage, but successful production of variants confirms redundancy in the nisin 
biosynthetic and/or immunity machinery.  
Of the three natural nisin variants used in this study, nisin P (structural gene plus leader 
sequence) is most similar to nisin A with a percentage identity of 90.91%, while nisin 
H and nisin J have percentage identities of 82.00% and 52.56% respectively. It is 
interesting to note that nisin P (160 AU/mL) CFS has higher activity as measured in 
AU/mL in TY broth compared to nisin H (80 AU/mL) and nisin J (80 AU/mL). The 
percentage identity of the nisin J biosynthetic machinery compared to nisin A is 
considerably lower than that of nisin H and P, see Figure 5. Overall, the successful 
production of nisin H, J and P demonstrates the promiscuity of the nisin A 
biosynthetic/modification machinery. 
These results demonstrate the potential of heterologous expression and suggest that, 
with further optimisation, this system could be utilised to express and harness nisin 





Bacteriocins have major potential for applications in food preservation, food safety 
and both animal and human healthcare (45–47). Although many novel lantibiotics, 
(Class I RiPPs), have been discovered, production of these peptides at high levels from 
their original hosts can be challenging and costly due to the natural producer not being 
a GRAS approved strain or difficulties growing the host strain. The increasing threat 
of an AMR crisis means that potentially potent lantibiotics should not be overlooked 
and attempts should be made to harness them through heterologous expression in 
alternative hosts. Their gene encoded nature allows for easier modification resulting 
in the development of novel lantibiotics with improved properties, giving them an 
advantage over other antimicrobial classes (48). Previous studies have heterologously 
expressed bacteriocins for applications in food or medicine (49–51). The aim of this 
study was to express the natural nisin variants H, J and P in a GRAS strain, L. lactis 
NZ9800, under the control of the nisin A promoter. The main advantage of this 
approach is that it does not require potentially pathogenic host strains for the 
production of antimicrobial peptides that possess potent activity against food spoilage 
and pathogenic strains.  
Nisin is the prototypical lantibiotic that exhibits potent broad-spectrum antimicrobial 
activity against a wide array of pathogens. Several bioengineering studies of wild type 
nisin A have been carried out to improve its antimicrobial properties and functions 
(52–55). Numerous elegant studies have established that the nisin A 
biosynthetic/modification machinery demonstrates tolerance to a broad range of 
substrates (40, 53, 56). Majchrzykiewicz et al., (2010) effectively used the nisin 
modification proteins to produce, modify and secrete entirely unrelated putative 
lantibiotics, identified from in silico screening, via the nisin expression system (40). 
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Specifically, novel two component lantibiotic pneumococcin, from Streptococcus 
pneumoniae R6, was selected as the substrate for the nisin enzymes. Introduction of a 
fusion peptide, consisting of nisin leader and mature peptide, into an L. lactis host that 
overproduces NisBTC, resulted in modification of the peptides and inhibition of 
Micrococcus flavus. 
Another noteworthy example involved using the nisin expression/modification system 
to effectively dehydrate, secrete and, in a few cases, form ring structures, in derivatives 
of a variety of different peptide hormones that mediate a myriad of physiological 
functions including enkephalin, luteinizing hormone, angiotensin and erythropoietin 
(56, 57). Moreover, the modified angiotensin derivatives exhibited increased 
resistance to proteases and enhanced biological activity relative to their linear 
counterparts (57, 58). Fusion of the wild type nisin leader sequence to 54 genes 
encoding novel lantibiotics resulted in the successful expression of 30 peptides using 
the prototypical nisin A machinery system, five of which exhibited good antimicrobial 
activity (41).   
Induction of the transformants with nisin A supernatant was required for production 
of antimicrobial activity in the nisAL-nisH/J/P supernatants demonstrating that the 
expression of these natural nisin variants in L. lactis is dependent on induction of the 
NisRK system. Induction by the antimicrobial of interest is a requirement for 
production that switches on the NICE system in clones, thereby stimulating the nisin 
A biosynthetic machinery to produce peptides of interest (31, 59). 
Purification of nisin H, nisin J and nisin P from the L. lactis host was performed 
following detection of antimicrobial activity from the clones though yields were low 
compared to nisin A. The low production yield may be attributed to the low percentage 
identity between the biosynthetic machinery (LanB and LanC) of nisin H, nisin J, nisin 
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P to nisin A, with lanB and lanC of nisin H/ J / P~58% , ~25%, ~ 90% similar to that 
of nisin A. Also, the transporters of nisin H, J, P are ~76%, ~33% and ~59% similar 
to the nisin A LanT, while the nisin A protease is ~54%, ~31%, ~30% similar to those 
of nisin H, J and P respectively. Thus, the nisin A biosynthetic machinery, transporters 
and protease may not cleave and export the nisin H, nisin J and nisin P variants 
efficiently. Indeed, in the study by Lagedroste and co-workers (60) a systematic 
characterization of position one variants of nisin A expressed in the nisin A 
background revealed an extensive variation in the ability of the protease NisP to cleave 
the leader peptide and release the active nisin derivative. The greatest impact was 
observed when charged (His, Arg, Lys, Asp, Glu) and aromatic amino acids (Trp, Phe, 
Tyr) were substituted in place of the normally present valine. Notably, I1F which 
corresponds to the first amino acid in nisin H displayed approximately 13% cleavage 
compared to the wild type peptide. While this highlights one of the reasons for the 
relatively poor production of nisin H in our study, nisin P contains valine at position 
one and so should not impact on NisP activity. Furthermore, a study by Piper and 
colleagues (44), demonstrated that, although the heterologous expression of the natural 
nisin variants NisF, NisZ and NisQ facilitated the production of sufficient peptides for 
direct specific activity comparisons with NisA, no Nisin U and U2 production was 
observed in the nisin A background.  
MALDI TOF mass spectrometry of active fractions revealed the presence of the 
expected masses for nisin H, nisin J and nisin P confirming that the correct fully 
processed nisin variants are being produced in the GRAS strain. Codon usage may also 
be a factor in the poor expression levels as this was not considered in the design of the 
nisAL-nisH/J/P genes. However, the use of L. lactis codon utilization preferences when 
nisU and nisU2 genes incorporated with the nisin A leader by Piper et al., (2011) did 
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not result in successful production of these peptides even though nisin A was added 
exogenously to ensure that induction of the Pnis promoter was not a concern (44). This 
suggests that, although heterologous peptide production was successful using this 
system, poor efficiency is possibly due to the low similarity of the transporters and 
machinery of the nisin variants to wild type nisin A. Low percentage identity leading 
to the failure of one or more of the biosynthetic (NisBC), leader removal (NisP) or 
export (NisT) proteins to recognize the encoding peptides was also suggested by Piper 
et al. (2011) (44). 
Further optimisation of this system is required for increased production of nisin 
variants and their further characterisation. Indeed, a recent study involving synthetic 
biology approaches describes the development of a genetic system whereby cloning 
an entire nisin biosynthesis pathway from a nisin-producing strain facilitates 
significant overproduction of nisin (61). Furthermore, extra copies of nisFEG, nisRK 
and nisI cloned under strong constitutive promoters has been shown to improve 
production levels and is an approach that may be employed in future studies to improve 
the heterologous production of nisin H, nisin J and nisin P (62, 63).  
 
3.1.6 Conclusion 
This is the first description of the heterologous production of different naturally-
occurring nisins in L. lactis. From this, it is apparent that there is considerable 
redundancy in the nisin modification and transport machinery which can be employed 
to process different nisin structures. Furthermore, the system represents a powerful 
tool that could facilitate the production of novel nisin derivatives as well as aid in the 
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Table 2 Gene hybrid synthesis design. 
 
Blue = nisin A promoter, Red = nisin A leader sequence, yellow highlight= nisin J 
structural gene, blue highlight= nisin H structural gene, green highlight= nisin P 
structural gene, pink highlighted ‘taa’= stop codon. 
 

















Figure 1 Graphical representation (A) of nisin A with nisin H, nisin J and nisin P 
amino acid substitutions highlighted; and sequence alignment (B) of nisin A with 


















Figure 2 Description of cloning strategy adapted for this study. Synthetic genes 
consisting of nisA promoter and leader fused to nisH/J/P were separately amplified by 
PCR from pUCIDT-KAN-nisJ, pUCIDT-KAN-nisH and pUCIDT-KAN-nisP, 
digested with EcoRI and XbaI, and subsequently ligated with pCI372 of each 
construct. The constructs were transformed into L. lactis NZ9800 following 




Figure 3 Well diffusion assays of nisin A, nisin H, nisin J and nisin P WDA of cell 
free supernatants (CFS) of uninduced (top row) and induced (bottom row), overnight, 
cultures of nisin A (A), H (H), J (J) and P (P) with L. delbrueckii ssp. bulgaricus LMG 
6901 as the target indicator. GM17 media (M) and GM17 containing 1 µL/ mL nisin 












Figure 4 Purification of nisin A, nisin H, nisin J, and nisin P from their respective 
producing strains. HPLC chromatogram (mAU vs time in minutes) acquired at 214 
nm, MALDI TOF mass spectra (% intensity of mass to charge ratio (m/z)) and zone 
of inhibition for active fractions are shown for nisin A (4a) nisin H (4b), nisin J (4c) 
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The potency of the broad-spectrum bacteriocin, bactofencin A, 
against staphylococci is highly dependent on primary structure, N-
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Bactofencin A is a novel class IId bacteriocin, produced by the intestinal isolate 
Lactobacillus salivarius DPC6502, which has potent activity against medically 
significant pathogens including Staphylococcus aureus. This bacteriocin is unusual in 
that it has a highly cationic N terminus and a single disulfide bond between Cys7 and 
Cys22, resulting in a large C terminal loop. In this study, a library of synthetic 
bactofencin A variants was screened against the mastitis isolate, S. aureus DPC5246, 
to identify key residues responsible for activity. It was apparent that substituting either 
cysteine of the disulfide bond with either serine or alanine significantly reduced the 
activity of the bacteriocin, confirming the importance of the C terminal loop. 
Substituting N terminal amino acids with alanine had no effect on activity, whereas 
sequential removal of the N terminal positively charged residues resulted in an 
increasingly inactive peptide. A complete (synthetic) alanine scanning analysis 
revealed that the residues between Val9 and Gly17 were most affected by substitution, 
suggesting that this area has a major influence on the potency of the bacteriocin. 
Substituting residues in the loop region between Cys7 and Cys22 for D-amino acid 
equivalents had a more detrimental effect on activity than L-alanine substitutions. 
Specifically Y10A, N11A, P15A and T16A are active at 4, 16, 1 and 16 μM 
respectively while their D equivalents were inactive at 1000 μM, the highest 
concentration tested. Ultimately, this study identifies the critical features in the primary 
structure of the bacteriocin which gives it such potent activity against pathogenic 
staphylococci. 
 
4.1.2 Introduction  
Concerns about the increased incidence of antimicrobial resistance (AMR) against 
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human pathogens have led to calls for global efforts to combat this worrying 
phenomenon. If left untackled, once treatable infections will again become incurable 
(1). The Global Antimicrobial Resistance Surveillance System (GLASS) was set up in 
2015 to standardise the collection and sharing of data on AMR at a global level and to 
promote coordinated action. In support of this initiative, the WHO recently surveyed 
the development of new antibiotics in the clinical pipeline against priority pathogens 
and found that there is particular need for new classes of antimicrobial to abate the 
threat of AMR. Specifically, they found that most antibiotics are derived from existing 
antibiotic classes and these are only considered a temporary solution to AMR as they 
will be quickly rendered ineffective by existing resistance mechanisms. Expressly, 
they state that more investment is needed in fundamental drug discovery to discover 
more innovative antimicrobials against priority pathogens including Mycobacterium 
tuberculosis, Clostridium difficile and Staphylococcus aureus (2). 
One class of antimicrobial that is receiving increased attention is the bacteriocins. 
These are stable peptides naturally produced by many bacteria and have potent 
activity against other bacteria including antimicrobial resistant pathogens (3). 
Bacteriocin production by intestinal strains is considered a desirable probiotic trait 
that could potentially mediate an effect in three different ways; it may allow the 
producing strain to compete in the crowded gut ecosystem, it could provide protection 
to the host against pathogens and could potentially signal the immune system in a 
similar fashion to host antimicrobial peptides (AMPs) (4-7). 
Recently, we described bactofencin A, a small, positively charged bacteriocin 
produced by the porcine gut isolate L. salivarius DPC6502. Structurally, it consists of 
a positively charged N terminal attached to a C terminal loop formed via a disulfide 
bond between Cys7 and Cys22. Bactofencin A is highly cationic and has been 
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compared to eukaryotic defensins which contain a high Lys/Arg molar ratio, 
considered essential for bactericidal activity (8, 9) Another unusual feature of 
bactofencin A is that immunity is mediated through a dltB homologue proposed to 
decrease the negative charge of the cell wall thereby reducing attraction between 
bacteriocin and cell, rather than a specific immunity protein. Bactofencin A displays 
activity against S. aureus and Listeria spp. and has been shown to subtly modify gut 
populations (10, 11).  
The rational design of novel antimicrobials is rapidly evolving via the use of 
bioengineering to generate novel bacteriocin variants with enhanced functionality. 
This has been realised through the recent generation of both one and two peptide 
bacteriocins with greater activity against foodborne and medically significant Gram-
positive and Gram-negative pathogens (12-17). Indeed, nisin V, a single Met21Val 
substitution variant of the well characterised commercial bacteriocin nisin A 
generated in our laboratory, has greater in vivo efficacy against Listeria 
monocytogenes when compared with the native peptide (18). In many cases, the 
identification of enhanced derivatives has been realised following initial studies in 
which saturation or scanning mutagenesis have been employed to reveal key important 
residues and structures within the peptide (12). 
The aim of this study was to determine the importance of specific residues and regions 
within bactofencin A to its anti-S. aureus activity. Bactofencin A is a relatively short 
Class IId peptide in which a disulfide bond naturally forms, making it especially 
amenable to peptide synthesis as a means of carrying out such structure-function 
investigations. Specifically, a saturation approach was undertaken as follows; firstly, 
both cysteines were substituted with serine and alanine, individually and in tandem, 
to elucidate their role in peptide structure. Secondly, deleted variants were synthesised 
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to assess the function of the positively charged N terminal. Thirdly, alanine was 
substituted for each amino acid (alanine scanning) and finally, a series of D-amino 
acid variants specific to the loop were synthesised to determine if chiral interactions 
with a receptor were likely to be involved in activity. 
 
4.1.3 Materials and methods 
Peptide synthesis 
Bactofencin A and variants were synthesised from the C terminus to the N terminus 
using microwave-assisted solid phase peptide synthesis (MW-SPPS) on a Liberty 
Blue microwave peptide synthesizer (CEM Corporation. Mathews, North Carolina, 
USA). Peptides with a C terminal cysteine were synthesized on an H-Cys(Trt)-HMBP 
pre-loaded resin, bactofencin C22A on an H-Ala-HMBP resin and bactofencin 
C22Cd on HMBP resin where the initial D-Cys was manually added to the resin 
(PCAS BioMatrix Inc., Quebec, Canada). The amino acid attached to the resin and 
the following two amino acids were deprotected conventionally at 25°C, 0 W for 900 
seconds in 5% piperizine in DMF to limit the formation of an undesirable 51 Da 
modification commonly seen in C terminal cysteine peptides. Following deprotection, 
the exposed amino group is coupled conventionally with the carbonyl group of the 
next amino-protected amino acid at 75°C, 0 W for 3600 seconds in the presence of 
the activator, 0.5 M N,N′-diisopropylcarbodiimide in DMF, and activator base, 1.1 M 
hydroxybenzotriazole in DMF. The fourth and subsequent amino acids were added 
using microwave deprotection at 75 °C, 60 W for 600 seconds and microwave coupling 
at 75 °C, 35 W for 600 seconds. Arginines were double coupled at 75 °C, 35 W, 300 
seconds and histidine and cysteine coupled at 25°C, 0 W, 300 seconds and then 50°C, 
35 W for 900 seconds. Following synthesis, the peptide was cleaved from the resin by 
 
164  
adding a cleavage mix containing 9.25 ml trifluoroacetic acid (TFA), 250 µl water, 250 
µl 2′2-(ethylenedioxy)-diethanethiol and 500 µl triisopropylsilane. This mixture was 
then heated at 37 °C for 1 hour to cleave the peptide from the resin. Resin was removed 
from the cleavage mix using an Accent Cleavage system (CEM, Corporation. 
Mathews, North Carolina, USA) and the TFA evaporated by bubbling with nitrogen. 
Peptide was precipitated from the remaining solution by adding 45 ml of diethyl ether 
pre-cooled to −20°C and centrifuging at 1000 g for 3 minutes. The precipitated peptide 
was washed free of scavengers by resuspending in a second aliquot of 45 ml ice cold 
diethyl ether and the centrifugation step repeated. 
 
Purification of synthetic peptides  
Crude peptide was purified using Reversed Phase-HPLC on a semi preparative 
Jupiter Proteo (10 × 250 mm, 4 µ, 90 Å) column (Phenomenex, Cheshire, UK) running 
an 11–45% acetonitrile 0.1% TFA gradient over 40 minutes where buffer A is Milli Q 
water containing 0.1% TFA and buffer B is 90% acetonitrile containing 0.1% TFA. 
Fractions with the desired molecular mass were identified using matrix assisted laser 
deionisation -time of flight-mass spectrometry (MALDI-TOF-MS) on an Axima 
TOF2 MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) 
operating in positive ion reflectron mode and were pooled and lyophilized on a 
Genevac HT 4X lyophilizer (Genevac Ltd., Ipswich, UK). Peptides were resuspended 
in 50 mM sodium phosphate buffer pH 6.8 at approximately 1000 µM and kept at 
room temperature for 24–48 hours until the disulfide bond between Cys7 and Cys22 
fully formed as monitored by MALDI-TOF-MS. Peptides were then further purified 
by a second HPLC run as described above except the gradient used was 15–30% 
acetonitrile 0.1% TFA gradient over 30 minutes. Again fractions containing pure 
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bactofencin A were identified and lyophilised for specific activity experiments. 
 
Purification of natural bactofencin A  
Bactofencin A was purified from MRS culture media as described by O’Shea et al. (10). 
Briefly peptide was purified from an overnight culture of L. salivarius grown in 1 litre 
of MRS media using SP sepharose Cation Exchange, C18 Solid Phase Extraction 
(SPE) and Reversed Phase HPLC. 
 
Specific activity of bactofencin A variants 
Peptides were resuspended at 1000 µM in 50 mM sodium phosphate buffer pH 6.8 
and checked for purity by MALDI-TOF-MS. Peptides were serially diluted 1 in 4 to 
give a dilution series of 250, 62.50, 15.63, 3.91, 0.98 and 0.24 µM and assayed by the 
agar well diffusion assay described by Ryan et al. (19). Briefly, 50 µl aliquots of each 
peptide concentration were plated on a S. aureus DPC5246 indicator plate and the plate 
incubated at 37 °C. Peptide activity (Minimum Inhibitory Concentration (MIC)) 
was taken as the lowest concentration of peptide to give a zone of inhibition. All 
assays were performed in triplicate. The dilution series values were rounded to the 
nearest whole number to give 1000, 250, 63, 16, 4, 1 and 0.25 µM and data is colour 
coded for ease of interpretation. 
 
Bactofencin variants synthesised for specific activity studies  
Bactofencin A, KRKKHRCRVYNNGMPTGMYRWC, is a 22 amino acid bacteriocin 
with a disulfide bond between Cys7 and Cys22. Bactofencin variants are labelled 
according to the amino acid position number using the one letter code followed by 
the change it undergoes e.g. a lysine at position 1 to alanine change is labelled K1A. 
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Bactofencin Cys7 and Cys22 were substituted with serine both individually and in 
tandem to give bactofencin C7S, bactofencin C22S and bactofencin C7S-C22S. These 
amino acids were also substituted with alanine to give bactofencin C7A, bactofencin 
C22A and bactofencin C7A-C22A. 
To assess the importance of the positively charged N terminal, the following deletion 
variants were synthesised; bactofencin R2-C22, K3-C22, K4-C22, H5-C22, R6-C22 
and C7-C22. 
Each amino acid in bactofencin A was changed to alanine to give a library of alanine 
scanning variants, these are specifically; K1A, R2A, K3A, K4A, H5A, R6A, C7A, 
R8A, V9A, Y10A, N11A, N12A, G13A, M14A, P15A,T16A, G17A, M18A, Y19A, 
R20A, W21A and C22A. Bactofencin C7A and C22A were also used to assess the role 
of cysteine in activity as described above. 
Each amino acid in the loop from Cys7 to Cys22 was substituted for a D-amino acid 
equivalent to give a series of variants, namely bactofencin C7Cd, R8Rd, V9Vd, 
Y10Yd, N11Nd, N12Nd, M14Md, P15Pd, T16Td, M18Md, Y19Yd, R20Rd, W21Wd 
and C22Cd. An all D-amino acid variant for a preliminary MIC50 assay was 
synthesised by Alta Bioscience (Birmingham, UK). 
 
Comparison of bactofencin A and bactofencin R8Q  
Bactofencin R8Q and bactofencin R8K were synthesised as described above and their 
activity compared to bactofencin A against S. aureus DPC5246, Listeria innocua 
DPC3572 and L. monocytogenes ATCC 23074. 
 
4.1.4 Results 
Formation of the disulfide bond in synthetic bactofencin A  
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To investigate how specific residues and domains within bactofencin A contribute to 
its potency against staphylococci, a series of bactofencin variants were synthesized, 
purified and assayed. Natural bactofencin A is encoded on a four gene operon that 
includes an accessory protein that ensures the correct formation of the disulfide bond 
(10). Although synthetic peptides are initially synthesized without a disulfide bond, 
this bond appears to form naturally, given that we can detect it by MALDI TOF MS. 
Synthetic bactofencin A (2784 Da) in the reduced form was resuspended in sodium 
phosphate buffer pH 6.8 at 1000 µM, and bond formation (i.e. presence of peptide at 
2782 Da) monitored over time by MALDI TOF MS analysis (data not shown). For 
subsequent investigations, synthetic peptides were HPLC purified, resuspended in 
sodium phosphate buffer until disulfide bond formation occurred (where 
appropriate), as confirmed by MALDI TOF MS, and then HPLC purified for a second 
time to obtain pure peptide with an intact disulfide bond. 
 
Comparison of natural and synthetic bactofencin A  
The yield of natural bactofencin A following purification from L. salivarius DPC6502 
culture media is generally very low (<0.3 mg/L) making it difficult to generate 
sufficient peptide for structure/function experiments and making genetic approaches 
to generating peptide variants impractical. Bactofencin A, being a small 22 amino acid 
peptide with a single disulfide, is well suited to peptide synthesis and this approach 
generated milligram quantities of peptide variants for specific activity studies. 
Comparison of activity of natural bactofencin A (2782 Da) with synthetic reduced 
bactofencin A (2784 Da) and synthetic oxidised bactofencin A (2782 Da) showed that 




The role of cysteines in bactofencin A 
To assess the contribution of the cysteines to the activity of bactofencin A, Cys7 and 
Cys22 were replaced with serine. The results (Figure 2) show that replacing Cys7 
with serine results in a 63 fold reduction in activity and replacing Cys22 caused an 
even more detrimental 250 fold reduction in activity. Notably, replacing both Cys7 and 
Cys22 with a serine residue resulted in activity comparable to the C7S change alone. 
Replacing individual cysteine residues with alanine had less of a negative effect than 
serine substitution as a C7A change reduces activity 16 fold and C22A is reduced 63 
fold. The C7A-C22A variant is, like the serine equivalent, comparable with the single 
C7A variant being 16 fold reduced. Overall, it was apparent that substituting Cys22 
with either serine or alanine resulted in peptides with lower activity than those 
generated containing Cys7-Cys22 substitutions. 
 
The role of the N terminal positively charged tail  
Bactofencin is characterized by a cationic N terminal, KRKKHR, where 5 out of 6 
amino acids are positively charged at neutral pH. To determine how this feature 
contributes to the activity of the peptide, a series of deletion variants were synthesized 
including R2-C22, K3-C22, K4-C22, H5-C22, R6-C22 and C7-C22. The specific 
activity of each peptide against S. aureus was determined and reveals that deleting the 
first two amino acids has no effect on activity. The further exclusion of Lys3 (K4-
C22), Lys4 (H5-C22) and His5 (R6-C22) resulted in sequential 4 fold reductions in 
activity resulting in MICs of 4 µM, 16 µM and 63 µM, respectively. Deleting the entire 
positively charged N terminal region resulted in a looped peptide for which no activity 





A series of alanine scanning variants, where each individual amino acid was replaced 
by alanine, were synthesized and their activity assessed. The results show that 
changing individual amino acids to alanine within the N terminal region had no effect 
on activity. This was also the case for the R8A, P15A, M18A, Y19A, R20A and W21A 
containing peptides. As noted previously, the C7A and C22A variants were 16 fold and 
63 fold less active respectively. Substitutions between V9A and G17A show reduced 
activity with V9A, Y10A, N12A and G17A being 4 fold less active and N11A, G13A, 
M14A and T16A being 16 fold less active (Figure 4), thereby highlighting that this 
region is highly important for the antimicrobial activity of the peptide. 
 
D-amino acid substitution of the loop  
The generation of peptides containing D-amino acids provides an insight into the 
importance of chirality across the whole peptide or within specific regions. As 
preliminary experiments showed that an all D-variant with every amino acid changed 
was inactive (MIC50 >20 µM; data not shown), a series of D-amino acid variants 
from C7-C22 were synthesized. The D-amino acid substitutions (Figure 5) were all 
found to be detrimental to activity – even more so than the equivalent alanine 
substitutions (with the exception of C7 and N12 which are equally detrimental at 16 
and 4 μM, respectively). In the case of C22, the Ala substitution (MIC = 63 µM) is 
much less active than the C22Cd equivalent (MIC = 4 µM). As for the alanine-
containing variants, the substitution of amino acids within the R8-Y19 region of the 
peptide has a particularly deleterious impact as bactofencin R8Rd, V9Vd, M14Md and 
Y19Yd are 63 fold less active than wild type and Y10Yd, N11Nd, P15Pd and T16Td 




Comparison of bactofencin A with bactofencin R8Q (plantaricin ST31), a potential 
natural variant 
Todorov et al. (1999) previously described plantaricin ST31, a bacteriocin with an 
amino acid sequence determined to be KRKKHRXQVYNNGMPTGMYR, produced 
by a sourdough isolate Lactobacillus plantarum ST31, with a reported mass of 2755 + /− 
0.3 Da (20). Substitution of Cys for X results in a peptide with a mass of 2468 Da. 
However, if tryptophan and cysteine, the C terminal amino acids of bactofencin A are 
included, a mass of 2757 Da is obtained and subsequent oxidation of cysteines gives the 
published mass, 2755 Da. This suggests that plantaricin ST31 is likely to be a variant of 
bactofencin A with an arginine to glutamine change at position 8. Although plantaricin 
ST31 was reported as inactive against Listeria spp., bactofencin A is active against 
Listeria at high concentrations. For this reason, it was decided to directly compare the 
activity of bactofencin R8Q (i.e. plantaricin ST31) and bactofencin A against S. aureus 
DPC5246, L. innocua DPC3572 and L. monocytogenes ATCC 23074. Although 
bactofencin A and bactofencin R8Q (plantaricin ST31) were equally active at 1 µM 
against S. aureus DPC5246, it was established that bactofencin A is indeed more active 
(63 µM) than bactofencin R8Q (plantaricin ST31; 250 µM) against L. innocua DPC3572 
and L. monocytogenes ATCC 23074. The reduced activity of R8Q was not evident after 
a substitution that retained the charge at position 8, i.e. R8K (Figure 6). 
 
4.1.5  Discussion  
There is an urgent need for new antimicrobials to combat infection and bactofencin is 
a clear candidate. Although it is produced in small amounts by the producing strain, 
the lack of post-translational modifications makes it very accessible to synthesis 
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strategies. With this in mind, we generated a bank of synthetic variants which 
included a number of amino acid substitution and deletion variants. Preliminary 
experiments showed that the disulfide bond forms naturally over time and that 
synthetic bactofencin with an intact disulfide is as active as the native peptide making 
this a valid approach (Figure 1). The synthetic peptide with reduced cysteines was also 
found to be as active as natural bactofencin suggesting that the disulfide bond is not 
essential for full activity (Figure 1). 
Substituting either cysteine with serine resulted in peptide variants with lower activity 
than alanine equivalents proving that serine is not a good substitute for cysteine in 
bactofencin A (Figure 2). Cysteines and serines differ in both chemical and physical 
properties as cysteines are often found in the interior of a molecule especially when 
involved in disulfide bond formation while comparatively hydrophilic serines are 
typically exposed (21, 22). Alanine, however, is hydrophobic so it is possible that 
hydrophobic interactions between C7A and C22A are stronger than serine equivalents 
and so can better maintain structural conformation. This was seen when Cys9 and 
Cys14 residues of the Class IIa leucocin A were replaced with hydrophobic equivalents 
(23). It appears that single C22 changes to either serine or alanine have a greater 
negative impact on activity than the corresponding C7 and C7-C22 changes. The 
possibility here is that substituting C22 alone with serine or alanine may introduce 
steric hindrance, thus preventing any semblance of loop conformation resulting in a 
less active peptide. Disulfides have a very distinct role in stabilizing protein structure 
(22) and the results of this study suggest that the presence of both cysteines play a key 
role in maintaining peptide structure and are required for full activity of bactofencin 
A. 
Sequential deletion of the positively charged N terminal from Lys3 to Arg6 resulted 
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in a series of variants with decreasing activity against S. aureus DPC5246, while 
removal of the entire N terminal region prior to the loop resulted in an inactive peptide 
(Figure 3). Interestingly, the C7-C22 variant contained an intact disulfide bond as 
determined by MALDI TOF MS. The N terminal, KRKKHR, with a charge of + 5 at 
neutral pH is unique among known Class II bacteriocin sequences and invites 
conjecture as to its function. Lysine and arginine play an important role in the 
interaction with negatively charged phospholipid membranes. Indeed, arginine is 
more effective than lysine in this regard as it forms more extensive H bonding, thereby 
stabilizing arginine-phosphate clusters enabling enhanced interfacial binding leading 
to membrane disruptions (24). In addition, a high positive charge allows bacteriocins 
and AMPs to insert further into membranes (25). It may be that KRKKHR plays a role 
in binding to anionic lipids in cell membranes and that a charge of at least +3 at the N 
terminus is required for full activity, given that variants with a lower charge were 
significantly less active (Figure 3). The highly positive charge of bactofencin A may 
also have played a role in the evolution of the unique bacteriocin immunity associated 
with the producer, L. salivarius DPC6502. In this respect, immunity is mediated 
through a homologue of DltB, a protein which results in the reduction in the charge of 
teichoic acids in the cell wall. Thus the mechanism mediating immunity could be 
through reducing the affinity of the positively charged bactofencin A to the producer 
surface (10).  
Alanine scanning mutagenesis approaches have been successfully used to study the 
lantibiotic, lacticin 3147 (26) and the Class IIa bacteriocin, durancin GL (27). In 
bactofencin A, replacing the amino acids of the N terminal with alanine did not lead 
to a reduction of activity when compared to the native peptide. This correlates with the 
results from the deletion experiment as it is expected that the loss of a single positive 
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charge would not adversely affect activity. Changing Cys7 to alanine does have an 
effect but this is expected due to possible structural changes in the peptide as 
speculated earlier. Changes to Arg8 and the C terminal side of the loop were also well 
tolerated as R8A, P15A, M18A, Y19A, R20A and W21A are as active as bactofencin 
A. However, when residues between Val9 and Gly17 are changed to alanine activity is 
significantly reduced, suggesting that this part of the loop makes an important 
contribution to activity (Figure 4). 
D-amino acid substitutions were used to investigate the importance of 
stereochemistry for target interaction as introduction of D-amino acids typically 
disrupts the helicity of AMPs (28). The retention of significant levels of activity in an 
all D variant of AMPs suggests the natural peptide functions by interacting with the 
lipid membrane, rather than a specific receptor, whereas a significant reduction in 
activity among such variants suggests that a stereospecific target, such as a membrane 
receptor, is involved in activity (29). The latter proved to be the case for bactofencin 
A. Substituting the amino acids of the loop for D equivalents was detrimental to 
activity in every case but most particularly in peptides with substitutions between Arg8 
and Tyr19. Indeed, Y10Yd, N11Nd, P15Pd and T16Td were totally inactive at 1000 
µM further suggesting a chiral interaction between bactofencin A and a specific 
receptor or that the introduction of a D residue disrupted structural conformation 
within this region. The inactivity of the P15Pd peptide is particularly notable and is 
in stark contrast to the activity observed with the P15A variant, suggesting that 
kinking the molecule in the opposite direction leads to detrimental structural changes. 
Taken together, the results from the N-Terminal deletion, alanine scanning and D 
amino acid variant studies make it tempting to suggest that bactofencin A interacts 
with the cell membrane through initial electrostatic interaction with the N terminal 
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and then disrupts the cell through binding with a putative receptor to amino acids in 
the interior of the loop. 
The existence of an apparent natural variant of bactofencin A is interesting and 
provides an opportunity to compare the activities of the two peptides, especially in 
light of the absence of activity in cell free supernatants of plantaricin ST31-producing 
L plantarum ST31 against L. innocua and L. monocytogenes (20). This natural 
substitution did indeed result in reduced activity against Listeria as evidenced by our 
studies with bactofencin R8Q (plantaricin ST31). Substituting glutamine for lysine, 
the other positively charged amino acid restored activity suggesting that a positive 
charge is necessary in this position for activity against Listeria. 
None of the bactofencin A variants investigated in this study resulted in enhanced anti-
staphylococcal activity with respect to the native bactofencin suggesting that wild type 
bactofencin A has close to maximal antimicrobial activity. However, the reduction in 
activity against Listeria spp. due to an R8Q change and its restoration with an R8K 
change suggests that there is potential to change the spectrum of activity of bacteriocins. 
Ultimately, it will now be possible to build on this blueprint to further investigate the 
fundamental biology underlying the activity of bactofencin and, in turn, enhance the 
spectrum and activity of this cationic bacteriocin. 
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Figure 1 Activity (µM) of oxidized synthetic bactofencin A (BFo), reduced bactofencin 
A (BFr) and natural bactofencin A (BFn) against S. aureus DPC5246 (A) and molecular 
mass of oxidized synthetic bactofencin A (Top), reduced bactofencin A (Middle) and 








Figure 2 (A) Cys7 and Cys22 were substituted individually and in tandem with serine 
and alanine to give bactofencin variants C7S, C22S, C7S-C22S, C7A, C22A, C7A-
C22A. Activity (µM) of bactofencin A compared to bactofencin cysteine variants C7S, 








Figure 3 (A) Activity (µM) of bactofencin A and deletion variants, R2-C22, K3-C22, 
K4-C22, H5-C22, R6-C22 and C7-C22 against S. aureus DPC5246. (B) Activity (µM) 
of bactofencin A and deletion variants against S. aureus DPC5246. Activity is colour 






Figure 4 (A) Serial dilutions of each alanine variant plated on S. aureus DPC5246 
indicator plates and (B) shows activity (µM) of bactofencin alanine variants against S. 







Figure 5 Activity (µM) of bactofencin D-variants C7Cd-C22Cd against S. aureus 
DPC5246. Activity is colour coded with green being most active and red inactive. 







Figure 6 Activity (µM) of bactofencin A (A) bactofencin R8Q (plantaricin ST 1) and 
bactofencin R8K against S. aureus DPC5246 (A) L. innocua DPC3572 (B) and L. 
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Bactofencin A displays a delayed killing effect on staphylococci 
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Bacteriocins can be considered a novel source of natural alternatives to antibiotics with 
the potential to fight against antimicrobial resistance in some instances. 
Commercialized as food preservatives, they also have the potential to treat drug 
resistant clinical pathogens and recent research shows that they play a role in immune 
modulation. To achieve their full potential an understanding of their mode of action 
and resistance mechanisms is required. We report that bactofencin A displays delayed 
inhibition against the mastitis pathogen, Staphylococcus aureus DPC5246, suggesting 
that it employs an unusual mode of action. This characteristic was clearly visible on 
plate media where formation of inhibition zones against the staphylococcal strain was 
very much delayed when compared to zones resulting from the action of nisin. This 
delayed killing and injury was also evident using flow cytometry where damage was 
evident four hours after bacteriocin addition. In particular, treatment with 2 μM 
bactofencin A resulted in approximately 20 fold higher injured and 50 fold higher dead 
cells. Combining bactofencin A with the nisin A resulted in faster killing at lower 
bacteriocin concentrations. When combined in an equal ratio, the combination 
exhibited a four-fold increase in inhibition compared to nisin A alone. These results 
demonstrate that the combination may be very effective in therapeutic applications 
against pathogenic staphylococci.  
 
5.1.2 Introduction 
Antimicrobial resistance (AMR) is a worsening global public health crisis that has 
been associated with overuse and misuse of antibiotics in both human and animal 
welfare. The emergence of multidrug-resistant pathogens threatens to undo a century 
of medical advances, placing anticancer treatments and routine surgeries at risk. At 
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present, at least 700,000 people die each year from superbugs that arise due to AMR 
and it has been predicted that this could lead to 10 million deaths by 2050 unless action 
is taken (1, 2). It is also expected that health expenditure will have to increase by $300 
billion to $1 trillion per year to deal with this problem as patients are sick for longer, 
require more healthcare interventions and more expensive drugs to combat their illness 
(3, 4). The cost of AMR to the economy is also significant and, when combined with 
healthcare costs, could rise to $100-$200 trillion per year by 2050 (4, 5). In 2017, the 
WHO published a report highlighting the lack of new antimicrobials in development 
against priority pathogens and the need for new classes of antimicrobials to combat 
the crisis (6). Recently, the WHO launched an AMR Action Fund in collaboration with 
financial investors and the pharmaceutical industry to ensure a sustainable pipeline of 
new antibiotics effective against superbugs, with a specific aim of developing two to 
four new antimicrobial treatments for patients by 2030 (7). Interestingly, alternative 
therapeutic avenues using antibodies, probiotics, vaccines and antimicrobial peptides 
are now attracting increasing attention in the fight against AMR (8).  
Bacteriocins are ribosomally-synthesised antimicrobial peptides, produced by most 
genera of bacteria, and can have a broad or narrow-spectrum of inhibition (9). The 
production of bacteriocins by Generally Regarded As Safe (GRAS) strains makes them 
of particular interest to the food industry where they (mainly nisin) have been used as 
food biopreservatives (10). The increase in AMR has meant that new antimicrobials 
are required which is why bacteriocins are being increasingly looked at as an 
alternative for certain applications. In this respect their stability, low toxicity, target 
specificity or activity against a broad range of bacteria including pathogens that have 
acquired resistance are all distinct advantages (11). They are also ribosomally 
synthesised and can be bioengineered, an approach that has been effective for nisin in 
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producing variants with improved activity against certain pathogens (12). 
Antimicrobial efficacy and AMR can also be improved through combinations with 
other bacteriocins including those with different modes of action (13). In addition, 
recent studies suggest that commensal bacteriocin producers are modulators of the 
human microbiome with potential to play a role in treating intestinal infections (14, 
15). 
Bactofencin A, produced by the porcine gut isolate Lactobacillus salivarius DPC6502, 
is a Class IId bacteriocin that is particularly potent against Staphylococcus aureus. A 
DltB homologue that may increase dealanylation of teichoic acids thereby reducing 
the negative charge on the cell wall and preventing binding of cationic bactofencin A, 
is proposed to provide immunity to the producing strain. Bactofencin A is a twenty 
two amino acid bacteriocin with a positively charged N terminal containing a series of 
positively-charged amino acids (KRKKHR) and a C terminal loop formed via a 
disulphide bond between Cys7 and Cys22 (16). Charge and structure play a significant 
role in its potency and its proposed mode of action is through an initial attraction to 
the cell membrane via the cationic N terminal, with inhibition occurring through 
interaction of the loop with a putative receptor. Bactofencin A has also been shown to 
effect subtle changes in the microbiome with potential to inhibit anaerobic inhabitants 
such as Clostridium and Bacteroides (17). 
Nisin A is a Class I lantibiotic produced by strains of Lactococcus lactis that displays 
broad-spectrum activity against most Gram-positive microorganisms (18).  It has been 
used as a food preservative by the food industry since the 1950s (9) and, more recently, 
its use has been extended to biomedical applications including inhibition of drug-
resistant pathogens such as methicillin resistant Staphylococcus aureus (MRSA), 
enterococci and Clostridioides difficile (19). Nisin A is a thirty four amino acid peptide 
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containing five lanthionine rings (20) that are responsible for its intrinsic stability and 
potent activity that is often reported at nanomolar concentrations (21-22).  Nisin exerts 
its antimicrobial effect by way of multiple modes of action including, blocking of cell 
wall biosynthesis through lipid II binding, pore formation and most recently, DNA 
condensation (23-25). It is noteworthy that significant spontaneous nisin resistance 
rarely occurs in nature despite widespread use in the food industry and this is attributed 
to its multiple modes of action (19). 
Combining bacteriocins with alternative antimicrobials, referred to as antimicrobial 
combinatorial therapy, has the dual advantage of improving potency while reducing 
the incidence of AMR. Furthermore, these synergistic combinations can result in 
cheaper treatments and reduced toxicity to the host due to lower concentrations of 
antimicrobial required for effective treatment (26). Recently, this approach has been 
used to improve potential treatments against the foodborne clinical pathogen, S. 
aureus. Specifically, the lantibiotic nisin has shown promising results when assessed 
in combination with other antimicrobial compounds including citric acid (27) essential 
oils (28) antibiotics (29-31), phage endolysins (32) and other bacteriocins (33). 
The aim of this study was to assess the effectiveness of bactofencin A and nisin A, 
both alone and in combination, at killing the mastitis isolate S. aureus DPC5246.  
 
5.1.3 Materials and Methods  
Staphylococcus aureus DPC5246 culture conditions  
S. aureus DPC5246 (34), a mastitis clinical isolate, was grown aerobically in BHI broth 
at 37°C. 
 
Bactofencin A synthesis and purification 
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Bactofencin A, KRKKHRCRVYNNGMPTGMYRWC, was synthesised using 
microwave-assisted solid phase peptide synthesis (MW-SPPS) on a Liberty Blue 
microwave peptide synthesizer (CEM Corporation. Mathews, North Carolina, USA) 
and purified by Reversed Phase HPLC according to the method described by 
O’Connor et al (2018) (35).  
 
Purification of nisin A  
Nisin A was purified from nisinA®P provided by Handary SA (Brussels, Belgium) by 
Reversed Phase HPLC. Specifically, 60 mg of nisinA®P was resuspended at 10 mg ml-
1 in Milli Q water and 2 ml aliquots run on a semi preparative, Jupiter Proteo (10 x 250 
mm, 4µ, 90Å), Reversed Phase HPLC column (Phenomenex, Cheshire, UK) running 
a 25-45% acetonitrile gradient, over 40 minutes, where buffer A is 0.1% trifluoroacetic 
acid (TFA) and buffer B is 100% acetonitrile 0.1% TFA. Eluent was monitored at 214 
nm and fractions collected at 30 second intervals. Fractions containing nisin A were 
assayed to confirm the nisin A molecular mass (3352 Da) by MALDI TOF mass 
spectrometry and those deemed pure were pooled and lyophilised.  
 
Preparation of peptides for activity assays 
Bactofencin A was resuspended in 50 mM sodium phosphate buffer pH 6.8 at 1000 
µM while nisin A was resuspended in Milli Q water at 1000 µM. Resuspended peptides 
were assessed for purity before use by analytical Reversed Phase HPLC. Fifteen µl of 
bactofencin A was added to 135 µl of Milli Q water and a 100 µl aliquot run on an 
analytical Aeris Peptide (4.6 x 250 mm, 5µ, 100Å) Reversed Phase HPLC column 
(Phenomenex, Cheshire, UK) running a 10-30% gradient over 40 minutes where buffer 
A is 0.1% TFA and buffer B is 100% acetonitrile 0.1% TFA. Eluent was monitored at 
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214 nm and fractions collected at approximately 1 minute intervals. Bactofencin A 
eluted as a single peak and the bactofencin A containing fraction was assessed for the 
bactofencin A mass (2782 Da) by MALDI TOF mass spectrometry.  
Nisin A (3352 Da) was assessed as described for bactofencin A except a 20-50% 
acetonitrile 0.1% TFA gradient was used. 
 
MALDI TOF mass spectrometry  
MALDI TOF mass spectrometry was performed on HPLC fractions of interest from 
purification protocols and resuspended pure peptides using an Axima TOF2 MALDI 
TOF mass spectrometer (Shimadzu Biotech, Manchester, UK). 0.5-µl aliquot of matrix 
solution (α - cyano 4-hydroxy cinnamic acid), 10 mg/ml in 50% acetonitrile-0.1% 
TFA) was deposited onto the target and left for 20 seconds before being removed. The 
residual solution was allowed to air-dry and 0.5 µl sample solution was deposited onto 
the pre-coated sample spot. 0.5µl of matrix solution was added to the deposited sample 
and allowed to air-dry. The sample was subsequently analysed in positive-ion linear 
or reflectron mode.  
 
Effect of bactofencin A on the growth of S. aureus DPC5246 
An overnight culture of S. aureus DPC5246 was diluted 200 fold in BHI broth to give 
a 0.5% inoculum containing ~ 1 x 106 colony forming units/ml (cfu ml-1). A 100 μM 
stock solution of bactofencin A was serially diluted twofold in 100 μl aliquots of BHI 
broth and 80 μl aliquots of each dilution added to 3920 μl of inoculum to give 4 ml 
samples containing 2, 1, 0.5, 0.25, 0.125 and 0.063 μM bactofencin A. Four ml of the 
inoculum without bactofencin A was included as a control. Samples were prepared in 
duplicate and incubated in a 37°C water bath and growth measured 
 
192  
spectrophotometrically (Jenway 6300 spectrophotometer, Staffordshire, UK) via 
optical density at 600 nm (OD600) at hourly intervals. Viable cells were enumerated by 
determining cfu ml-1 at 0, 2, 4, 6, 8, 10 and 23 hours. Specifically, 100 μl aliquots of 
sample were 10 fold serially diluted in 900 µl Maximum Recovery Diluent (MRD) 
and 10 µl aliquots of each dilution spotted onto BHI agar plates and allowed to dry. 
Plates were incubated overnight at 37°C and the cfu ml-1 calculated at each time point.  
 
Assessment of cell viability via flow cytometry  
The proportion of live, injured and dead cells in S. aureus DPC5246 cultures grown in 
the presence of bactofencin A, nisin A and bactofencin A/nisin A combinations was 
assessed by flow cytometry at 4, 9 and 23 hours. Cells were stained with a BDTM Cell 
Viability Kit which uses thiazole orange (TO) and propidium iodide (PI) to distinguish 
live and dead cell populations. Cultures for assay were diluted to ~ 106 cells ml-1 in 
staining buffer which is phosphate buffered saline containing 0.01% Tween 80 and 1 
mmol/L EDTA. Two µl of each dye (TO and PI) was added to 200 µl of diluted sample 
and analysed on a BD AccuriTM C6 flow cytometer (Becton, Dickinson and Company, 
BD Biosciences, San Jose, CA 95131, USA). Gates, to distinguish between live and 
dead cells, were assigned using the BD Accuri’s associated software in line with the 
manufacturer’s guidelines. 
 
Inhibition of S. aureus DPC5246 by bactofencin A and nisin A assayed by agar 
well diffusion 
Inhibition of S. aureus DPC5246 by bactofencin A and nisin A was demonstrated 
initially by the agar well diffusion assay described by Ryan et al. (1996) (36). An 
indicator plate containing S. aureus DPC5246 was prepared by adding 225 μl of an 
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overnight culture to 45 ml of molten BHI agar (0.5% inoculum) which was allowed to 
solidify in a 120 mm square petri dish. Fifty µl aliquots of bactofencin A were placed 
close to 50 µl of nisin A in pre-bored wells and the plate incubated at 37°C. The plate 
was photographed at 6, 8, 10 and 23 hours.  
 
Inhibition studies with bactofencin A and nisin A 
Four ml samples were prepared by adding aliquots of 10 μM bactofencin A and/or 10 
µM nisin A to the S. aureus DPC5246 inoculum containing ~ 1 x 106 cfu ml-1 to give 
the required bacteriocin concentration. Four ml of the inoculum without bactofencin 
A or nisin A was included as a control. Samples were prepared in duplicate and 
incubated in a 37°C water bath. OD600 was recorded every hour. Viable cells were 
enumerated, where required, by determining cfu ml-1 at 0, 2, 4, 6, 8, 10 and 23 hours 
as described above. 
 
5.1.4  Results 
In previous studies we had shown that bactofencin A is particularly effective against 
S. aureus including MRSA strains. In this study, we tested the effectiveness of 
bactofencin A alone and when combined with nisin A against a strain that was isolated 
from the milk of a cow with mastitis (inflammation of the udder).  
 
Purification of peptides for activity assays 
The stock solutions of bactofencin A and nisin A were assessed for purity prior to use 
in activity assays by analytical HPLC and MALDI TOF Mass Spectrometry. 
Bactofencin A eluted as a single peak at 29 minutes on the HPLC chromatogram and 
MALDI TOF mass spectrometry of the bactofencin A containing fraction detected a 
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mass of 2782 Da (Figure 1A) which is within the expected mass range (2782 +/- 1 Da) 
for bactofencin A. Nisin A also eluted as a single peak at 31 minutes and MALDI TOF 
mass spectrometry detected a mass of 3353 Da in the nisin A containing fraction which 
is also within the expected range (3352 Da +/- 1 Da) (Figure 1B). 
The delayed inhibition displayed by bactofencin A and its inability to fully lyse the 
target culture required an alternative approach to the traditional 96 well assay 
procedures for assessment of inhibition, minimal inhibitory concentration (MIC) and 
fractional inhibitory concentration (FIC) measurements. Consequently, assays were 
carried out at 4 ml scale to provide a sufficient volume for cell number enumeration at 
intervals throughout the growth time period.  
 
The inhibitory effect of increasing concentrations of bactofencin A on S. aureus 
DPC5246  
Initially, the effect of a wide range of two-fold increasing concentrations of 
bactofencin A (0.063, 0.125, 0.250, 0.5, 1 and 2 µM) on the OD600 and viable cell 
numbers of a growing culture of S. aureus DPC5246 was measured. The optical 
density readings (Figure 2A) suggest that bactofencin A had little or no effect on 
growth for the first 3-4 hours regardless of concentration. After 4 hours, the growth of 
bactofencin A treated cultures slowed down compared to the control; this became more 
apparent from five hours onwards when the OD600 decreased suggesting the cells were 
starting to lyse. Following seven hours incubation, the cultures appeared to recover in 
a concentration dependent manner with samples containing lower bactofencin A 
concentrations recovering before those containing higher concentrations. Interestingly, 
after 23 hours the OD600 for higher bactofencin A concentrations (0.5, 1 and 2 μM) 
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was found to be significantly lower than the control, suggesting that bactofencin A was 
still having an effect on the culture at these concentrations.  
The viable count results (Figure 2B) showed a similar delayed response with no 
significant difference in viability after 2 hours, while at 4 hours a 0.4 log reduction in 
cell numbers for 2 μM bactofencin A, the highest concentration tested, was detected. 
At six hours, all bactofencin A concentrations showed a ten-fold reduction compared 
to the control with the exception of 0.063 μM which had a slightly less effect at 0.7 
log, while at 8 hours the maximum effect is achieved with bactofencin A 0.5-2 µM 
showing a 1.5 log reduction compared to the control. Taken together, the OD600 and 
viable plate count results suggest a delayed action of the bacteriocin on the culture 
which is first slowed down and then killed.  
 
Flow cytometry analysis of S. aureus DPC5246 grown in the presence of 0, 0.2 
and 2 μM bactofencin A  
Flow cytometry can be used to study the real time effect of bacteriocins on cell 
membranes through the use of fluorescent dyes such as thiazole orange (TO) and 
propidium iodide (PI) (37). TO can enter and label live cells whereas PI can only label 
cells with compromised membranes thereby allowing distinction between live (green), 
injured (orange) and dead (red) cells. The separation of each cell type through gating 
optimisation results in a reliable assay that can quantify the number of each cell type. 
Here, we used flow cytometry to study the effect of bactofencin A on S. aureus 
DPC5246 cells.  
S. aureus DPC5246 was grown in BHI broth in the presence of 0, 0.2 and 2 μM 
bactofencin A and growth assessed hourly by OD600 (Figure 3A). The OD600 results 
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showed that 0.2 and 2 μM bactofencin A inhibited the culture compared to untreated 
control with reductions in OD600 following a dose response behavior.  
Comparison of cell numbers by traditional plating and flow cytometry at 4, 9 and 23 
hours compared very well (Figure 3B) demonstrating that flow cytometry is a fast, 
reliable method to enumerate viable cells for this strain. The OD600 and cell 
enumeration results again suggest that bactofencin A has minimal effect on growth in 
the first 4 hours of exposure with maximum killing occurring at eight hours, followed 
by a limited recovery of the culture at 23 hours for both concentrations tested.  
In addition to enumerating live cells (green), the flow cytometry results, which were 
corrected to exclude background debris (black), show the number of dead (red) and 
injured (orange) cells (Figure 3C) at 4, 9 and 23 hours. At four hours, the untreated 
control contains 2 x 108 live cells and about 100-fold fewer injured cells (1.2 x 106) 
and dead cells (3 x 106) which is indicative of a “healthy” log phase culture (Figure 
3C 1a). In comparison, the 0.2 μM (Figure 3C 1b) and 2 μM bactofencin A (Figure 3C 
1c) treated cultures contained live cells numbers slightly lower than the untreated 
control (1.3 x 108 and 1.0 x 108) but approximately 20-fold higher levels of injured 
(2.3 x 107 and 2.6 x 107) and 50-fold higher numbers of dead cells (1.3 x 107 and 1.7 
x 107). At nine hours the effect of bactofencin A on live cells is apparent as the 
untreated control sample contained 8.8 x 108 (Figure 3C 2a) compared to a 1.3-1.6 log 
reduction (5.6 x 107 and 2.6 x 107) detected for 0.2 μM (Figure 3C 2b) and 2 μM 
(Figure 3C 2c) bactofencin A respectively. However, the number of injured (3.4 x 106, 
and 3.3 x 106) and dead cells (3.4 x 106 and 4.3 x 106) were now just three-fold higher 
than the control sample (1.0 x 106). At 23 hours, we again observed that bactofencin 
A had a slight inhibitory effect on the culture as the untreated control contained 1.1 x 
109 live cells (Figure 3C 3a) while 0.2 μM bactofencin A (Figure 3C 3b) contained 6.4 
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x 108 and 0.2 μM bactofencin A (Figure 3C 3c) contained 3.4 x 108 live cells. Notably, 
at this stage the numbers of injured and dead cells are comparable to the untreated 
control.  
In summary, flow cytometry suggests that bactofencin A is causing considerable 
damage to the cell within four hours of exposure suggesting that the antimicrobial 
effect is delayed.   
 
Antimicrobial interaction between bactofencin A and nisin A on an S. aureus 
DPC5246 indicator plate 
Inhibition of S. aureus DPC5246 by bactofencin A and nisin A was assessed by well 
diffusion assay. The indicator plate (Figure 4) showed that the zone of inhibition for 
bactofencin A appeared gradually between eight and 23 hours, reflecting the growth 
curve results (Figure 2A) again suggesting a delayed action by the bacteriocin. In 
contrast, the zone of inhibition for nisin A was already apparent after six hours, 
confirming the lytic nature and rapid killing effect of nisin. Interestingly, a small 
enhancement of activity was observed at the point where the two zones of clearing 
intersect, suggesting the possibility of synergism between bactofencin A and nisin A.  
 
Inhibitory effect of bactofencin A and nisin A alone on growth of S. aureus 
DPC5246 
The observation that bactofencin activity is enhanced by nisin prompted us to 
investigate whether this phenomenon could be observed in liquid media. The effect of 
a narrow range of concentrations of bactofencin A at 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 
µM and nisin A at 10 fold lower concentrations 0.005, 0.01, 0.02, 0.03, 0.04 and 0.05 
µM on S. aureus DPC5246 was assessed with a view to selecting optimum bacteriocin 
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concentrations for combinatorial studies. The OD600 results (Figure 5A) for the 
bactofencin A concentration range again showed a delayed inhibition curve for all 
bactofencin concentrations tested in line with the trends seen for the wider bactofencin 
A concentration range in Figures 2A and 3A. The plate count results (Figure 5B) 
showed no significant reduction in viable cell counts compared to the control at four 
hours and optimum killing at eight hours, so again a delayed killing effect was 
observed. 
Nisin A was assayed at a ten-fold lower concentration range (0.05-0.005 µM) than 
bactofencin A given its greater potency at earlier stages of growth. One thing to note 
is that the higher nisin A concentrations inhibit the cultures immediately (Figure 5C) 
and also that the delay in recovery is concentration dependent. At 23 hours, all nisin A 
treated cultures grew to the same extent as the untreated control, regardless of nisin A 
concentration, suggesting that nisin A is no longer effective against the culture at these 
concentrations. The plate count results (Figure 5D) show a similar trend in terms of 
viability where the higher concentrations reduced the viability of the culture for the 
first four hours which then recovered in a dose response fashion.  
Given that nisin appeared to enhance the inhibitory effect of bactofencin, we then 
evaluated the effect of different bactofencin A/nisin A concentrations where nisin A 
was present in ten-fold lower concentrations. 
 
Inhibitory effect of bactofencin A/nisin A combinations  
Initially, bactofencin A concentrations (0.05-0.5 µM) were combined with ten-fold 
less nisin A concentrations (0.05-0.005 µM) to assess their effect on S. aureus 
DPC5246 growth (Figure 6). The highest bacteriocin concentrations alone 
(bactofencin A 0.4 µM and nisin A 0.04 µM) were included as controls.  
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The optical density results (Figure 6A) showed that the untreated control is fully grown 
at six hours, 0.4 µM bactofencin A showed delayed inhibition while 0.04 µM nisin 
inhibited the culture for seven hours after which it recovered to levels comparable to 
the untreated control. Interestingly, all bactofencin A/nisin A combinations suppressed 
growth for eight hours. The two lowest combinations, bactofencin A 0.05 µM/nisin A 
0.005 µM and bactofencin A 0.1 µM/nisin A 0.01 µM, inhibited S. aureus DPC5246 
for nine hours (Figure 6). This is noteworthy considering that nisin A alone at these 
concentrations has no significant effect on growth (see Figure 5C) while equivalent 
bactofencin A concentrations are recovering (Figure 5A), suggesting possible additive 
or synergistic action between the two bacteriocins. At 23 hours, the inhibitory effects 
of the bacteriocin combinations are dose dependent with the OD600 for the highest 
combination tested comparable to the OD600 at T0, suggesting complete suppression 
of culture growth.  
The plate count results (Figure 6B) confirmed that the delayed killing effect of 
bactofencin A no longer occurs at all bactofencin A/nisin A combinations including 
the lowest concentrations tested. The lower combinations are equivalent to nisin A 
0.04 µM alone while the higher combinations are significantly better with the highest 
combination resulting in complete killing of the culture. Overall, we see that both 
killing and regrowth occur in a dose response manner. 
Flow cytometry was used to assess the effect of the lower bactofencin A/nisin A 
combinations on live, dead and injured cell numbers at 4 hours. The untreated control 
at 4 hours (Figure 6C a) was similar to that shown in Figure 3C with 2 x 108 live cells, 
and 3.0 x 107 injured cells, again commensurate with a control untreated culture. The 
numbers of live, dead and injured cells are comparable for bactofencin A alone at 0.1 
(Figure 6C b) and 0.2 (Figure 6C e) µM and it is interesting to note the high proportion 
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of injured cells even at the lower bactofencin A concentration. The number of live and 
injured cells in the presence of nisin A 0.01 µM alone was similar to the control though 
more injured cells were detected (5.8 x 107 vs 3.0 x 107) while nisin 0.02 µM resulted 
in an almost 2 log reduction in live cells compared to the control in agreement with 
Figure 5D. Notably, both combinations resulted in a 3-4 log reduction in cell numbers 
demonstrating the effectiveness of the combinations compared to either bacteriocin 
alone.  
 
The effect of decreasing nisin A concentrations in combination with 0.4 µM 
bactofencin A and decreasing bactofencin A concentrations in combination with 
0.04 µM nisin A on S. aureus DPC5246  
The effect of decreasing nisin A concentrations in relation to bactofencin A (Figure 
7A) and decreasing bactofencin A in relation to nisin A (Figure 7B) was assessed to 
determine the contribution each bacteriocin makes to activity. In both experiments 
(Figure 7A and 7B) the control samples (untreated control, bactofencin A alone and 
nisin A alone) are similar to those shown in Figure 6A. Treatment of S. aureus 
DPC5462 with 0.04 µM bactofencin A and decreasing nisin A concentrations resulted 
in inhibition of culture for seven hours at all combinations tested (Figure 7A). 
Recovery was in a dose response manner as evidenced by bactofencin A 0.4 µM/nisin 
A 0.005 µM and bactofencin A 0.4 µM/nisin A 0.01 µM starting to recover at eight 
and nine hours respectively while the three higher nisin A concentrations were still 
inhibitory at eleven hours. At 23 hours there was a reduction in OD600 at all bactofencin 
A/nisin A combinations assayed compared to the untreated control while bactofencin 
A 0.4 µM/nisin A 0.04 µM was totally inhibited. Overall, the results suggest that while 
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the cultures are significantly inhibited at all combinations tested, decreasing the nisin 
A concentration results in less inhibition. 
In contrast to the constant bactofencin A and decreasing nisin A concentrations, the 
OD600 does not recover in samples with constant nisin A 0.04 µM and decreasing 
bactofencin A concentrations (Figure 7B) as inhibition is maintained for 23 hours, 
suggesting that bactofencin A levels can be reduced once sufficient nisin A is present.  
As it appeared that the bactofencin A concentration could be reduced in relation to 
nisin A and bactofencin A 0.05µM/nisin A 0.04 µM was inhibitory for up to 23 hours, 
it was decided to assess the effectiveness of the bacteriocins in a 1:1 ratio against S. 
aureus DPC5246. 
 
Assessment of a 1:1 ratio of bactofencin A and nisin A on S. aureus DPC5246   
The effect of bactofencin A (0.0025, 0.005, 0.01 and 0.02 µM) and nisin A (0.0025, 
0.005, 0.01 and 0.02 µM) both alone and in a 1:1 ratio on the OD600 of a growing 
culture of S. aureus DPC5246 was determined. Interestingly, at eight hours the culture 
was inhibited by bactofencin A 0.02 µM/nisin A 0.02µM which is particularly 
impressive as the equivalent controls were almost fully grown at this time point (Figure 
8). 
 
Assessment of the FIC of bactofencin A/nisin A combinations against S. aureus 
DPC5246 
As bactofencin A 0.02µM/nisin A 0.02 µM inhibited the culture for eight hours, it was 
decided to see if 1x, 0.5x and 0.25x combinations had an effect on efficacy at this time 
point. None of the single bacteriocin controls were inhibitory at eight hours (Figure 
9A) and bactofencin A 0.02 µM/nisin A 0.02 µM was inhibitory at eight hours as 
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expected, though reducing the nisin A concentration to 0.01 and 0.005 µM resulted in 
less inhibition (Figure 9D). Reducing the bactofencin A concentration to 0.005 µM 
reduced the effectiveness of the combinations (Figure 9B), while bactofencin A 0.01 
µM nisin A 0.02 µM was inhibitory at eight hours (Figure 9C) suggesting that there 
may be potential to reduce the bactofencin A concentration even further. In a 
subsequent experiment (not shown) we observed that nisin A 0.08 µM was as 
inhibitory as bactofencin A 0.02 µM/nisin A 0.02 µM at eight hours suggesting that 
the combination is four times more effective than nisin A alone. Bactofencin A 0.08 
µM alone resulted in a ~0.6 OD600 reduction compared to the control.  
Finally, the effect of a wide range of two-fold increasing concentrations of bactofencin 
A (0.015, 0.031, 0.063, 0.125, 0.250, 0.5, 1 and 2 µM) and nisin A (0.015, 0.031, 
0.063, 0.125, 0.250, 0.5, 1 and 2 µM) both alone and in a 1:1 ratio on the OD600 of a 
growing culture of S. aureus DPC5246 was measured every hour for 23 hours. The 
results (data not shown) showed that the MIC of nisin A was 0.125 µM compared to 
0.031 µM bactofencin A/nisin A at eight hours, a 4 fold improvement in efficacy 
compared to nisin A alone, while at 23 hours it required 2 µM nisin A to inhibit the 
culture compared to 0.25 µM bactofencin A/nisin A, an 8 fold improvement indicative 
of a synergistic effect.  
 
5.1.5  Discussion 
Bactofencin A is a novel bacteriocin with potential to fight infection as, in addition to 
its potency against S. aureus, its small size and lack of post-translational modifications 
make it amenable to peptide synthesis. Synthetic bactofencin A is as active as the 
naturally-produced peptide and the disulphide bonds form naturally over time making 
it a suitable source of peptide for characterization studies (35). Interestingly, the studies 
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presented in this chapter demonstrate that the bacteriocin has a delayed action when 
compared to nisin and probably has a very different mechanism. Initially, stock 
solutions of bactofencin A and nisin A were assessed for peptide purity by Reversed 
Phase HPLC and MALDI TOF mass spectrometry and the presence of a single HPLC 
peak containing the correct peptide mass was taken as evidence of sufficient purity for 
inhibition studies (Figure 1). 
Class II bacteriocins typically act through an initial electrostatic interaction with 
negatively charged components of the cell membrane, and in some cases (class IIa in 
particular), bind to a cell receptor, resulting in a loss of ion gradients, membrane 
integrity and cell death (38-39). It has been tentatively proposed that bactofencin A 
interacts with the cell wall via the positively charged N terminal and also binds to an 
unknown receptor by interaction with amino acids found in the C terminal half of the 
peptide given that some of these are essential for activity. 
Teichoic acids, including lipoteichoic acids attached to the cell membrane (LTA) and 
wall teichoic acids (WTA) attached to peptidoglycan, are major components of Gram-
positive cell walls that play a role in adhesion, growth, virulence and biofilm formation 
(40-42). The addition of D-alanine esters to teichoic acids via the D-alanyl lipoteichoic 
acid (DLT) pathway reduces the overall negative charge on the cell wall making the 
cell more resistant to cationic peptides (41). In S. aureus, the DLT pathway proteins 
are encoded on the dlt operon, dltABCD, with DltA catalyzing the alanylation of D-
alanine in the cytoplasm and transferring it to DltC, a D-alanyl carrier protein (41, 42). 
Activated DltC forms a tight complex with DltB, a channel/funnel forming 
acyltransferase that moves the activated D-alanine across the membrane where DltD, 
which is located outside the cell membrane, transfers it to the teichoic acids (43). 
Interestingly, the DLT pathway, and DltB in particular, have been proposed as targets 
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for drug resistant S. aureus infections (44). Indeed, numerous Gram-positive bacteria 
with mutated dlt genes have a higher negative charge on the cell wall making them 
more susceptible to cationic AMPs (45). Furthermore, wild type S. aureus strains with 
extra copies of the dlt operon result in teichoic acid with increased D alanylation 
making the cell more positively charged and consequently more resistant to cationic 
antimicrobial peptides (46). The delayed action of bactofencin A on S. aureus 
DPC5246 (Figure 2), in addition to the cell damage observed at 4 hours by flow 
cytometry (Figure 3) and the absence of significant cell lysis, suggest that bactofencin 
A executes its antimicrobial action via a mechanism that takes considerable time. Cell 
disruption by bactofencin A may simply be due to the strong interaction between the 
bacteriocin and the cell surface due to its strong positive charge (+7 at neutral pH) and 
an as yet unknown receptor; further research is required to identify this possible 
receptor.  
The ability of ten-fold less nisin A to bactofencin A (Figure 5) to completely inhibit 
the culture may be attributable to the different modes of action as pore forming 
bacteriocins often act at nanomolar concentrations while cell wall disrupters require 
higher peptide concentrations to exert an effect (47). Combining bactofencin A with 
ten-fold less nisin A resulted in increased killing compared to either bacteriocin alone 
(Figure 6), again suggesting that the two different modes of action are complementary 
to each other.  
Lowering the bactofencin A concentration in relation to nisin A resulted in greater 
inhibition compared to lowering the nisin A concentration in relation to bactofencin A 
(Figure 7); further investigation revealed that combining the bacteriocins in a 1:1 ratio 
(Figures 8 and 9) could effectively inhibit S. aureus DPC5246. 
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In summary, bactofencin A is very effective against S. aureus when combined with 
nisin A - a phenomenon that is most likely due to acting synergistically through two 
different modes of action.  
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Figure 1 Assessment of peptide purity of bactofencin A (A) and nisin A (B) stock 
solutions by Reversed Phase HPLC and MALDI TOF mass spectrometry (inset). 
(Ai) Bactofencin A  
 
 
(Aii) Bactofencin A HPLC and MALDI TOF MS  
 
(Bi) Nisin A  
 




Figure 2 Inhibitory effect of 0.063, 0.125, 0.25, 0.50, 1 and 2 μM bactofencin A on S. 
aureus DPC5246 in BHI broth at 37°C as measured by OD600 (A) and viable cell 
counts (cfu ml-1) (B).  
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Figure 3 The effect of 0 (Control), 0.2 and 2 μM bactofencin A on cell viability of S. 
aureus DPC5246 at 4, 9 and 23 hours as measured by OD600 (A), cell numbers by flow 
cytometry (FC Live) and conventional plating (plating) (B) and flow cytometry (C). 
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Figure 4 Antimicrobial interaction between 10 μM bactofencin A (B) and 10 μM nisin 






Figure 5 Inhibitory effect of 0.05-1 μM bactofencin A on OD600 (A) and cfu ml
-1 (B) 
and 0.005-0.05 μM nisin A on OD600 (C) and cfu ml
-1 (D) of S. aureus DPC5246 in 
BHI broth at 37°C.  
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Figure 6 The effect of bactofencin A/nisin A combinations on S. aureus DPC5246 as 
measured by OD600 (A) and cfu ml
-1 (B) and flow cytometry of bactofencin A 0.1 or 
0.2 µM alone, nisin A 0.01 or 0.02 µM alone and bactofencin A/nisin A 0.1/0.01 or 
0.2/0.02 µM combinations at 4 hours (C). The flow cytometry results at 4 hours shown 
in Figure 6C were generated from a subsequent growth experiment (OD600 data not 
shown). 
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Figure 7 Inhibitory effect of decreasing concentrations of nisin A (0.05-0.005 μM) in 
the presence of 0.4 μM bactofencin A on OD600 (A) and decreasing concentrations of 
bactofencin A (0.5-0.05 μM) in the presence of 0.04 μM nisin A on OD600 (B) on 
growth of S. aureus DPC5246 in BHI broth at 37°C.  
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Figure 8 Inhibitory effect of bactofencin A (0.02-0.0025µM) and nisin A (0.02-
0.0025µM) combined at 1:1 ratio on growth of S. aureus DPC5246 in BHI broth at 
37°C.  
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Figure 9 Growth (OD600) of S. aureus DPC5246 in bactofencin A 1x, 0.5x and 0.25x 
in relation to nisin A 0.02µM and nisin A 1x, 0.5x and 0.25x in relation to bactofencin 
A 0.02µM in BHI broth at 37°C.  
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Bacteriocins represent a rather underutilized class of antimicrobials despite often 
displaying activity against many drug-resistant pathogens. Lantibiotics are a post-
translationally modified class of bacteriocins, characterized by the presence of lanthionine 
and methyllanthionine bridges. In this study, a novel two-peptide lantibiotic was isolated 
and characterized. Formicin was isolated from Bacillus paralicheniformis APC 1576, 
an antimicrobial-producing strain originally isolated from the intestine of a mackerel. 
Genome sequencing allowed for the detection of the formicin operon and, from this, the 
formicin structural genes were identified, along with those involved in lantibiotic 
modification, transport and immunity. The identified bacteriocin was subsequently 
purified from the bacterial supernatant. Despite the degree of conservation seen amongst 
the entire class of two-peptide lantibiotics, the formicin peptides are unique in many 
respects. The formicin α peptide is far less hydrophobic than any of the equivalent 
lantibiotics, and with a charge of plus two, it is one of the most positively charged α 
peptides. The β peptide is unique in that it is the only such peptide with a negative 
charge due to the presence of an aspartic acid residue in the C-terminus, possibly 
indicating a slight variation to the mode of action of the bacteriocin. Formicin also 
displays a broad-spectrum of inhibition against Gram-positive strains, inhibiting many 
clinically relevant pathogens such as Staphylococcus aureus, Clostridium difficile and 
Listeria monocytogenes. The range of inhibition displayed against many important 
pathogens indicates a potential therapeutic use against such strains where antibiotic 
resistance is such a growing concern.  
 
6.1.2  Introduction 
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With the increased prevalence of many drug-resistant bacterial strains, the 
development of new antimicrobials is becoming a growing necessity. One such 
class of antimicrobials that appear to be underrepresented in clinical applications 
are bacteriocins (Cotter et al., 2013). Unlike traditional antibiotics, bacteriocins 
are gene-encoded, ribosomally synthesized peptides, making them suitable for 
genetic manipulation, with the potential for novel and specialized drug design 
(Gillor et al., 2005). The spectrum of inhibition of bacteriocins can range from 
broad to narrow, the latter may allow for highly targeted antibacterial therapies 
that may reduce the collateral damage associated with the use of broad-
spectrum antibiotics (Rea et al., 2011). 
The lantibiotics (lanthionine-containing antibiotics) comprise a well-studied class 
of bacteriocins, the most notable of which is nisin (Rogers, 1928), which is 
commonly used as a food preservative. Lantibiotics are classified based on the 
presence of lanthionine or methyllanthionine bridges. In these peptides, serine and 
threonine residues are post-translationally modified and dehydrated to form 2,3-
didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb) residues. The thiol 
group of a cysteine residue subsequently reacts with the Dha or Dhb residues 
resulting in the formation of lanthionine or methyllanthionine thioether crosslinks 
(Xie & van der Donk, 2004). 
The lantibiotic gene cluster encodes an array of genes required for modification, 
regulation and transport of the bacteriocin. Lantibiotics are divided into classes 
depending on the mechanism by which they are synthesized. Class I lantibiotics 
encode the enzymes LanB and LanC within the bacteriocin operon where LanB 
catalyses the dehydration of the serine and threonine residues, whilst LanC 
catalyses the cyclization of the lanthionine rings. In Class II lantibiotics, LanM 
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alone catalyses both dehydration and cyclization of the lantibiotics (Willey & van 
der Donk, 2007). LanR and LanK play key roles in the regulation of lantibiotic 
production (Lee et al., 2011). Once the mature lantibiotic is produced, its cleavage 
and transport are carried out by LanP and LanT respectively (Escano et al., 2015). 
In some cases, LanT can carry out both leader sequence cleavage and peptide 
secretion functions (Furgerson Ihnken et al., 2008). Immunity to lantibiotics can 
be afforded by immunity proteins such as the lipoprotein LanI that likely binds the 
secreted lantibiotic and the ABC transporter LanFEG that transports bacteriocin 
peptides from the membrane to the extracellular medium. Here LanF binds and 
hydrolyses ATP that provides the energy required for the transport of the 
bacteriocin through the LanEG membrane complex (Stein et al., 2005; Takala et 
al., 2004; Alkhatib et al., 2012). For a review on this class of bacteriocins, see 
Willey & van der Donk (2007). 
Within the lantibiotic class of bacteriocins exist a small subgroup of two-peptide 
lantibiotics. Such bacteriocins are produced by an array of genera, including 
Staphylococcus and Lactobacillus (Navaratna et al., 1998; Holo et al., 2001). 
Interestingly, of the few two-component lantibiotics that have been described, two 
of these bacteriocins identified prior to this study are produced by Bacillus species. 
Bacillus species are known to produce a vast range of antimicrobials, whether 
antibiotics (e.g. gramicidin, bacitracin) or bacteriocins (e.g. thuricin CD, 
mersacidin) (Katz & Demain, 1977; Rea et al., 2010; Chatterjee et al., 1992). The 
currently identified two-component lantibiotics include lacticin 3147 (Lactococcus 
lactis) (Ryan et al., 1996), lichenicidin (Bacillus licheniformis) (Begley et al., 2009; 
Dischinger et al., 2009), haloduracin (Bacillus halodurans) (McClerren et al., 
2006), enterocin W (Enterococcus faecalis) (Sawa et al., 2012), plantaricin W 
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(Lactobacillus plantarum) (Holo et al., 2001), BHT (Streptococcus rattus) (Hyink 
et al., 2005), Smb (Streptococcus mutans) (Yonezawa & Kuramitsu, 2005) and 
staphylococcin C55 (Staph. aureus) (Navaratna et al., 1998). In this subclass of 
bacteriocins, the two peptides produced tend to act synergistically and usually 
display negligible antimicrobial activity on their own. 
The mode of action of lacticin 3147 identifies a likely model for the mode of action 
of similarly structured lantibiotics. The α peptide of lacticin 3147 (Ltnα) resembles 
the globular lantibiotic mersacidin, mirroring its activity by binding to lipid II that 
acts as an important docking molecule. Binding to lipid II results in a 
conformational change of Ltnα, which presents a site to which the β peptide (Ltnβ) 
can then bind. Ltnβ resembles an elongated lantibiotic, which, once recruited by 
Ltnα, inserts itself into the target membrane inducing pore formation resulting in 
cell death. Here the cooperative activity of both peptides is necessary for optimal 
antimicrobial activity, as the stability of the total bacteriocin–lipid II complex is 
important for both pore formation and the inhibition of cell wall biosynthesis 
(Martin et al., 2004; Wiedemann et al., 2006). 
In this study, we extend the class of two-peptide lantibiotics by identifying a novel 
bacteriocin known as formicin that is produced by a marine isolate, Bacillus 
paralicheniformis APC 1576. Whilst this lantibiotic resembles the previously 
described two-peptide lantibiotics, it contains a number of features that 
differentiate it from the rest of the class. 
 
6.1.3 Methods 
Isolation of bacteria from fish samples  
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Marine fish were caught off the coast of Ireland and stored on ice prior to analysis. 
The intestinal contents of the fish and a sample of the skin and gills were 
aseptically removed. Samples were suspended in maximum recovery diluent 
(Oxoid), serial dilutions were then plated on brain–heart infusion (BHI) agar 
(Merck) and marine media 2216 (Difco Laboratories) and were incubated 
aerobically at 30°C for 3 days. Colonies were isolated from these plates and 
analysed for antimicrobial activity using deferred antagonism assays, whereby 
spots of the bacterial cultures were overlaid with 10 ml de Man, Rogosa and Sharpe 
agar (Difco Laboratories) seeded with 25 µl of a Lactobacillus delbrueckii subsp. 
bulgaricus LMG 6901 overnight culture. Colonies that displayed significant zones of 
inhibition were further characterized. 
In this study, the strain of interest, B. paralicheniformis APC 1576, was isolated from 
the intestinal tract of a mackerel (Scomber scombrus) and grown on BHI aerobically 
at 37°C. The strain was identified by 16S rRNA sequencing using the UniF (5’-
AGAGTTTGATCCTGGCTCAGG-3’) and UniR (5’-ACGGCAACCTTGTTAC 
GAGT-3’) primers to amplify the sequence. PCR products were cleaned using an 
illustra GFX PCR DNA and Gel Band Purification kit (GE Healthcare) and subsequent 
sequencing was completed by Cogenics (Essex). 
 
Colony MS 
Colony MALDI-TOF MS (Axima TOF2 MALDI-TOF mass spectrometer, 
Shimadzu Biotech) was used to determine the molecular mass of the peptides 
produced as follows: cells were first mixed with 70% 2-propanol/0.1% TFA (IPA) 
and vortexed, the sample was separated by centrifugation and the supernatant was 
subsequently used for analysis. A MALDI target plate was precoated with CHCA 
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matrix solution, 0.5 µl of the supernatant from the cell extract was then placed on 
the target and a final layer of matrix solution was added. Positive-ion reflectron 
mode was used to identify the peptide masses. The masses detected were then 
compared to those of known bacteriocins. 
 
Draft genome sequencing  
Genomic DNA was extracted using the GenElute bacterial genomic kit (Sigma-
Aldrich) and the Nextera XT DNA kit (Illumina) was used for library preparation. 
The DNA was quantified using a Qubit 2.0 fluorometer. Sequencing was 
performed using Illumina’s MiSeq platform using paired-end 2×300 base pair reads 
in the Teagasc Sequencing Centre, Teagasc Food Research Centre, Moorepark. 
Reads were assembled de novo, using SPADES (version 3.1.1), resulting in 70 
contigs. ORFs were identified and annotated using Prokka (version 1.1). Further 
manual annotation was implemented with ARTEMIS and Artemis Comparison 
Tool. Genomic data are available from GenBank/EMBL under accession no. 
LXPD00000000. 
 
Bacteriocin identification  
The bacteriocin mining tool BAGEL3 was used to identify the bacteriocin 
operons encoded in the genome (van Heel et al., 2013). BAGEL3 scans small 
ORFs to identify potential bacteriocin-encoding genes. The surrounding genes 
were then analysed for other bacteriocin-related components such as transporters 
and immunity proteins, thus allowing the entire bacteriocin operon to be identified 
(de Jong et al., 2006). The program antiSMASH was also used to identify antibiotic 
and secondary metabolite encoding genes within the genome, as these compounds 
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are often associated with the Bacillus genus (Medema et al., 2011). Sequence 
alignments of the bacteriocin were performed using the Clustal Omega software. 
 
Bacteriocin purification  
Cultures of B. paralicheniformis APC 1576 were grown statically overnight in 400 
ml volumes of BHI broth aerobically at 37°C. The cell-free supernatant (CFS) was 
passed through a column containing 30 g of Amberlite XAD-16N beads (Sigma-
Aldrich). The column was washed with 250 ml of 35% ethanol and antimicrobial 
activity eluted with 250 ml of IPA. The IPA was removed via rotary evaporation 
and the sample was then applied to a 10 g, 60 ml Strata C18-E solid-phase 
extraction (SPE) column (Phenomenex). The SPE column was washed with 90 ml 
of 35% ethanol and 90 ml of IPA. The IPA was once again removed via rotary 
evaporation from the eluent and the sample applied to a semiprep Jupiter Proteo 
HPLC column (10 x 250 mm, 90 Å, 4 µm) running a 27.5–65 % acetonitrile/0.1 % 
TFA gradient where buffer A was 0.1 % TFA and buffer B was 90% 
acetonitrile/0.1% TFA. Fractions were collected at 1 min intervals and were 
subsequently analysed with MALDI-TOF MS and agar well diffusion assays as 
described below using Lb. delbrueckii subsp. bulgaricus LMG 6901 as the target 
organism to identify active fractions containing peptides of interest. 
 
Antimicrobial assays  
The antimicrobial activity of the isolated peptides was analysed using well diffusion 
assays against a range of indicator organisms (Table 1). Briefly, this involved 
seeding 20 ml of the appropriate agar with 50 µl of an overnight indicator culture; 
the agar was allowed to cool and 7 mm wide wells were then bored in the agar. 
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The purified bacteriocin peptides were lyophilized and diluted separately in 
potassium phosphate buffer (pH 6.8) to a concentration of 50 µM. The combination 
of these peptides in a 1:1 ratio thus gave a total bacteriocin concentration of 25 µM 
for each peptide. Fifty microlitres of this solution was then placed in wells in the 
indicator plate, and these were subsequently incubated overnight under the 
appropriate growth conditions as outlined in Table 1. 
 
Peptide stability 
The stability of the bacteriocin was determined using purified peptides. To 
determine the active temperature range of the lantibiotic, we treated 25 µM aliquots 
of the bacteriocin at 60, 70, 80, 90 and 100°C for 30 min; a sample was also treated 
at 121°C for 15 min. These samples were then tested for inhibitory activity against 
Lb. delbrueckii subsp. bulgaricus LMG 6901 in well diffusion assays as previously 
described. To determine the susceptibility of the bacteriocin to proteases, we 
treated 5 µM aliquots of the α and β peptides separately with proteinase K and α-
chymotrypsin each at a concentration of 10 mg ml-1 (Sigma-Aldrich). Samples 
were incubated at 37°C for 3 h followed by treatment at 100°C for 10 min to 
inactivate these proteases. Both bacteriocin peptides were then combined post-
treatment to give a final total concentration of 2.5 µM; these were then screened 
against Lb. delbrueckii subsp. bulgaricus LMG 6901 in well diffusion assays to 
determine the antimicrobial activity. 
 
6.1.4    Results 
Isolation of B. paralicheniformis APC 1576 
B. paralicheniformis APC 1576 was isolated from the intestinal microbiota of a 
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freshly caught mackerel. In an initial screen for bacteriocin producers, the strain 
was found to inhibit Lb. delbrueckii subsp. bulgaricus LMG 6901 in an overlay 
assay (Figure 1a). In addition, CFSs also inhibited Lb. delbrueckii subsp. 
bulgaricus LMG 6901 in a well diffusion assay, indicating that the antimicrobial 
substance was secreted by the cells into the media (Figure 1b). Colony MS was 
used to determine the molecular masses of the peptides produced by the cell; 
however, the detected peptide masses (Figure 1c) failed to match any previously 
characterized bacteriocin, including lichenicidin, a bacteriocin produced by B. 
licheniformis (Begley et al., 2009). Moreover, more than one source of 
antimicrobial activity was found following purification of the antimicrobial 
peptides. MALDI-TOF MS identified a molecule with a mass of 1422.54 Da, which 
displayed activity against Lb. delbrueckii subsp. bulgaricus LMG 6901 once purified; 
this mass correlates closely with that of bacitracin, which is encoded on the 
genome. The production of more than one antimicrobial from Bacillus species is 
not unexpected. Therefore, in order to identify all potential antimicrobials with 
activity against Lb. delbrueckii subsp. bulgaricus LMG 6901, we sequenced the 
genome of B. paralicheniformis APC 1576. 
 
Identification of a novel two-peptide lantibiotic operon 
Once the draft genome was obtained, the sequence was analysed with BAGEL3 
and antiSMASH to identify the antimicrobials encoded. Gene clusters encoding 
the antibiotics bacitracin, surfactin and fengycin were found within the genome. 
The strain likely produces at least one of these antimicrobials, as antifungal 




A novel lantibiotic operon was also identified within the genome of the strain 
(Figure 2). This operon spans approximately 17 kb and was located on a single 
contig of the draft bacterial genome. Two putative lantibiotic-encoding structural 
genes were identified on this operon. ORF1 (frcA1) encodes a 66-amino-acid 
peptide and ORF3 (frcA2) encodes a 71-amino-acid peptide. Analysis of the 
prepropeptides (including the bacteriocin leader sequence) of these lantibiotics 
shows that the formicin A1 prepropeptide displayed 47.8% amino acid identity 
with that of the unmodified haloduracin A1 equivalent and 35.9% identity with 
that of the lantibiotic mersacidin. As the putative bacteriocin appears to be a two-
peptide bacteriocin, two lantibiotic modification enzymes should be present. The 
order of the genes in the operon would suggest that ORF2 (frcM1) is the 
modification enzyme associated with frcA1. Upon analysis, this ORF displayed 
38.7% identity with that of the haloduracin HalM1 modification enzyme. The 
second lantibiotic gene, ORF3 (frcA2), appears to resemble the elongated β 
peptides of the other two-peptide lantibiotics that are involved in membrane 
insertion (Wiedemann et al., 2006). Upon analysis, formicin A2 revealed 42.4% 
identity with the unmodified lichenicidin LchA2 prepropeptide. ORF4 (frcM2) 
encodes the modification enzyme, which follows this structural peptide, and 
displayed 33.6% identity with that of the lichenicidin LchM2 modification 
enzyme. 
ORF5 located downstream of LchM2 is predicted to encode a lantibiotic 
transporter, displaying 52.5% identity with that of the haloduracin transporter, 
HalT. In addition to its function in bacteriocin transport, a sequence encoding a 
C39 peptidase domain (cd02425) can also be found within the gene; this is likely 
involved in the cleavage of the leader sequence from the prebacteriocin. BLAST 
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analysis of ORF6 identified the gene as encoding a hypothetical protein; the 
sequence, however, did show 28.4% identity with that of LanY encoded within 
the lichenicidin operon (Begley et al., 2009). ORF7, ORF8 and ORF9 all encode 
ABC transporter-related peptides, as do ORF11, ORF12 and ORF13. These are 
likely to be involved in bacteriocin immunity. ORF7 and ORF11 both encode 
domains resembling that of the ABC-binding cassette domain of the bacitracin 
resistance transporter (cd03268) and displayed 44.5% identity with that of each 
other. Instead of the common Q-loop motif found in the nucleotide-binding 
domains of such transporters, both these proteins instead encode an E-loop motif 
that is indicative of lantibiotic immunity proteins (Okuda et al., 2010; Alkhatib et 
al., 2012). Each of the other components encodes ABC-2-type transporter domains 
(cl21474). The presence of these gene clusters may suggest a dual mechanism of 
bacteriocin immunity. Immunity to the lichenicidin bacteriocin is thought to 
follow a similar mechanism, with two transporters being encoded, with one 
showing homology to the bacitracin transporter (Dischinger et al., 2009). Such 
mechanisms, however, do not confer a general immunity against all two-peptide 
lantibiotics, as the producers of both lichenicidin (B. licheniformis ATCC 14580) 
and lacticin 3147 (Lc. lactis subsp. lactis DPC 3147) displayed sensitivity to 
formicin (Table 1). 
ORF10 (frcR) that splits the transporter clusters encodes a LanR-equivalent 
transcriptional regulator. This gene encodes helix–turn–helix XRE family 
domains, crucial for binding DNA and regulating gene expression. This LanRtype 
protein displayed 49.4% and 60.3% identity with those of the regulators found 
within the lichenicidin and haloduracin operons, respectively. ORF14 (frcP) 
encodes a lanthionine-specific protease displaying 29.8% identity with that of LicP 
 
233  
found in the lichenicidin operon. As in lichenicidin, the LanT-like ORF (frcT) 
likely cleaves the N-terminal glycine leader sequence from both propeptides upon 
transport, whilst the LanP-like protease (frcP) possibly cleaves the six newly 
exposed N-terminal amino acids from the β peptide to generate the mature 
bacteriocin (Tang et al., 2015). The final ORF found in the gene cluster encodes a 
DNA damage-inducible protein. 
 
Bacteriocin structure prediction and analysis 
The spectrum of activity and characteristics of the bacteriocin could not be 
determined from the crude bacteriocin supernatant alone due to the interference 
from other antimicrobials produced by the strain. Thus, it was necessary to purify 
the bacteriocin from the CFS in order to determine the activity of formicin. With 
the use of the predicted masses of the lantibiotic structural peptides identified from 
genomic data, it was possible to determine if the formicin peptides were present 
in active HPLC-derived fractions using MALDI-TOF MS. 
From the purified peptides, masses of 3254.34 and 2472.06 Da were detected for 
the α and β peptides respectively. The predicted mass of the Frcα peptide based on 
the amino acid sequence from the genome is 3310.80 Da; the difference between 
the predicted and observed masses correlates with the loss of three water residues, 
which is most likely associated with the formation of lanthionine and 
methyllanthionine bridges, as well as also the possible formation of one disulfide 
bond, resulting in a predicted mass of 3254.80 Da. Due to the similarities between 
the two, the structure of Halα was used as a basis for the prediction of the structure 
of Frcα. Based on the Halα template, the formation of a lanthionine bridge may 
occur between Ser-7 and Cys-17, whilst methyllanthionine bridges could form 
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between Thr-18 and Cys-23, as well as between Thr-20 and Cys-27, whilst 
Ser-26 remains unaltered. In addition, a disulfide bridge is also likely to form 
between Cys-1 and Cys-8 (Figure 3). 
The second mass determined by MALDI-TOF MS relates to the β peptide of the 
bacteriocin. Due to the presence of the extra LanP serine protease encoded in the 
bacteriocin operon and the similarity formicin displays to haloduracin and 
lichenicidin, it is likely that the first six amino acids following the lantibiotic 
leader sequence are also cleaved from the formicin peptide. Once these amino 
acids are discounted, the predicted mass of the peptide is 2614.95 Da, a difference 
of 142.89 Da from the mass detected by MALDI-TOF MS. This mass difference 
corresponds closely with the loss of 144 Da, which would be associated with eight 
dehydration reactions. Using the β peptides of lichenicidin and lacticin 3147 as 
templates, we predicted that the peptide is most likely to form bridges between 
Thr-1 and Cys-8, Thr13 and Cys-17, Ser-19 and Cys-22, and Thr-23 and Cys-26. 
This would result in Thr-2, Ser-4, Ser-5 and Thr-10 being dehydrated to their 
respective Dha and Dhb residues, whilst Ser-24 remains unaltered (Figure 3). 
The purified peptides were screened against a range of indicator organisms to 
determine the spectrum of inhibition (Table 1). Purified formicin inhibited 29 of 
the 35 indicator strains screened, exhibiting a broad-spectrum of activity against 
a range of bacterial genera including lactobacilli and enterococci, as well as 
notable pathogens such as Staph. aureus, Strep. mutans, Ls. monocytogenes, C. 
difficile and B. subtilis. The Frcα peptide alone at a concentration of 50 µM also 
displayed antimicrobial activity against a number of indicators, whilst Frcβ alone 
displayed no detectable antimicrobial activity. 
In terms of thermostability, the bacteriocin retained a high degree of activity after 
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treatment at 100°C for 30 min, displaying a reduction in the size of the zone of 
inhibition of approximately 28%. Activity was, however, lost after treatment for 
15 min at 121°C. The bacteriocin was also found to be susceptible to digestion by 
a-chymotrypsin and proteinase K, indicating its proteinaceous nature. 
 
Homology between bacteriocins 
The previously described two-peptide lantibiotics all display a degree of homology 
with certain conserved residues found throughout. As a result, sequence 
comparisons of these structural peptides were carried out with formicin to 
determine if this conservation extended to the new bacteriocin (Figure 4). The 
results indicate that formicin complies with the conservation that is seen amongst 
the other bacteriocins. The mersacidin-like α peptides display the greatest levels of 
conservation and this reflects the shared mode of action in specifically binding to 
lipid II. This homology, especially in the lanthionine and methyllanthionine 
bridgeforming regions, confers a structural similarity in each of the peptides. The 
broader role of the β peptides in membrane insertion is reflected in a greater degree 
of divergence in the composition of these peptides. The regions of conservation 
that are seen amongst the β peptides extend to Frcβ also, with the C-terminus of 
the peptides showing a relatively conserved pattern of lanthionine and 
methyllanthionine bridge formation. The N-terminus of the β peptides displays a 
much lower degree of conservation amongst the bacteriocins; despite this, these 
N-terminal regions are rich in hydrophobic amino acids, which likely play an 





Formicin represents a novel member of the class of two-peptide lantibiotics. This 
class of bacteriocins are themselves unusual given that the lipid II-binding and 
pore-forming activities of the bacteriocin are performed by two separate peptides, 
whilst certain lantibiotics such as nisin and subtilin have the ability to carry out 
both functions on a single peptide. It is unclear as to whether these two-component 
lantibiotics have evolved due to a divergence of a nisin-like lantibiotic into two 
separate genes due to a duplication event or whether they have come about due to 
the convergence of a mersacidin-like lipid II-binding lantibiotic and a pore-
forming lantibiotic. If the latter is the case, it is interesting as to how such different 
peptides would have evolved to depend on each other for antibacterial activity, and 
in some cases, lose the activity each would have shown on its own. 
Sequencing of B. paralicheniformis APC 1576 allowed for the elucidation of the 
formicin bacteriocin operon (Figure 2). Analysis of the bacteriocin operon 
identified two lantibiotic structural genes (frcA1 and frcA2) and two modification 
enzymes (frcM1 and frcM2) that convert the formicin structural peptides into the 
mature lantibiotics. Transport and leader cleavage are likely to be carried out by 
frcT, whilst frcP may act as a further protease, cleaving six N-terminal amino acids 
from Frcβ. ORF7, ORF8 and ORF9 and ORF11, ORF12 and ORF13 all predict to 
encode ABC transporters that are likely to comprise the strain’s immunity 
mechanism, protecting itself from attack by its own bacteriocin. Comparative 
analysis of the bacteriocin structural genes allows for the homology between 
bacteriocins to be determined (Figure 4). In the case of both Frcα and Frcβ, the 
closest homologues are the haloduracin α and β mature peptides, displaying 71% 
and 39% identity respectively. Such homology reflects the close relationship of the 
two producers, both belonging to the Bacillus genus. The differences between the 
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formicin and lichenicidin peptides are surprisingly large, given that both are 
produced from related species, with the α peptides displaying 46% identity and the 
β peptides displaying 36% identity. This would suggest that both strains may have 
acquired these operons independently. The layout of the formicin operon itself 
differs from that of the previously characterized two-peptide lantibiotics, and 
transcription of the formicin operon would appear to be unidirectional whereby the 
genes for the structural peptides are separated by those encoding the LanM 
modification enzymes, an arrangement that seems to be unique to formicin. Both 
the haloduracin and lichenicidin structural genes (Figure 2) would likely be 
transcribed in opposite directions, possibly indicating that gene inversion may 
have taken place. Such differences again display the evolutionary divergence seen 
between this class of bacteriocins. 
Analysis of the primary structure of these peptides indicates that some key 
differences exist between the formicin peptides and other members of the class 
despite such strong regions of homology found throughout. The α peptide of 
formicin, for example, contains only five hydrophobic amino acids, whilst others 
in the class contain an average of nine. Whilst hydrophobic residues are crucial for 
membrane activity in certain bacteriocins, it has been suggested that it is the 
charged residues of these lantibiotics that control binding to lipid II as opposed to 
hydrophobic interactions. This indicates that binding of formicin to lipid II is not 
compromised despite its lower hydrophobicity, a fact that is supported by the 
activity of the α peptide independent of the β peptide (Hsu et al., 2003; Fimland et 
al., 2006). As with the α peptides from enterocin W and plantaricin W, the α 
peptide of formicin contains six charged amino acids, with an overall positive 
charge of plus two, rendering them amongst the most highly charged in the class. 
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Not only do these charged residues affect the structure of the peptide but also the 
higher positive charge may lead to an increased affinity for the anionic bacterial 
membrane. The formicin β peptide differs most when compared to other lantibiotic 
β peptides with regard to charge. As is common in this class, the N-terminal tails 
of the β peptides are composed largely of hydrophobic residues, crucial for 
membrane insertion and pore formation. Whilst the previously described β 
peptides all contain a positively charged C-terminus, containing Lys and Arg 
residues, formicin is unique in that it encodes a negatively charged β peptide. The 
lone charged residue found in the peptide is the penultimate C-terminal Asp 
residue. This portion of the peptide is believed to be involved in the interaction 
between the α and β peptides (Wiedemann et al., 2006); thus, this negative residue 
may suggest an increased affinity for the positively charged α peptide, possibly 
representing a stronger complex compared to previously described pairs. 
The tertiary structure of these peptides has an important functional role in the 
antimicrobial activity of these lantibiotics. Analysis of the N-terminus of Frcα 
suggests the formation of a disulfide bridge between Cys-1 and Cys-8. Whilst this 
has been shown to be inessential for antimicrobial activity, it may reduce the 
degradation of the peptide once secreted (Cooper et al., 2008). Of the lantibiotic 
rings believed to be formed in Frcα, only the C ring is thought to be essential, with 
alterations abolishing all activity completely in both haloduracin and lacticin 3147 
(Cooper et al., 2008; Cotter et al., 2006). The B ring found in these α peptides has 
been shown to be unnecessary, which is unusual given the high degree of 
conservation amongst such bacteriocins, including mersacidin. Disruption of the 
A ring in haloduracin has been shown to reduce but not eliminate activity, thus 
showing that this region is important but not essential for the antibacterial activity 
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of the bacteriocin (Cooper et al., 2008). As per analysis of the haloduracin β 
peptide, the A ring of the peptide has been found to be dispensable, whilst loss of 
the C and D rings led to a reduction in activity but not total elimination. Disruption 
of the B ring could not be achieved without disruption of the other ring structures 
(Cooper et al., 2008). 
 
6.1.6 Conclusion 
In this study, formicin, a novel member of the class of two peptide lantibiotics has 
been identified. Key regions of homology, primarily those involved in lanthionine 
and methyllanthionine bridge formation, seen throughout this class have been 
shown to be extended to formicin. Such homology is expected to confer a similar 
mode of action to all lantibiotics in this class, with the α peptide of the bacteriocin 
binding to lipid II and subsequently recruiting the β peptide for membrane 
insertion and pore formation. Whilst formicin likely conforms to such 
mechanisms, there are certain key variations differentiating it from the rest of the 
class. The reduction of hydrophobicity of Frcα and the unusual negative charge of 
Frcβ make formicin a unique member of the two-peptide lantibiotics. Further 
studies are required to determine the effects of such changes on the activity of the 
bacteriocins, as it is recognized that charge and hydrophobicity play a central role 
in the activity of these lantibiotics and in bacteriocins in general. Formicin itself 
displays a broad range of inhibition, inhibiting several clinically relevant Gram-
positive pathogens, such as C. difficile, Staph. aureus, Strep. mutans and Ls. 
monocytogenes. With the continued progression of antibiotic resistance in 
pathogenic bacteria, the discovery of novel therapies against such agents is a 
priority and since the bacteriocin is produced by a species long associated with 
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biotechnology applications, a straightforward route towards large-scale processing 
of the readily purified peptides is anticipated. Thus, formicin represents a potential 
novel antimicrobial therapy against a range of pathogenic bacteria. 
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Table 1. Growth conditions of indicator strains and inhibition spectrum of formicin 
pure peptides following well diffusion assays. 
 
 
MRS, de Man, Rogosa and Sharpe; BHI, brain–heart infusion; RCM, reinforced 
clostridial media. -, No activity; +, 0.5–1.5 mm inhibition zone; ++, 2-3.5 mm 






Figure 1 Formicin identification and activity. (A) Deferred antagonism assay against 
Lb. delbrueckii subsp. bulgaricus LMG 6901 identified B. licheniformis APC 1576 as 
an antimicrobial producer. (B) Antibacterial activity of the B. licheniformis APC 1576 
CFS against Lb. delbrueckii subsp. bulgaricus LMG 6901 in a well diffusion assay. (C) 
Colony MALDI-TOF MS displaying the masses of the peptides produced by B. 
licheniformis APC 1576, allowing identification of the antimicrobials produced 
(3255.92 Da = Frcα (formicin); Frcβ is not seen using colony MALDI-TOF MS; 
1423.94 Da = bacitracin) 
 






Figure 2 Formicin operon and visualization of the formicin, lichenicidin and 
haloduracin bacteriocin gene clusters. Clear bacteriocin homologues are identified using 
the accepted nomenclature for describing lantibiotics. For formicin, frcA1 and frcA2 
encode the putative bacteriocins, frcM1 and frcM2 encode the accompanying 
modification enzymes and frcT and frcP are involved in bacteriocin transport and leader 
cleavage. Similar nomenclature is used for lichenicidin (lic) and haloduracin (hal) 







Figure 3 Lantibiotic structure prediction. The structures of the formicin α and β 
peptides were predicted using the Halα and Licβ peptides, respectively, as templates. 
The conservation of key amino acids suggests a structural homology between the 
peptides. The rings formed from lanthionine and methyllanthionine bridges are labelled 
alphabetically, with the N-terminal ring of Frcα excluded as it is predicted to be formed 
via a disulfide bond. The bacteriocin prepropeptides are shown below each structure, 





Figure 4 Sequence alignment of formicin structural peptides. Using Clustal Omega, 
the formicin peptides FrcA1 (top image) and FrcA2 (bottom image) were aligned 
against the previously described two-component bacteriocins. The percentage amino 
acid identities of each peptide with the formicin peptides are shown. The conservation 
scores between the peptides were calculated with Clustal Omega for the alignments 
containing less than 25% gaps; asterisk (*) represents a score of 10. The sequences in 
bold face represent the six amino acids cleaved from the N-terminus of these peptides 
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6.2.1  Abstract  
We identified a strain of Actinomyces ruminicola which produces a potent 
bacteriocin with activity against a broad range of Gram-positive bacteria, many of 
which are pathogenic to animals and humans. The bacteriocin was purified and 
found to have a mass of 4,091 ± 1 Da with a sequence of 
GFGCNLITSNPYQCSNHCKSVGYRGGYCKLRTVCTCY containing three 
disulfide bridges. Surprisingly, near relatives of actifensin were found to be a series 
of related eukaryotic defensins displaying greater than 50% identity to the 
bacteriocin. A pangenomic screen further revealed that production of actifensin-
related bacteriocins is a common trait within the genus, with 47 being encoded in 
161 genomes. Furthermore, these bacteriocins displayed a remarkable level of 
diversity with a mean amino acid identity of only 52% between strains/species. 
This level of redundancy suggests that this new class of bacteriocins may provide 
a very broad structural basis on which to deliver and design new broad-spectrum 
antimicrobials for treatment of animal and human infections. 
 
6.2.2  Importance  
Bacteriocins (ribosomally-produced antimicrobial peptides) are potential 
alternatives to current antimicrobials given the global challenge of antimicrobial 
resistance. We identified a novel bacteriocin from Actinomyces ruminicola with 
no previously characterized antimicrobial activity. Using publicly available 
genomic data, we found a highly conserved yet divergent family of previously 
unidentified homologous peptide sequences within the genus Actinomyces with 
striking similarity to eukaryotic defensins. These actifensins may provide a potent 
line of antimicrobial defense/offense, and the machinery to produce them could be 
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used for the design of new antimicrobials given the degeneracy that exists 
naturally in their structure. 
 
6.2.3  Introduction 
Novel antimicrobial compounds are increasingly important in the food, agriculture and 
medical fields due to decreasing efficacies of current antimicrobial treatments. 
Bacteriocins are ribosomally-synthesized antimicrobial peptides produced by bacteria 
which can target another bacterium of the same species (narrow spectrum) or bacteria 
of other species/genera (broad spectrum) (1). Bacteriocin producers are self-protected 
through the production of specific immunity proteins and, as bacteriocins are gene 
encoded, they can be genetically modified. Bacteriocins produced by Gram-positive 
bacteria have been grouped according to their primary structure into class I (post-
translationally modified bacteriocins) and class II (unmodified or cyclic bacteriocins) 
(2). Class II is split into several subgroups, including the class IId bacteriocins, which 
are a heterogenous group of linear, unmodified, nonpediocin-like peptides (3). 
Defensins are antimicrobial peptides ubiquitous among eukaryotes which play a 
role in innate immunity but have also been found to act as signaling peptides, toxins, 
enzyme inhibitors and abiotic stress responders, and to have anticancer properties. 
Defensins are small (<10 kDa) cysteine-rich (forming three to six disulfide bonds) 
peptides with low amino acid identity, and the two superfamilies are thought to have 
evolved convergently (4). Only two expressed defensin-like bacteriocins have been 
described; the laterosporulins were previously identified among prokaryotes and 
contain disulfide bonds in positions homologous to those in eukaryotic defensins (5, 
6). Other disulfide bond-containing bacteriocins, such as bactofencin, have been 
compared with eukaryotic defensins due to their highly cationic nature (7, 8). 
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Laterosporulin and its homolog laterosporulin10 are class IId bacteriocins produced 
by Brevibacillus spp. which have been described as broad-spectrum antimicrobials 
against both Gram-negative and Gram-positive bacteria. The two peptides are 5.6 kDa 
and 6.0 kDa and share only 57.6% amino acid sequence identity but have conserved 
cysteines, which are characteristic of eukaryotic defensins (6). 
Actinomyces spp. are a heterogenous group of high-GC-content, Gram-positive 
non-spore-forming facultative or obligate anaerobes that belong to the 
Actinomycetaceae family within the phylum Actinobacteria (9). In humans, a 
number of species are known colonizers of hard surfaces in the oral cavity, where 
they play a key role in plaque biofilm formation (10, 11). They have been identified 
as core members of the oral bacteriome, present in moderate abundance (>0.1% to 
>2.0%) among geographically diverse populations (10, 12–15). Actinomyces spp. 
have been implicated in oral health as being associated in greater abundance in 
individuals with dental caries, one of the most prevalent chronic oral diseases 
worldwide (14, 15). Most characterized strains are clinical isolates of human 
origin, while some opportunistically pathogenic species such as Actinomyces 
israelii and Actinomyces gerencseriae are known to cause the uncommon 
infectious disease actinomycosis (16). Though Actinomyces spp. are abundant in 
the oral cavity, little is known about their presence in the gut, probably due to their 
low abundance (<0.1%) (10). Many Actinomyces spp. have been isolated from 
fecal material and from the gastrointestinal tracts of different animals, indicating a 
propensity for gastric transit survival, and their presence has also been noted in the 
urogenital tract (17–24). Here, we identify a new group of bacteriocins using a 
pangenomic in silico approach paired with functional screening. Many in silico 
genome mining tools have been developed for the successful detection of novel 
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antimicrobial producing operons (25, 26). Obviously, these methods rely on 
relationships with previously known genes and therefore, functional screening is 
crucial for the identification of unrelated antimicrobials. In this study, we isolated 
a potent bacteriocin-producing strain of Actinomyces ruminicola from sheep feces; 
the bacteriocin produced resembled eukaryotic defensins, having three 
characteristic disulfide bridges. A subsequent pangenus Actinomyces analysis 
revealed that such bacteriocins are widely distributed in these bacteria, albeit with 
a highly variable structure. 
 
6.2.4 Materials and Methods 
Isolation of bacteria and identification of bacteriocin production 
Samples of raw milk, unpasteurized cheeses, sheep feces and honey were serially 
diluted in maximum recovery diluent (MRD) (Oxoid) and plated on several medium 
types for the isolation of bacteriocin-producing bacteria: Streptococcus 
thermophilus selective agar (tryptone, 10.0 g liter-1; sucrose, 10.0 g liter-1; yeast 
extract, 5.0 g liter-1; K2HPO4, 2.0 g liter-1; bromocresol purple, 0.03 g liter-1; 
agar, 15.0 g liter-1) incubated aerobically at 42°C; M17 (Merck) supplemented with 
10% (wt/vol) lactose incubated at 30°C aerobically; de Man, Rogosa, and Sharpe 
(MRS; Difco) agar supplemented with 30 µg ml-1 L-vancomycin hydrochloride 
incubated at 37°C; MRS adjusted to pH 5.4 incubated at 42°C anaerobically; 
Lactobacillus selective agar (LBS) incubated at 30°C anaerobically; and TOS 
(transgalactosylated oligosaccharide) agar supplemented with 50 µg ml-1 lithium 
mupirocin incubated at 37°C anaerobically. 
Isolates were subject to an initial bacteriocin production screen by overlaying with 
10 ml “sloppy” MRS agar (7.5 g liter-1 agar) tempered to 50°C and seeded with an 
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overnight culture of Lactobacillus delbrueckii subsp. bulgaricus LMG 6901 (0.25% 
[vol/vol]). Cultures which were found to produce distinct zones of inhibition in the 
agar overlay were cultured in broth for well diffusion assays. For well diffusion 
assays, 20 ml of sloppy MRS agar seeded with L. delbrueckii subsp.  bulgaricus 
LMG 6901, as described above, was poured and allowed to set, in which 6-mm-wide 
wells were then bored. Fifty microliters of cell-free supernatant was added to each 
well, and plates were incubated at 37°C overnight. Zones of inhibition were 
indicative of antimicrobial activity. 
 
Bacterial strains, media, reagents 
Strains used in this study and their incubation conditions are listed in Table S3 in 
the supplemental material. A. ruminicola DPC 7226 was routinely maintained in 
brain heart infusion (BHI) broth (Oxoid) anaerobically at 37°C. Medium reagents 
were sourced from Sigma Aldrich (Co. Wicklow, Ireland) unless stated otherwise.  
 
Purification of actifensin 
A. ruminicola DPC 7226 was grown anaerobically and statically at 37°C in 500-ml 
volumes of BHI broth for 48 h. Following centrifugation, cell-free supernatant was 
applied to an Econo column containing 30 g Amberlite XAD beads prewashed with 
Milli-Q water. The column was washed with 300 ml 30% ethanol and 300 ml 2-
propanol–0.1% trifluoroacetic acid (TFA) (IPA). IPA was removed by rotary 
evaporation, and the sample was applied to a 60-ml 10-g Strata-E C18 SPE column 
(Phenomenex, Cheshire, UK) preequilibrated with methanol and water. The 
column was washed with 60 ml 25% ethanol and then 60 ml IPA. 
Centrifuged cells were combined with 100 ml IPA and stirred at room temperature 
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for 3 to 4 h. The resulting suspension was centrifuged, and the cell extract and 
purified CFS were assayed by MALDI-TOF mass spectrometry to determine the 
molecular mass of antimicrobial compounds (Axima TOF2 MALDI-TOF mass 
spectrometer; Shimadzu Biotech, Manchester, UK). A MALDI target plate was 
precoated with a-cyano-4-hydroxycinnamic acid (CHCA) matrix solution, 0.5 µl of 
the supernatant from the cell extract was then placed on the target, and a final layer 
of matrix solution was added. Positive-ion linear or reflectron mode was used to 
detect peptide masses. 
 
Actifensin characterization 
Characterization was performed using purified bacteriocin. To test protease 
susceptibility, 100 µl aliquots of 50 µg ml
-1 were subjected to treatment with 20 mg ml
-
1 proteinase K (Sigma-Aldrich) and a-chymotrypsin (Sigma-Aldrich) at 37°C for 3 h, 
followed by a 10-min incubation at 100°C to denature the enzymes. Fifty-microliter 
aliquots were assayed on L. delbrueckii subsp. bulgaricus LMG 6901 indicator plates. 
Heat stability was determined by 30 min incubations at 60°C, 70°C, 80°C, 90°C, and 
100°C and by autoclaving at 121°C for 15 min.  
For spectrum of activity, a well diffusion assay was carried out as described above 
with the strains in the appropriate medium. Fifty microliters of purified bacteriocin at 
a concentration of 50 µg ml
-1 was added to a well. Following overnight incubation 
under the appropriate conditions, zones of activity were measured and categorized 
as no inhibition, weak inhibition (0.5 mm to 2 mm), strong inhibition (2.5 mm to 5 
mm), and very strong inhibition (>5 mm). MIC against selected pathogens was 
assayed as described above, starting at 100 µg ml
-1 peptide solution and serially 






Draft genome sequencing 
DNA was extracted using a GenElute bacterial genomic DNA kit (Sigma) and prepared 
for sequencing using a Nextera XT kit (Illumina) for library preparation. DNA was 
quantified using a Qubit 2.0 fluorometer. Sequencing was carried out using an Illumina 
MiSeq platform with paired-end 2 x 300-bp reads by the Teagasc Sequencing Centre, 
Teagasc Food Research Centre, Moorepark, Fermoy, Ireland. Assembly was performed 
using tools available on the public server at https://usegalaxy.org (30). Assembly was 
performed de novo using SPADES (version 3.0.0) and resulted in 116 contigs. Contigs 
were aligned to a reference genome using Mauve (version 20150226, build 10), 
followed by annotation with RAST (version 2.0). The annotated genome was analyzed 
for predicted bacteriocin and secondary metabolite production clusters using BAGEL4 
(37), and any further annotation was carried out using Artemis genome browser 
(version 16.0.0). 
 
BAGEL screen and phylogenetic analysis of Actinomyces species 
GenBank and FASTA assemblies of the genus Actinomyces were acquired from the 
NCBI assembly database and screened using BAGEL4 (37). Where available, 
corresponding 16S rRNA sequences were acquired from the RDP database (38) and, 
where unavailable, Actinomyces sp. genomes were subject to analysis using 
RNAmmer (32). 16S rRNA sequences were aligned using MUSCLE (33), and a 
phylogram was generated using iTOL (39). The phylogram was then overlaid with 
the BAGEL screen data.  
 




Two hundred micrograms freeze-dried purified peptide was sent for N-terminal 
amino acid sequencing (AltaBioscience, UK). The resulting 15-residue sequence, 
GFGXNLITSNPYQXS, was used to search for a bacteriocin structural gene with 
Artemis genome browser. Following identification of the structural gene, other 
genomes were searched for genes homologous to the active propeptide using 
BLASTp; genes on contigs consisting of less than 5 kbp were excluded. Additional 
actifensin homologs were identified from the study by Dash et al. (27) among 147 
nonredundant bacterial CSaþ peptide sequences (27). Alignments were generated 
using Clustal Omega (40) and visualized with Jalview (41). Structural modeling 
was performed using SWISSMODEL (42) online software, and structural images 
were generated using PyMOL (43). 
 
Data availability 
Genomic data analyzed in this study were deposited in GenBank/EMBL under 




Identification of a novel bacteriocin-producing Actinomyces sp.  
Actinomyces ruminicola DPC 7226 was isolated from sheep feces. During an initial 
screen of >10,000 colonies for bacteriocin producers, this strain was found to 
produce a large zone of inhibition when overlaid with an acid-tolerant indicator 
species, Lactobacillus delbrueckii subsp. bulgaricus LMG 6901 (Figure 1a). The 
neutralized cell-free supernatant (CFS) was also found to produce a zone of 
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inhibition against L. delbrueckii subsp. bulgaricus LMG 6901, indicating 
production of a soluble antimicrobial molecule (Figure 1b). This activity was 
eliminated when the supernatant was treated with proteinase K, demonstrating that 
the antimicrobial is proteinaceous in nature (data not shown). 
Antimicrobial activity was purified from pelleted bacterial cells (C18 SPE; reversed 
phase high-performance liquid chromatography [HPLC]) and CFS (Amberlite 
XAD16N, C18 SPE; reversed-phase HPLC), and matrix-assisted laser desorption 
ionization–time of flight mass spectrometry (MALDI-TOF MS) of active peaks 
detected a mass of 4,091 ± 1 Da (Figure 2a and 2b). The mass was also detected 
by colony MS (Figure 2c). The activity of the HPLC-purified fraction from CFS 
was assayed against L. delbrueckii subsp. bulgaricus LMG 6901 and found to be 
active at <1 µg ml—1 (Figure 2d). The antimicrobial peptide was found to be heat 
stable, retaining almost all activity after treatment for 30 min at 100°C, but was 
completely lost after treatment at 121°C for 15 min.  
 
Spectrum of inhibition 
A range of indicator organisms was tested against the purified antimicrobial to 
determine the spectrum of inhibition. The antimicrobial was active against a broad 
range of genera, with 22 of the 27 strains screened inhibited to various degrees, 
including species of the genera Lactococcus, Enterococcus, Lactobacillus, 
Streptococcus, Pediococcus, Bacillus, Staphylococcus, other Actinomyces spp., and 
Clostridium spp. (Figure 3). No inhibition against the Gram-negative species 
Salmonella enterica or Escherichia coli was observed. Listeria spp. and Bacillus spp. 
were inhibited weakly or not at all (Figure 3). Inhibition against other Actinomyces spp. 
was found, and activity was particularly strong against Staphylococcus aureus and 
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Clostridium difficile.  
MICs were determined against Enterococcus faecium APC1031, E. faecium 
NCDO0942, S. aureus R693, Streptococcus agalactiae APC1055, and C. difficile 
DPC6534 (see Figure S1). Enterococci were inhibited at 3.05 to 6.10 µM. S. aureus 
was inhibited at 3.05 µM. S. agalactiae and C. difficile were inhibited at 0.76 µM (Figure 
S1). 
 
Distribution of genes encoding bacteriocins in the genus Actinomyces 
As the active mass could not be matched to any previously known antimicrobial 
peptide and no antimicrobial compounds were previously described within the 
species, the genome of A. ruminicola DPC 7226 was sequenced. Following genome 
annotation, the draft genome was analyzed using BAGEL4 to search for potential 
antimicrobial-encoding operons. Gene clusters were identified containing putative 
genes for thiopeptide production (data not shown), but the masses predicted, 2,195.4 
Da and 1,152.5 Da, did not correspond with the mass detected in the antimicrobial 
HPLC fraction. 
In conjunction with screening of the genome of A. ruminicola DPC 7226, we also set 
out to characterize the antimicrobial potential of the genus. One hundred and sixty one 
Actinomyces species genomes in various stages of assembly were screened using 
BAGEL4. The isolates were obtained from humans (78.2%) or other animals (16.1%) 
or were of unknown origin (4.9%), while one was an environmental isolate (0.6%). One 
hundred and six areas of interest were revealed in 76 strains, covering 18 species. 
Ninety areas of interest contained complete operons for antimicrobial production. 
Twenty-nine were predicted to encode class I bacteriocins, including 7 LanBC modified 
lantibiotics, 16 LanM modified lantibiotics, 1 single-peptide sactibiotic, 3 lasso 
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peptides, and 2 thiopeptides. Thirteen operons were predicted to encode class IId 
bacteriocins, and a further 48 operons were predicted to encode bacteriolysins. A 
phylogenetic tree was generated from the 16S rRNA sequences of 142 Actinomyces 
genomes with Bacteroides fragilis ATCC 25285 as the root and overlaid with operon 
type and strain source (Figure 4). Bacteriocin production was widely distributed across 
the Actinomyces pangenome, though bacteriolysin production was found exclusively 
among human isolates (Figure 4) 
 
Genetic and molecular characterization of the actifensin determinant 
To identify the gene encoding the 4,091 ± 1 Da peptide within the genome of A. 
ruminicola DPC 7226, pure peptide was subjected to N-terminal sequencing, which 
revealed a primary sequence consisting of Gly-Phe-Gly-X-Asn-Leu-Ile-Thr-Ser-
Asn-Pro-Tyr-Glu-XSer, with blanks at residue positions 4 and 14 denoted as 
probable cysteines (Figure 5a). This 15-amino-acid sequence was matched to a 69-
residue small open reading frame in the draft genome, capable of encoding a 37-
amino-acid mature peptide (hereafter referred to as actifensin) with a predicted mass 
of 4,097.7 Da preceded by a 32-residue leader sequence (Figure 5a). 
The genetic locus encoding actifensin is shown in Figure 5b, where afnA encodes 
actifensin. Within an approximately 6.5-kbp upstream region of afnA, genes 
encoding an ABC transporter permease (afnJ), an ATP binding ABC transporter 
(afnK), and another ABC transporter permease (afnL) were identified as being 
present. Downstream of afnA, three hypothetical genes of unknown function (afnG 
to afnI) were found, followed by genes encoding another ATP binding ABC 
transporter (afnF), a predicted α/β hydrolase superfamily protein (afnE), another 
protein of unknown function, a subtilisin-like protease, and a LuxR family 
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transcription factor (afnD, afnC, and afnB, respectively). Within afnE is a predicted 
RHO-independent transcription terminator, and upstream of the structural gene are 
four predicted promoters. A putative ribosome binding site was also identified nine 
base pairs upstream of the ATG start codon for the peptide consisting of a purine 
rich sequence, 5’-GAAAGG-3’ (Figure 5a). 
The leaderless structural peptide was found to have a predicted mass of 4,097.7 
Da. This mass was approximately 6 Da higher than detected by MALDI-TOF MS. 
The difference between predicted and observed masses most likely corresponds 
to the loss of six hydrogen atoms during the formation of disulfide bonds between 
the six cysteines. Short peptides with numerous disulfides in specific positions are 
characteristic of the defensin peptide families (4). To confirm the presence of 
disulfide bonds in actifensin, pure peptide was reduced and alkylated to break open 
the disulfide bonds and then subjected to trypsin digestion and peptide mass 
fingerprint analysis by MALDI-TOF MS. Reduction and alkylation of actifensin 
resulted in a 4,440-Da mass, which correlates with the expected increase in mass 
of 58 Da for each cysteine. MALDI-TOF MS analysis of the subsequent trypsin 
digest detected a mass of 2,257.02 Da, which corresponds to the first 19 amino 
acids of the peptide (Gly-1 to Lys-19) containing three alkylated cysteine residues. 
Three other predicted masses for Ser-20 to Arg-24, Gly-25 to Arg-31, and Thr-32 to 
Tyr-37 (predicted and alkylated masses of 581.30 Da, 584.25 Da, and 803.31 Da, 
respectively) were not detected. 
 
Discovery of actifensin homologs 
BLASTp analysis with AfnA found homologous open reading frames (ORFs) within 
the fungal genera Blastomyces, Emmonsia, and Emergomyces, Helicocarpus griseus, 
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and a defensin from the mollusk species Ruditapes philippinarum (58%, 58%, 55%, 
52%, and 61% identity, respectively) (see Figure S2). Characteristic conserved 
cysteines were noted, though low sequence identity was observed between the mature 
actifensin peptide and eukaryotic defensins. The same was found when AfnA was 
compared with known previously characterized arthropod, ascomycete, and 
mollusk defensins (Figure 6a) with conserved secondary structures (Figure 6b). 
BLASTp analysis using the 69-residue AfnA sequence identified 37 homologous 
structural genes within the genus Actinomyces and one homolog from a 
Corynebacterium sp. sequence (Figure 7a). Further analysis indicated that the 
homologs were present in 15 operons from 14 strains, in addition to conserved 
genes for transport, transcription regulation, and proteolytic activity (Figure 7b). 
Actinomyces sp. strain 2119, Actinomyces oris S64C, Actinomyces succiniciruminis 
AM4, A. oris CCUG34286, Actinomyces sp. strain F0337, Actinomyces sp. strain 
HMSC075C01, and A. oris MMRCO6-1 had at least two actifensin homologs, while 
Actinomyces sp. F0337 contained an operon with seven copies, the most observed 
within one genome (Figure 7b). The genome of A. oris MMRCO6-1 contained six 
encoded actifensin homologs detectable over two contigs, but only one (contig 50) 
contained the other conserved ORFs (afnB-I and afnJ-K) present in the actifensin 
operon. Twelve of 14 operons had a highly conserved arrangement of afnB-I, all of 
which also had ABC transporter genes directly upstream of the bacteriocin ORF. 
The mean amino acid identity between all structural genes was 52%. The highest 
identity observed between actifensin and a homolog was 77% identity with afnA in 
Actinomyces sp. strain CTC72, though higher identities were observed between 
other peptides (see Figure S3). We proceeded to characterize ten predicted cysteine-
stabilized aþ (CSaþ) peptides predicted by Dash et al. (27). The peptides are present 
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in five Actinomyces genomes bringing the total number of peptides to 47 
homologous structural genes in 19 strains. Actinomyces oris S24V, Actinomyces 
denticolens PA, Actinomyces sp. strain Chiba-101, Actinomyces johnsonii F0542, 
and Actinomyces sp. strain F0330 have genes which were not identified using 
BLASTp and the actifensin propeptide sequence (27). Strains S24V, PA, and 
Chiba-101 display the conserved afnB to afnI ORFs following afnA, which are 
absent in strains F0330 and F0542 (Figure 7b). 
The propeptide contains a conserved G-X-E motif prior to the start of the mature peptide 
(Figure. 7a). In 36 of the peptides, an alanine residue is present after the glycine, which 
may be involved in secretion and cleavage. This putative GA cleavage signal is replaced 
by a TS motif in 8 of the 49 peptides (A. oris S64C afnA5, A. oris CCUG34286 afnA7, 
A. oris MMRCO6-1 contig 75 afnA2, Actinomyces sp. F0337 afnA4, Actinomyces sp. 
HMSC075C01 afnA4, A. oris MMRCO6-1 contig 50 afnA4 and afnA3, and A. oris 
S24V afnA5). A conserved Pro residue was noted following the first conserved Cys 
in addition to a conserved G-Y-X-G-G-X-C sequence at positions 56 to 62 of the 
propeptide (22 to 28 in the active peptide) (Figure 7a). 
 
6.2.6   Discussion 
We describe a novel group of bacteriocins with broad-spectrum inhibitory activity 
within the Actinomyces genus. Actifensin is the first such bacteriocin to be 
discovered, which is produced by a strain of Actinomyces ruminicola.  
Actifensin inhibited a broad range of Gram-positive species, including notable 
pathogens such as vancomycin-resistant Enterococcus and methicillin-resistant 
Staphylococcus. Given the global challenge of the increase in antibiotic resistance, 
there is an urgent need for new classes of antimicrobials. Bacteriocins have been 
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suggested as an alternative to conventional antibiotics due to their effectiveness at 
low concentrations and their potential to be genetically modified (2). Class II 
bacteriocins are diverse in sequence and structure whose mechanism of action is 
through interaction with the cell membrane, causing permeabilization and pore 
formation and dissipating the membrane potential (3). The defensin-like bacteriocin 
laterosporulin10 has been found to act on the cell membrane of S. aureus Mtb 
H37Rv, disrupting cellular homeostasis (6). Plectasin and eurocin, fungal C6 
defensins, are known to bind lipid II, inhibiting bacterial cell wall biosynthesis (44, 
45). Actifensin possesses an N-terminal loop extension which, in other defensin 
peptides, has been implicated in membrane disruptive capability (31). The loop 
consists of nine residues between Cys-4 and Cys-14 beginning with an Asn. In most 
of the other peptide sequences identified, the N loop is six residues long, beginning 
with a Pro (except in AfnA from Actinomyces sp. strain F0588 or A. naeslundii 
S44D, which has an eight-residue N loop with a serine or arginine in the first 
position, respectively, followed by a Pro) (Figure 7a).   
Actifensin also inhibited the growth of C. difficile and Clostridium sporogenes. 
Clostridia are known colonizers of the rumen and, as A. ruminicola DPC7226 was 
isolated from the feces of a ruminant, actifensin production may provide a competitive 
advantage in the gut microbiome. Actinomyces neuii and Actinomyces radingae were 
both inhibited by actifensin; however, it would be interesting to see if cross-resistance 
between actifensin and other actifensin-like producers exists.  
A pangenus in silico screen revealed that the genus Actinomyces (Figure 4) is a rich 
source of antimicrobials and has genes for bacteriolysin and lantibiotic production 
(48/90 and 29/90 operons, respectively). Thirteen class II bacteriocins were predicted 
by BAGEL, but neither the actifensin operon nor its homologs were detected due 
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to lack of similarity with known systems. One previous study described 
odontolycin, a bacteriocin produced by an Actinomyces odontolyticus dental plaque 
isolate, though no further research on the peptide was reported (34). Interestingly, 
in our study, no operons for bacteriocin production were found among five A. 
odontolyticus genomes screened (Figure 4).  
The actifensin structural gene encodes a 37-amino-acid mature peptide preceded by a 
32-amino-acid leader sequence (Figure 5). A GA motif at positions -3 and -2 was 
identified, which is a known cleavage signal used in ABC transporter-mediated 
secretion (36). Indeed, there are a number of predicted ABC transporter genes within 
the actifensin operon. ABC transporter genes could also play a role in self-immunity to 
the actifensin peptide. Unusually, an additional glutamic acid residue is present at 
position-1 before the mature peptide. As the purified peptide was subjected to N-
terminal sequencing, we can be certain that the mature peptide begins with a glycine 
residue. Therefore, the additional glutamic acid residue at position-1 is most likely 
subject to exopeptidase cleavage prior to activity, and indeed, there are genes 
present with predicted protease activities (Figure 5).  
The GA cleavage motif is present in 36 of the homolog structural genes, with TS 
replacing the motif in eight instances, GT and GG in two cases, and GS, SA, and DA 
in one each (Figure 7a). A double glycine is the most commonly found motif for ABC 
transporter-mediated cleavage among bacteriocins, though GA and GS have also been 
observed (36). It will be interesting to see if the peptides bearing other residues at this 
location are indeed subject to ABC-mediated transport. We note that each operon 
containing a gene with a nontraditional TS/GT/SA/DA signal contains at least one more 
structural gene than those with a GG/GA sequence. This could indicate potential 
diversification of a repertoire of bacteriocins enabling improved ability to combat 
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multiple competitors. It was also surprising that an actifensin homolog was found in a 
distantly related Corynebacterium sp., though many of the conserved genes in the 
Actinomyces sp. operons were not present (Figure 7b). As such, this may be 
nonfunctional, as ABC transporter-related genes are missing upstream of the structural 
gene and the conserved afnB to afnI pattern is absent. The genera Corynebacterium and 
Actinomyces are distantly related members within the phylum Actinobacteria, and some 
species are known members of plaque biofilms, providing an opportunity for horizontal 
gene transfer (16). However, given the dissimilarity of the operons, they may have been 
acquired independently at some stage. 
As stated above, the laterosporulins produced by Brevibacillus spp. are two structurally 
defensin-like bacteriocins with broad-spectrum inhibitory activity (5, 6). Their amino 
acid sequences are 57.6% similar, which is comparable to that for actifensin and its 
predicted homologs, but share the conserved cysteine residues which form disulfide 
bridges. Conserved disulfides are characteristic of defensins and are present in 
vertebrate, invertebrate, plant, fungal defensins, and defensin-like peptides (4). 
Actifensin has a predicted mass of 4,097.7 Da, but the actual mass is 4,091 ± 1 Da by 
MALDI-TOF MS. The same discrepancy in predicted and observed masses was noted 
with laterosporulin, where six hydrogen atoms are lost in the formation of disulfide 
bonds. We hypothesize that bonds in actifensin likely form in the 1-4, 2-5, and 3-6 
formations, similar to that in ascomycete and arthropod C6 defensins (Figure 6), as the 
amino acid motifs (C-X5–12-C-X3-C-X9–10-C-X4–5-C-X-C) are conserved (5). The 
structure of laterosporulin10 has been determined to be architecturally similar to human 
a-defensin, though its disulfide connectivity is homologous to that of β-defensins 
(Figure 8) (6). The overall architecture and disulfide connectivity of actifensin are 
likely to be homologous to those of C6 defensins, consisting of an N-terminal α-
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helix followed by a two-stranded antiparallel β-sheet stabilized by disulfide bridges 
(Figure 8). Interestingly, an actifensin homolog we identify as AfnA from 
Actinomyces sp. oral taxon 171 strain F0337 has had its three-dimensional (3D) 
structure determined and is publicly available under PDB accession number 2RU0. 
The peptide labeled actinomycesin is strikingly similar to C6 fungal and arthropod 
defensins, which have also been characterized (Figure 6); however, no published 
material is available regarding its activity, antimicrobial or otherwise. Indeed, two 
antiparallel beta sheets stabilized by disulfide bonds with an interposed short turn 
region, previously described as the μ-core motif, are a ubiquitous feature of 
antimicrobial peptides (35). Actifensin exhibits the highly conserved GXC 
(positions 26 to 28 in the mature peptide) as do all of its homologs.  
CSaβ peptides comprise one of the most widespread families of defensins and defensin-
like peptides. A recent publication identified a number of CSaβ sequences in bacterial 
genomes with potential for antimicrobial, toxin, or signaling activity (27). Of 58 
peptides identified within the phylum Actinobacteria by Dash et al. (27), 34 were of the 
genus Actinomyces, 24 of which we identified using BLAST with the actifensin 
propeptide sequence (see Table S2 in the supplemental material). A further 113 
bacterial peptide sequences identified by Dash et al. (27) remain to be characterized 
from a functional perspective and may be a potent source for antimicrobials. 
Interestingly, a bacterial defensin-like peptide, AdDLP, identified in silico was 
synthesized and recombinantly expressed, and the peptide was found to have anti-
Plasmodium activity (28). The bacterial CSaþ peptides may be an untapped source of 
potential applications and have been proposed as the ancestral evolutionary origin of 
eukaryotic defensins (29).  
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In the search for novel antimicrobials for application in health and food, genomic and 
pangenomic approaches are becoming increasingly common (25, 26). These 
approaches are advantageous in that large amounts of genetic data can be analyzed to 
identify novel antimicrobials/bacteriocins and can even allow one to “reincarnate” 
otherwise “dormant” genes (46). However, such analyses are dependent on the ability 
of programs to predict based on databases of previously identified sequences, and so 
peptides with novel structures and operons may not be detected. Though a number of 
bacteriocin operons were found in the Actinomyces spp. genomes using BAGEL, 
actifensin was not identified by genome sequence alone, which highlights the 
importance of functional screening for antimicrobial compounds in addition to in silico 
screening. By using BLAST, 37 structural genes with homology to actifensin were 
found in Actinomyces spp. along with a single structural gene from a Corynebacterium 
sp. As some CSaβ peptides function as toxins, future applications will require any 
potential cytotoxic effects to be assayed. We propose that actifensins and the 
laterosporulins may constitute a new subgroup of class II bacteriocins: the defensin-
like bacteriocins. These bacteriocins share only moderate identity to each other but 




A series of novel defensin-like bacteriocins within the genus Actinomyces were 
identified using an in silico pangenomic approach coupled with a functional screen. 
The bacteriocins represent a potential new class of antimicrobial peptides, defensin-
like bacteriocins, which may have widespread applications as antimicrobials in food 
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Figure 1 Antimicrobial activity of Actinomyces ruminicola DPC 7226 from 
colonies overlaid with L. delbrueckii subsp. bulgaricus LMG 6901 in sloppy MRS 














Figure 2 Detection of actifensin 4,091 Da ± 1 Da (indicated by arrows) by MALDI-
TOF MS from cell-free supernatant (a), cell extract (b), and colonies on a plate (c). (d) 
The 4,091 (±1)-Da compound when purified was active to <1 µg ml-1; indicator, L. 






Figure 3 Inhibition of actifensin against a broad-spectrum of indicator species. Weak 
inhibition, 0.5- to 3-mm zone; strong inhibition, 3- to 5-mm zone; very strong 
inhibition, >5-mm zone. VRE, vancomycin-resistant Enterococcus; MRSA, 




Figure 4 Phylogram of Actinomyces genomes using 16S sequences overlaid with 








Figure 5 (a) Sixty-nine-residue propeptide identified following genome analysis 
using the 15-amino-acid sequence (underlined) determined by N-terminal amino 
acid sequencing. RBS, putative ribosome binding site highlighted 8 bp upstream 
of the start codon. (b) Genetic vicinity of structural gene containing nearby genes 






Figure 6 (a) Mature peptide sequence alignment of AfnA with characterized 
defensin family peptides from different phyla. Known disulfide connectivities are 
outlined above highlighted cysteine residues. (b) Available 3D structures of 
sequences in panel a. Alpha helices are colored red, and beta sheets are shown in 









Figure 7 (a) Sequence aligment of actifensin propeptide sequence (boxed) with 
structural genes predicted for Actinomyces sp. peptides. Amino acids with greater 
than 80% conservation are colored, and leader sequences and mature active peptides 
are indicated at the top. Putative disulfide connectivity between conserved cysteines 
of the mature peptide is indicated at the bottom right, and putative cleavage sites are 
indicated at the bottom center. (b) Diagrams of actifensin homolog production 





Figure 8 Conserved structures of the defensin peptide superfamily and defensin-like 
bacteriocins, laterosporulin and actifensin. β sheets are colored blue, α helices are 





Suplemental material with the exception of Table S3 and Figure S1 are available 
online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989792/ 






Actinomyces neuii LMG 19524t BHI 37°C,      O2
-
 
Actinomyces radingae LMG 15960t BHI 37°C,      O2
-
 
Bacillus cereus NCIMB700577 BHI 37°C,      O2
+
 
Bacillus subtilus S249 BHI 37°C,      O2
+
 
Bacillus thuringiensis DPC6431 BHI 37°C,      O2
+
 
Clostridium difficile DPC6534 RCM 37°C,      O2
-
 
Clostridium sporogenes LMG10143 RCM 37°C,      O2
-
 
Enterococcus faecium APC1031 TSY 37°C,      O2
-
 
Enterococcus faecium NCDO942 TSY 37°C,      O2
-
 
Escherichia coli DPC6054 BHI 37°C,      O2
+
 
Lactobacillus acidophilus DPC5377 MRS 37°C,      O2
-
 
Lactobacillus delbrueckii ssp. bulgaricus LMG6901  MRS 37°C,      O2
-
 
Lactobacillus delbrueckii ssp. lactis DPC5387 MRS 37°C,      O2
-
 
Lactobacillus helveticus DPC5353 MRS 37°C,      O2
-
 
Lactobacillus helveticus DPC5385 MRS 37°C,      O2
-
 
Lactococcus lactis ATCC11454 GM17 30°C,      O2
+
 
Lactococcus lactis ssp. lactis DPC3147 GM17 30°C,      O2
+
 
Listeria innocua DPC1768 BHI 37°C,      O2
+
 
Listeria monocytogenes DPC3572 BHI 37°C,      O2
+
 
Listeria monocytogenes DPC6893 BHI 37°C,      O2
+
 
Pediococcus acidilactici LMG2351 MRS 30°C,      O2
+
 
Salmonella enterica ser. Typhimurium DPC6046 BHI 37°C,      O2
+
 
Staphylococcus aureus DPC5645 BHI 37°C,      O2
+
 
Staphylococcus aureus R963 BHI 37°C,      O2
+
 






Figure S1 Minimum inhibitory concentration of actifensin peptide against Gram-
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Chilton J, Clements D, Coraor N, Eberhard C, Grüning B, Guerler A, 
Hillman-Jackson J, Von Kuster G, Rasche E, Soranzo N, Turaga N, Taylor 
J, Nekrutenko A, Goecks J (2016) The Galaxy platform for accessible, 
 
286  
reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids 
Res 44:W3–W10.  
31. Gao B, Zhu S (2012) Alteration of the mode of antibacterial action of a defensin 
by the amino-terminal loop substitution. Biochem Biophys Res Commun 426:630 
– 635.  
32. Lagesen K, Hallin P, Rødland EA, Staerfeldt H-H, Rognes T, Ussery DW. 
2007. RNAmmer: consistent and rapid annotation of ribosomal RNA genes. 
Nucleic Acids Res 35:3100 –3108.  
33. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy 
and high throughput. Nucleic Acids Res 32:1792–1797.  
34. Franker CK, Herbert CA, Ueda S (1977) Bacteriocin from Actinomyces 
odontolyticus with temperature-dependent killing properties. Antimicrob Agents 
Chemother 12:410 – 417.  
35. Yount NY, Yeaman MR (2004) Multidimensional signatures in antimicrobial 
peptides. Proc Natl Acad Sci USA 101:7363–7368.  
36. Twomey D, Ross RP, Ryan M, Meaney B, Hill C (2002) Lantibiotics produced 
by lactic acid bacteria: structure, function and applications. Antonie Van 
Leeuwenhoek 82:165–185. 
37. van Heel AJ, de Jong A, Song C, Viel JH, Kok J, Kuipers OP (2018) 
BAGEL4: a user-friendly web server to thoroughly mine RiPPs and bacteriocins. 
Nucleic Acids Res 46:W278 –W281.  
38. Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, Brown CT, 
Porras-Alfaro A, Kuske CR, Tiedje JM (2014) Ribosomal database project: 
 
287  
data and tools for high throughput rRNA analysis. Nucleic Acids Res 42:D633-
D642.  
39. Letunic I, Bork P (2016) Interactive tree of life (iTOL) v3: an online tool for the 
display and annotation of phylogenetic and other trees. Nucleic Acids Res 
44:W242-W245.  
40. Sievers F, Higgins DG (2014) Clustal omega. Curr Protoc Bioinformatics 
48:3.13.1-3.13.16.  
41. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ (2009) 
Jalview version 2–a multiple sequence alignment editor and analysis workbench. 
Bioinformatics 25:1189-1191.  
42. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer 
F, Gallo Cassarino T, Bertoni M, Bordoli L, Schwede T (2014) 
SWISSMODEL: modelling protein tertiary and quaternary structure using 
evolutionary information. Nucleic Acids Res 42:W252–W258.  
43. Schrodinger L (2015) The PyMOL molecular graphics system, version 1.8. 
Schrodinger LLC, New York, NY. 
44. Oeemig JS, Lynggaard C, Knudsen DH, Hansen FT, Nørgaard KD, 
Schneider T, Vad BS, Sandvang DH, Nielsen LA, Neve S, Kristensen HH. 
(2012) Eurocin, a new fungal defensin: structure, lipid binding, and its mode of 
action. J Biol Chem 287:42361–42372.  
45. Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Sönksen CP, 
Ludvigsen S, Raventós D, Buskov S, Christensen B, De Maria L, 
 
288  
Taboureau O. (2005) Plectasin is a peptide antibiotic with therapeutic 
potential from a saprophytic fungus. Nature 437:975–980.  
46. Collins FWJ, Mesa Pereira B, O’Connor PM, Rea MC, Hill C, Ross P (2018) 
Reincarnation of bacteriocins from the Lactobacillus pangenomic graveyard. 






Bacteriocin research has expanded greatly over the last decade, from an explosion in 
the number of newly discovered novel bacteriocins with potential as antimicrobial 
alternatives, to their use as gut microbiota modulators and signal molecules that play 
a role in the well-being of humans and animals. As bacteriocins are such a 
heterogeneous group of molecules with regard to size, charge, hydrophobicity, 
specificity and mode of action, they have potential for development as bespoke 
molecules to target specific microbial challenges for the food, pharma and veterinary 
industry. Indeed, it is envisaged that bacteriocins will be developed as a molecular 
arsenal produced by live bio-therapeutic strains to control food spoilage/pathogenic 
microorganisms, to reduce AMR with a particular emphasis on multidrug-resistant 
clinical pathogens and as microbiome modulators to fight disease and promote well-
being. For example, narrow-spectrum bacteriocins, such as Thuricin CD which is 
potent against Clostridioides difficle (1), have considerable potential as vancomycin 
alternatives in some instances, as they target specific pathogens without inducing 
substantial collateral damage to the microbiome (2).  
To date, bacteriocins have been discovered from every conceivable niche including 
fermented foods and beverages, animal gastrointestinal (GI) tract, human GI tract from 
all ages and states of health, human skin, soil and aquaculture. Indeed the bacteriocins 
described herein were isolated from a variety of habitats including nisin H from the 
porcine intestine (3), nisin J from human skin (4), nisin P: a human faecal isolate (5); 
bactofencin A: a porcine faecal isolate (6); formicin: a mackerel intestine isolate (7) 
and actifensin: a sheep faecal isolate (8). Interestingly, all were isolated initially from 
screening using solid media followed by DNA sequencing while peptide purification 
and MALDI TOF mass spectrometry were used to confirm the identity of the 
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bacteriocin. In contrast, novel bacteriocins produced by Lactobacillus spp. (9) and 
Actinomyces spp. were discovered using an in silico approach (8). It is generally 
accepted using that both approaches in parallel will be more successful, given that 
bacteriocin gene clusters could be “switched off” or incomplete, or that the bacteriocin 
produced may not kill any given indicator used in wetlab experiments. Specifically, 
traditional plate assays may miss bacteriocin producers due to incorrect media 
selection to support its growth or incorrect microbial target selection, while genome 
mining will detect bacteriocin gene clusters but does not establish if the bacteriocin is 
being produced.  
The prototypical bacteriocin, Nisin A (E234), produced by Lactococcus lactis, is a 
lantibiotic approved by regulatory agencies for use as a commercial food preservative 
and has been used by the food industry for over 65 years. Nisin A, is the first described 
natural nisin produced by L. lactis (10) and is now one of 15 natural nisin variants from 
a wide variety of organisms (L. lactis spp., Streptococcus spp., Staphylococcus capitis, 
Blautia spp. and Apilactibacillus) and habitats (catfish GI tract, porcine and human GI 
tract, pig GI tract, a river, human skin, bee), making nisin production a ubiquitous trait 
in many genera and many habitats.  
In addition to the diversity in the range of producing organisms and habitats, there is 
considerable heterogeneity within the structural gene in naturally-occurring nisin 
variants with 1-14 amino acid changes from the prototypical nisin A, for example: five 
for nisin H (Chapter 2.1), eight for nisin J (Chapter 2.2) and ten for nisin P (Chapter 
3.1). Furthermore, there are interesting differences within the nisin gene clusters with 
nisin A encoded by eleven genes whereas H lacks a nisI, equivalent, nisin J lacks nisI 
and nisRK equivalents (differences also common to the newest nisin variant kunkecin 
A 11) while nisin P contains the full complement of eleven genes, though in a different 
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gene order. The widespread abundance of nisin and its variants in nature suggest that 
production of the bacteriocin is a very useful trait for bacteria to have in different 
microbiome niches, either for reasons of competition or communication. Moreover, 
the fact that the nisin gene cluster can often be found on mobile gene clusters 
(transposon for nisA and plasmid for nisin J) suggests that horizontal gene transfer 
plays a significant role in dissemination of nisin genes in different environments. 
Interestingly, of the fifteen natural nisin variants reported to date, Teagasc/APC 
researchers discovered and characterised three with two more, currently unreported, 
natural nisin variants in the pipeline.  
Following discovery and identification, the emphasis turns to increasing their 
potential. Their gene-encoded nature makes bacteriocins, and lantibiotics in particular, 
amenable to bioengineering, resulting in “designer bacteriocins” possibly with 
improved physiochemical characteristics, including increased specificity and potency 
(12, 13). Indeed, using this approach the contribution that every amino acid residue 
makes to nisin A bioactivity has been examined by individually changing it to the 
nineteen other possible amino acids. In addition to increasing the understanding of the 
significance of each residue, post-translational modification and internal ring structure, 
this work has resulted in the availability of an arsenal of nisin variants for assessment 
against particular targets, thereby expanding the variety and scope of the application 
of nisin (14). Notable successes include nisin variants with increased activity against 
Gram-negative (15) and both food (16) and clinically (17, 18) significant Gram-
positive pathogens and variants that can overcome nisin resistance mechanisms (19).  
As the natural nisin variants, H, J and P, are produced by non GRAS strains, they are 
consequently of limited use for food or medical applications. Therefore, it was decided 
to improve their commercial potential (Chapter 3) by expressing the bacteriocins in a 
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Lactococcus lactis GRAS strain. This was achieved by fusing the Nisin A promotor 
and nisin A leader sequence to their respective structural genes, and using the nisin A 
biosynthetic machinery to produce the peptide. Successful production of the fully post-
translationally modified nisin variants confirmed the ability of the nisin A gene cluster, 
to produce nisin variants from genetically different backgrounds. While activity was 
low there is potential for improvement. The nisin A gene cluster (nisABTCIPRKFEG) 
is encoded on a transposon (20) and consists of four operons under the control of an 
inducible promotor in the case of nisABTC and three constitutive promotors for nisIP, 
nisRK, nisFEG (21). As the percentage identities differ so much between nisin A 
nisBTC, nisP, nisRK and nisFEG and nisin H, J and P equivalents, it would be 
interesting to clone the entire gene cluster from nisin H, J and P into L. lactis, as a first 
step, to improve production. If this was unsuccessful, it may be worth attempting to 
clone the nisin variant structural gene on nisBTC with, nisI, nisP, nisRK and nisFEG 
equivalents from the producer and assess their relevance for production as it is 
becoming apparent that the nisin encoding gene clusters differ with regard to gene 
content. It also would be interesting to mix and match the nisin biosynthetic genes 
from different backgrounds to see if improved generic gene clusters could be generated 
which are capable of producing significant quantities of peptide regardless of 
background. Reiners et al (2020) recently reported the cloning of the nisin H structural 
gene into a lactococcal background and, while their attempt was successful, they did 
find that nisP cleaves nisin H inefficiently due to the presence of a phenylalanine 
residue at position 1. They overcame this hurdle by changing this phenylalanine to 
isoleucine, the first amino acid residue of nisin A, and found that the peptide was then 
cleaved efficiently (22). Overall, bioengineering is a powerful tool used to improve 
functionality of and add value to bacteriocins.  
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Structure-Activity relationships can be used to predict the effect that chemical/physical 
structure has on biological activity. Alanine scanning, where each amino acid is 
sequentially changed to alanine, has been successfully used to identify the importance 
of particular amino acid residues to activity. This can be either achieved genetically, 
as described for lacticin 3147 (23) and durancin GL (24), or by peptide synthesis, as 
for Class II bacteriocins, and as described in Chapter 4.1 for bactofencin A. Crystal 
structure and site directed mutagenesis were used to show that cationic and aromatic 
residues were responsible for bioactivity of the broad spectrum, circular bacteriocin, 
plantacyclin B21AG (25). NMR has also been used to determine bacteriocin structure 
and provide insightful information into functionality. In the case of the Class IIb, two 
peptide plantaricin S, NMR and site directed mutagenesis, were used to show that the 
peptides formed an α helix between amino residues 7-24 and that the GxxxG motif 
was important for activity (26). Bactofencin A is structurally noteworthy due to the 
exceptionally positively charged N terminal (+7), and its C terminal loop resulting 
from the presence of a disulphide bond between Cys7 and Cys22. A series of peptide 
synthesis variants revealed that these three features are essential for full activity of this 
unusual bacteriocin.  
To achieve the full potential of any bacteriocin in practical applications, it is desirable 
to decipher their activity, spectrum of inhibition, production and mode of action. In 
Chapter 5.1, bactofencin A displayed delayed killing against S. aureus DPC5246, 
suggesting a mode of action that acts predominantly through cell wall inhibition. 
Combining bactofencin A with the pore forming nisin A resulted in faster killing at 
lower bacteriocin concentrations, most likely due to the combination of bacteriocins 
with different modes of action. This is known as a “hurdle approach” or antimicrobial 
combinatorial therapy and is commonly used to reduce the quantity of bacteriocin 
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required for efficacy, making a more cost effective treatment with lower toxicity 
potential (27). This combinatorial approach has been particularly effective in the case 
of nisin, which has been successfully combined with a range of antimicrobials 
including essential oils (28), antibiotics (29) and other bacteriocins (30). A 
combinatorial approach is also used to reduce the incidence of AMR and, in this 
instance, resistance to bactofencin A did not occur at low bactofencin A 
concentrations. Overall, the effectiveness of bactofencin A to treat S. aureus DPC5246 
was significantly improved when combined with nisin A and this interesting result 
warrants further investigation to discover the mechanisms underpinning this synergy. 
Future studies may also include assessing the effectiveness of bactofencin A/nisin A 
combinations against other S. aureus strains including MRSA and other genera such 
as Listeria monocytogenes, while the interaction between bactofencin A and other 
lantibiotics such as lacticin 3147 against different targets is also worth investigating.  
The search for new, novel bacteriocins is as relevant today as it was at the beginning 
of bacteriocin research. Mining studies from all conceivable habitats are ongoing and 
these endeavours are very successful as all bacteriocin classes have been expanded 
significantly and new subclasses discovered since the commencement of this thesis. 
Indeed, the work described herein contributes significantly to novel bacteriocin 
discovery as, in addition to the novel lantibiotics, nisin H, nisin J and nisin P described 
in Chapters 2.1, 2.2 and 3.1, Chapter 6.1 describes formicin, a novel two peptide 
lantibiotic and actifensin, a potential new subclass of antimicrobial. Since the 
discovery of formicin, the most recent addition to the two component lantibiotics is 
roseocin, discovered through in silico mining and described as the first two-component 
lantibiotic in an actinomycete, Streptomyces roseosporus NRRL 113789 (31). The 
peptides were heterologously expressed in Escherichia coli and found to act 
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synergistically when plated in close proximity. The peptides are less similar to those 
previously described, with the alpha peptide likely to contain a different ring structure.  
The actifensins (Chapter 6.2) are broad-spectrum single peptide bacteriocins, 
produced another by Actinomyces genera represent an exciting new type of bacteriocin 
due to the presence of multiple disulphide bonds potentially giving the bacteriocins 
enhanced stability. As these show a high redundancy in sequence and lack post-
translational modifications, there is potential to assess their efficacy by cloning the 
structural genes into a host capable of expressing them at high concentrations thus 
allowing selection of the most effective sequences for further development.  
The ultimate goal for bacteriocin research is the development of bacteriocins into 
viable antimicrobial products that are available for commercial use. Currently, the 
number and range of bacteriocin sequences, and our increased understanding of how 
best to use them, provide a good foundation for development of antimicrobial products 
available for uptake by industry. However, commercialisation is challenging as 
bacteriocins are often produced in low amounts, are peptide based and therefore 
susceptible to digestive enzymes and they require complex media for production 
making them expensive to produce. Another difficulty associated with 
commercialisation is the scarcity of information on safety and toxicity required for 
regulatory approval that can be a time consuming, lengthy process (32). However, 
these are issues that can be overcome once industry commits to invest in these 
fascinating molecules that have such potential as antimicrobials and microbiome 
modulators. It is hoped that the bacteriocins described in this thesis will be developed 
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